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Abstract 
Neurological disorders are complex traits, manifesting as a range of diverse phenotypes. 
The current diagnostic approach involves either stepwise testing, which is expensive 
and time consuming, or targeted next generation sequencing with a limited portfolio of 
genes. Both of these approaches have a lower diagnostic yield. Whole exome 
sequencing may be a more advantageous and faster method to discover disease causing 
gene mutations. 
This study evaluates the use of whole exome sequencing for diagnostic purposes in 
neurological disorders. Whole exome sequencing was performed in a heterogeneous 
cohort of patients with suspected inherited ataxia as an example of a neurological 
disorder, with the aim to identify candidate gene mutations. The study cohort consisted 
of 35 affected individuals from 22 randomly selected families of white European 
descent with no known consanguinity. All common sporadic, inherited and metabolic 
causes were excluded on routine clinical investigations prior to inclusion in this study. 
Whole exome sequencing was performed on 30 affected individuals. In-house 
bioinformatic analysis was based on previously published tools. A variant filtering 
algorithm excluded synonymous variants and focused on protein altering variants, 
nonsense mutations, exonic insertions/deletions and splice site variants. Minor allele 
frequency (MAF) was set at 1% in dbSNP137, 1000 genomes (April 2012 data release) 
and NHLBI-ESP6500 databases as well as in 286 unrelated in-house controls. Selection 
of the remaining variants was based on mode of inheritance. The variants were 
prioritized for brain and nerve cell expression and defined using carefully selected 
criteria. Genetic analysis was supported further by molecular genetic approaches 
(Sanger sequencing, reverse transcription PCR, quantitative pyrosequencing, cloning for 
allelic cis-trans study) and proteomics (Western blotting, immunohistochemistry). 
Confirmed pathogenic variants were found in 9/22 probands (41%) implicating 6 genes 
(KCNC3, SPG7, TUBB4A, SLC1A3, SACS and NPC1). Likely de novo dominant 
TUBB4A mutations were found in two families. In one family quantitative 
pyrosequencing revealed varying degrees of mosaicism in the mildly affected mother 
and heterozygosity in the severely affected offspring. In silico analysis further 
supported pathogenicity of the mutation and revealed that it could potentially disrupt 
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polymerizations of αβ-tubulin heterodimers.  
Possible pathogenic variants were identified in 5/22 probands (23%) implicating 5 
genes (ZFYVE26, ZFYVE27, WFS1, WNK1 and FASTKD2). A predicted splice site 
mutation was detected in three members of an autosomal dominant pedigree in the 
previously described gene ZFYVE27. The ZFYVE27 protein (protrudin) levels were 
increased approximately 2.5 fold in the cerebellum but not in the frontal cortex of the 
affected individual. Protrudin is an endoplasmic reticulum (ER) protein and its 
anomalies have previously been shown to cause ER stress. In this study levels of the 
master regulator of ER stress, BiP/GRP78, were significantly increased in the patient’s 
cerebellum, which may indicate the ER pathology. In one family with possible 
pathogenic compound heterozygous FASTKD2 mutations, the in silico splice-site 
prediction  was validated by sequencing analysis of cDNA clones. Likely de novo 
compound heterozygous mutations in ZFYVE26 (SPG15) in one family was validated 
with sequencing of cloned alleles and the result confirmed occurrence of the mutations 
in trans, therefore supporting their autosomal recessive inheritance.   
In conclusion, the likely molecular diagnosis in 14 out of 22 families (64%) was 
defined; a total of 11 genes were implicated. Disease genes previously described in 
isolated families were validated and the clinical phenotypes of known disease genes was 
broadened. This study has also demonstrated genetic heterogeneity of hereditary ataxias 
but shows the impact of exome sequencing in a group of patients difficult to diagnose 
genetically.  
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Chapter 1. Introduction 
1.1. Neurological diseases 
Neurological diseases form a large group of disorders which exhibit a vast variation in 
age of onset, severity, clinical presentation, genetic background and response to 
therapeutics (Boone et al., 2011). Neurological diseases caused by mutations are 
characterized by significant genetic and phenotypic heterogeneity and are challenging to 
diagnose and treat because of the highly divergent nature of each case. Analysis of the 
genetic cause of neurological diseases will lead to the characterization of novel 
molecular pathways and the identification of therapeutic targets. This in turn will aid the 
development of personalized medicines and genetic counselling. The hereditary nature 
of neurological diseases can be subdivided on the basis of their mode of inheritance into 
Mendelian, sporadic and mitochondrial. 
1.1.1. Mendelian neurological diseases 
Mendelian diseases are those, in which the phenotype is largely caused by mutation(s) 
in a single gene and inherited in an autosomal dominant, autosomal recessive or X-
linked manner. 
The simplest type of Mendelian neurological disease is a group of monogenic disorders, 
where the phenotype is caused by the presence of one (for a dominant trait) or two (for a 
recessive trait) mutant alleles. These disorders constitute only a small group of 
neurological diseases and are generally rare (Bras et al., 2012). Nevertheless, 
understanding the mechanisms of diseases with simple inheritance patterns demonstrate 
how pathogenic mutations could affect gene functions and this knowledge could be 
subsequently applied to study more complex neurological diseases (Antonarakis and 
Beckmann, 2006). 
1.1.2 Sporadic neurological diseases 
Sporadic neurological diseases are those that occur in the absence of family history and 
a known genetic cause. De novo mutations are usually rare, often affect reproductive 
fitness and therefore are rarely transmitted to the next generation. De novo mutations 
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have not been subjected to purifying selection. Hence, they are usually more deleterious 
than inherited rare genetic variation and are the most likely cause of genetic diseases 
that occur sporadically (Foo et al., 2013).  
1.1.3. Mitochondrial diseases 
Mitochondrial diseases are generally understood as diseases that arise as a result of 
dysfunction of the mitochondrial oxidative phosphorylation (OXPHOS) system, due to 
improper function of one or more of the mitochondrial respiratory chain complexes 
(Ylikallio and Suomalainen, 2012). They affect ~1 in 5000 live births (Schaefer et al., 
2004). 
Mitochondrial diseases are a clinically heterogeneous group of inherited diseases, which 
can potentially affect any organ at any age and can be inherited in an autosomal 
dominant or recessive, X-linked, or maternal manner (Nunnari and Suomalainen, 2012). 
1.2. Classical methods for identification of causative gene variants 
1.2.1. Monogenic hereditary neurological disorders 
Several major techniques were so far used for identification of the causative variants for 
monogenic hereditary neurological disorders. 
 
Genetic linkage analysis 
Genetic linkage analysis is a statistical method to identify regions on chromosomes that 
could contain the genes responsible for a particular phenotype. This method is based on 
the idea that the neighbouring genes on the chromosome are inherited together 
(“linked”) during the meiosis. This method involves studying large pedigrees with 
multiple affected and unaffected individuals. DNAs from affected and unaffected 
individuals are genotyped for certain DNA sequence polymorphisms with known 
chromosomal locations (markers), which are scattered throughout the genome. If certain 
markers show segregation with the disease, then it could be assumed that these markers 
are located close on the chromosome to the disease gene. Linkage analysis makes use of 
linkage disequilibrium, which occurs when genetic markers are inherited together with a 
higher probability than would be expected if they were inherited by chance. This would 
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occur if markers are situated close to each other on the chromosome and thus are less 
likely to be separated during recombination in meiosis. Taking into consideration a 
recombination event, which takes place in meiosis, it is possible to determine the 
chromosomal region which segregates with the disease (Hossjer, 2005). The 
chromosomal region, which shows segregation with the disease, will probably contain 
the gene that harbours causative mutations. Subsequent Sanger sequencing is employed 
to pinpoint the mutation. An example of the successful application of genetic linkage 
analysis is the discovery that hereditary dysphasic disinhibition dementia, a 
frontotemporal dementia, is linked to 17q21-22 (Lendon et al., 1998).  
A significant drawback of linkage analysis is that it can only be performed in large 
families with multiple affected individuals. This limitation is particularly pronounced in 
families with a late disease onset, where affected individuals are already deceased and 
the young generation is yet to reach the disease onset (Bras et al., 2012). In addition, the 
linkage analysis only identifies linkage regions and not a particular causative gene. 
Sometimes these regions are very large which makes it very difficult to prioritize the 
disease genes. 
Homozygosity mapping 
For consanguineous pedigrees, where an autosomal recessive mode of inheritance is 
hypothesized, homozygosity mapping has proved to be a powerful technique of 
mapping causative genes. Homozygosity mapping, a form of linkage analysis, defines 
the regions on chromosomes that are homozygous because they are inherited from a 
common ancestor and therefore could potentially contain a causative mutation (Seelow 
et al., 2009). Homozygous regions are identified by genome-wide high-density single 
nucleotide polymorphism (SNP) genotyping arrays. The main principle of 
homozygosity mapping is that DNA markers, within close proximity to the disease 
gene, will be homozygous by descent due to being inherited from a common ancestor 
(Lander and Botstein, 1987). An example of the successful application of this technique 
is identifying a COL18A1 mutation as a cause of an autosomal recessive neurological 
disorder in an Indian family (Paisan-Ruiz et al., 2009). 
Homozygosity mapping, however, does not always result in identifying a gene that 
harbours causative mutations. As in the case with linkage analysis, this technique would 
yield only the regions on chromosomes, which are predicted to be homozygous, rather 
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than a particular gene.  
Array comparative genomic hybridization (aCGH) 
DNA copy number variations (CNVs) were recently associated with common and rare 
diseases (Weischenfeldt et al., 2013). CNV is a change in normal gene/loci dosage, 
which could occur due to multiplications or deletions of genomic regions. CNVs are 
commonly detected with array comparative genomic hybridization (aCGH). In this 
technique a reference and a patient’s DNA samples are differently labelled with 
coloured fluorescent dyes, mixed and subjected to a competitive hybridization on a chip 
containing DNA probes (microarray). CNVs are called by comparison of fluorescence 
signal intensity of the two samples hybridized to each DNA probe. 
However, the resolution of aCGH used for CNV calling is not high enough and is 
currently limited to deletions and duplications longer than 250 kb (Retterer et al., 2015). 
This could result in missing smaller CNVs, which potentially could be implicated in 
diseases. 
Candidate gene association study 
A candidate gene association study could be performed when genes known to carry 
disease causing mutations were already identified. In these studies different populations 
would be screened for the genes of interest and information such as prevalence and 
clinical significance would be obtained (Bras et al., 2012). 
The candidate gene association study approach would require prior knowledge about the 
genes to be studied. It is not always easy to obtain such information.  
Case-control studies 
In case-control studies the genes of interest would be investigated in a group of cases 
and a group of controls from the same population. Rare mutations are an evolutionary 
recent event that have occurred due to explosive accelerated population growth over the 
past 10000 years. It is anticipated now that most rare variants in the human genome are 
population-specific (Tennessen et al., 2012). That is why case-control studies are of a 
particular importance.  
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1.2.2. Common disorders 
Common, complex disorders, are those where phenotypes are caused by a combination 
of variants in several genes, none of which individually have an impact on the trait. 
These disorders form a group of complex diseases. There are two hypotheses as to 
which exact variants are contributing most to the development of the common complex 
disorders - “common disease, common variant” and “common disease, rare variant” 
(Schork et al., 2009). 
“Common disease, common variant” hypothesis 
“Common disease, common variant” hypothesis postulates that common variants (i.e. 
variants with a Minor Allele Frequency (MAF) >1%), with relatively low penetrance, 
are major contributors to the risk of developing a common disease (Reich and Lander, 
2001). By this hypothesis, not one of these variants individually is sufficient to cause 
the disease. This hypothesis was prevalent in the scientific community during the past 
decade.  
Despite the progress in elucidating genes that harbour causative mutations for 
Mendelian diseases, common diseases have proved to be more difficult to dissect, 
mainly due to the locus heterogeneity. That is why a classical method for identification 
of causative mutations, such as linkage analysis, could not be successfully applied for 
common diseases (Altmuller et al., 2001).  
Genome-wide association study (GWAS) used the “common disease, common variant” 
hypothesis to investigate a large number of common single nucleotide polymorphisms 
(SNPs), in a large number of case and control samples, and to identify association 
between these common variants and the disease. GWAS was successfully applied to 
diseases such as Parkinson’s disease (Pihlstrom et al., 2012), Alzheimer’s disease 
(Harold et al., 2009) and multiple sclerosis (Matesanz et al., 2012) yielding some 
common variants and loci which potentially modulate the risk of these common 
diseases. However, in each of these studies the identified loci explain only a small 
proportion of the heritable component of the disease. This means that inherited common 
variants alone cannot explain the majority of common diseases. 
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“Common disease, rare variant” hypothesis 
The “common disease, rare variant” hypothesis argues that multiple rare variants 
(MAF<1%), each with relatively high penetrance, have a higher impact on the risk of 
developing common, complex diseases than common variants (Pritchard, 2001). Studies 
by several research groups subsequently demonstrated an effect of rare variants on 
common traits (Ji et al., 2008; Nejentsev et al., 2009). These high-risk variants do not 
cause disease directly, but rather have a higher impact on the risk of developing disease 
than common variants. Rare variants are hard to detect by GWAS because this 
technique employs common SNPs and thus would not account for rare variations. Rare 
variants, therefore, may explain “missing heritability” (Manolio et al., 2009). The 
“common disease, rare variant” hypothesis is relatively recent and marks a major 
hypothesis shift in human genetics (McClellan and King, 2010). This hypothesis has 
several implications. For example, it has been proposed that in common diseases, which 
are highly heterogeneous, rare mutations in different genes involved in the same or 
related pathway could potentially cause the same disorder (McClellan and King, 2010). 
Indeed, recent studies in schizophrenia found that multiple genes harbouring multiple 
rare mutations in this disease are not a random group of genes. The majority of the 
mutated genes were, in fact, involved in signalling and critical neurodevelopmental 
pathways (Walsh et al., 2008). 
Employing GWAS for the identification of rare variants, that influence common 
disease, is not effective due to the low statistical power in detecting an association in 
these situations. Statistical power will decrease with a decreasing variant frequency, 
meaning that very large sample sizes are required in order to detect association of rare 
variants with common disease. (Raychaudhuri, 2011). 
Considering that the traditional GWAS approach could not be successfully employed to 
reveal the association of rare variants with common disease, other methods are required. 
One of the approaches that could be used to identify rare variants involved in common 
disease is sequencing the extremes (Harismendy et al., 2010). 
To identify rare variants, involved in common disease, it has been suggested that 
sequencing candidate genes in individuals, at the high and low ends (extremes) of the 
distribution of a quantitative phenotype, should be performed (Figure 1.1).   
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Figure 1.1: Sequencing of the extremes. 
This figure shows the strategy of sequencing the extremes in order to identify rare 
variants involved in common disease (reproduced from Brunham and Hayden, 2013). 
The number of rare variants in each of the candidate genes relevant to the study is 
compared between the “high” and “low” groups. It is anticipated that an excess of rare 
variants in a given gene in the “high” group versus “low” provides evidence of 
involvement of this gene in the phenotype. 
To study the impact of rare and private variants on the disease in a large number of 
individuals was very difficult until recent advances in technology. Next generation 
sequencing (NGS) technology is an emerging tool for identification of rare variants 
(Figure 1.2).  
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Figure 1.2: Research strategy for identification of disease-causing variants, based 
on the relationship between allele frequencies of variants in the population and the 
size of the effect caused by the variant. 
For “common disease common variant” cases, where variants with high frequency and 
small effect size are thought to be major contributors to the risk of developing a 
common disease, the most effective study approach is genome-wide association studies 
(GWAS). These studies employ common single nucleotide polymorphisms (SNPs). 
Likewise, for “common disease rare variant” cases, where multiple variants with low 
frequency and substantial effect size are thought to contribute to developing the disease, 
next generation sequencing techniques such as whole genome and whole exome 
sequencing will be the most promising approach. For Mendelian diseases, which 
constitute a group of diseases caused by very rare variants with a large effect size, 
studying multiple or single genomes or exomes in the affected family is the most 
effective strategy (adapted from Tsuji, 2010).   
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1.3. Sequencing technologies 
Automated Sanger sequencing is considered a “first generation” technology, and all 
newer sequencing technologies are referred to as “massively parallel sequencing” or 
“next generation sequencing” (NGS) (Rizzo and Buck, 2012).  
1.3.1. Sanger sequencing as “first generation sequencing” 
Sanger sequencing is a classical method of sequencing genes. This technology is based 
on the principle of chain termination and high-resolution electrophoresis. Fluorescently-
labelled dideoxynucleotides (ddNTPs) are added to the reaction in addition to standard 
nucleotides (dNTPs). ddNTPs do not have a 3’-hydroxyl group, therefore incorporation 
of such nucleotides would result in termination of the DNA template elongation. This 
occurs by the DNA polymerase creating a pool of randomly terminated elongation 
products. Subsequently these terminated products are subjected to electrophoretic 
separation by size on a capillary-based polymer gel. Laser detection of fluorescent 
ddNTPs results in a fluorescence peak trace chromatogram.  
1.3.2. Next Generation Sequencing  
NGS refers to the technologies, which allow sequencing of massive amounts of DNA 
fragments in parallel. NGS allows, firstly, de novo sequencing, where the genome is 
assembled from short reads without prior knowledge of the reference genome sequence. 
This approach is suitable for de novo sequencing of smaller genomes, such as bacterial 
genomes (Chaisson and Pevzner, 2008). Secondly, larger genomes, like the human 
genome, are normally sequenced by alignment of the short reads to the reference 
sequence allowing mutation detection. NGS can also be applied  in large-scale analysis 
of DNA methylation and transcriptome sequencing (Shendure and Ji, 2008). 
NGS is not one single technology. There are numerous commercially available 
platforms. The most widely used platforms are Illumina HiSeq 2000 (Illumina, Inc.), 
Roche/454 (454 Life Sciences), SOLiD/ABI 5500 (Life Technologies Corporation), 
however, there are many others. They all differ in template preparation methods as well 
as the way the templates are sequenced and the data analysed (Metzker, 2010; 
Foo et al., 2013).  
!! 11!
Illumina HiSeq® Series (Illumina, Inc.) 
The principal of the Illumina HiSeq® system is that the template is amplified on the 
solid surface of the flow cell using reversible dye terminator. The DNA sample is 
sheared into small fragments of about 200 bp and adapters are ligated to both ends of 
the fragments, creating a sequencing library. The library is then loaded on a flow cell 
and bound to its solid surface. Each fragment is amplified by bridge amplification 
polymerase chain reaction (PCR), which creates clusters of the fragments on the surface 
of the flow cell (Figure 1.3). The clusters are then sequenced through sequencing-by-
synthesis. 
 
Figure 1.3: Illumina HiSeq® cluster amplification by bridge amplification PCR. 
For cluster generation, sample preparation DNA fragments, containing adapters ligated 
on both ends, are loaded on a flow cell where the fragments are captured on a flow cell 
surface. Each fragment is then amplified by bridge amplification PCR creating a clonal 
cluster (adapted from Metzker, 2010). 
At the time of writing this Thesis, Illumina HiSeq® series included three platforms: 
HiSeq® 2500, HiSeq® 3000 and HiSeq® 4000, which differ in output range (from 10-
300 Gb for HiSeq® 2500 to 125-1500 Gb for HiSeq®4000) and number of reads per 
flow cell (from 300 million for HiSeq® 2500 to 2.5 billion for HiSeq® 4000). The 
Illumina HiSeq® series allows sequencing of the whole genome, exome or transcriptome 
on a production scale. 
Major applications of NGS 
The two major applications of NGS, with regards to identification of disease causing 
gene variants, are whole genome sequencing and whole exome sequencing. Whole 
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genome sequencing (WGS) technology allows sequencing of a whole genome of a 
single individual, enabling identification of variants in coding and non-coding regions 
(Brunham and Hayden, 2013). WGS doesn’t require a prior knowledge of target regions 
and covers the entire genome universally (Warr et al., 2015). One of the main 
difficulties of WGS is interpretation of variations found in non-coding regions due to 
lack of knowledge about the importance of such regions. Hence, the consequences of 
variations in non-coding regions of the genome are less well understood than variations 
in coding regions (Ward and Kellis, 2012). WGS produces over 100 Gb of data and, 
despite being ultra-high-throughput technology, at present it is considered to be an 
expensive option in clinical practice. However, the cost of WGS is gradually going 
down and at present the whole genome of an individual could be sequenced in under 2 
weeks for approximately US$ 4000 (Keogh and Chinnery, 2013). It is predicted that the 
cost of WGS will continue to fall and in the near future will drop below US$ 1000 (Foo 
et al., 2012). Such a dramatic fall in cost of WGS, coupled with its high throughput 
abilities, can make WGS more accessible for clinicians in future (Keogh and Chinnery, 
2013). 
WGS has demonstrated its ability to successfully identify causative variants in 
neurological diseases. For example, in a recent study of a family with a recessive form 
of Charcot-Marie-Tooth disease, for which the genetic cause has not been identified, 
researchers sequenced the whole genome of the proband and identified all possible 
causative variants. Subsequent genotyping of all affected family members revealed 
segregation with the disease of a compound heterozygous mutation in the SH3 domain 
and tetratricopeptide repeats 2 (SH3TC2) gene (Lupski et al., 2010). 
Targeted sequencing of all known protein coding parts of the human genome (exome) is 
referred to as whole exome sequencing (WES). The other type of exome sequencing, 
which targets protein coding regions of only a set of chosen genes (panel) is known as 
targeted exome sequencing.  
WES produces around 10 Gb of final data (Bras et al., 2012), which is 10-fold less than 
WGS. WES and targeted exome sequencing are considerably less expensive than WGS 
(approximately 5-fold and 10-fold, respectively) (Kingsmore and Saunders, 2011). The 
current cost of targeted and whole exome sequencing is around US$ 620 (Nemeth et al., 
2013) and US$ 1000 (Foo et al., 2012), respectively, which is considerably less than the 
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cost of WGS. The principles of exome sequencing and its applications, as well as the 
advantages and disadvantages of this technique, are discussed in detail in subsequent 
sections of this Thesis. 
First proof of principle studies by Choi and colleagues and by Ng and co-workers 
demonstrated that exome sequencing could be successfully applied to identify causative 
mutations of Mendelian disorders and thus could be a potential diagnostic tool in the 
future (Choi et al., 2009; Ng et al., 2009).  
1.4. Exome sequencing as a tool for dissecting neurological diseases 
Neurological disorders manifest as a range of diverse phenotypes with varying age of 
onset, clinical presentation, severity and response to treatment (Foo et al., 2013). For 
most neurological disorders there is no cure available at present (Foo et al., 2013). 
Precise diagnosis is important because it could lead to the discovery of novel 
biochemical pathways involved in the pathogenesis of neurological disorders. This 
would aid in the discovery of new therapeutics and accurate genetic counselling 
(Biesecker et al., 2012). The current diagnostic approach is stepwise testing, which is 
expensive, time consuming and has a low diagnostic yield. Exome sequencing is an 
emerging powerful technique for dissecting neurological disease (Foo et al., 2013).  
Exome sequencing is a hypothesis-free technique which allows an unbiased approach to 
mutation studies. The majority of allelic variants, known to be a cause of Mendelian 
disorders, disrupt protein-coding sequences, which account for approximately 1% of the 
human genome but harbour about 85% of disease mutations (Choi et al., 2009; Stenson 
et al., 2009). Also, a large fraction of rare non-synonymous variants in the human 
genome are predicted to have functional consequences and to be deleterious (Kryukov 
et al., 2007).  
1.4.1. Targeted next-generation sequencing panels 
Disease specific sequencing panels allow interrogation of genes previously linked             
to a particular disease (Rehm et al., 2013). Several custom-made panels, consisting of 
genes linked to neurological disorders, have been designed recently. Such panels enable 
targeted sequencing of genes of interest in patients with neurological disorders. For 
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example, the Nimblegen SeqCap EZ Neurology Panel targets 256 genes associated                         
with 87 neurological disorders (Roche, Burgess Hill, UK) (available at 
http://www.nimblegen.com/products/seqcap/ez/designs/index.html). Another example 
of a targeted sequencing panel is the mitochondrial genome sequencing panel enabling 
sequencing of mitochondrial DNA and over 1000 nuclear genes encoding mitochondrial 
proteins (Calvo et al., 2012). The latter panel could be used in patients with suspected 
mitochondrial disorders.  
More recently several disease-specific sequencing panels were designed. Nemeth and 
co-workers used an ataxia panel consisting of 118 known and putative ataxia genes. 
They performed a pilot targeted exome sequencing study on a cohort of 50 highly 
heterogeneous ataxia patients (Nemeth et al., 2013). The authors found 13 different 
mutations, with 9 being novel, in 8 different genes, namely: PRKCG, TTBK2, SETX, 
SPTBN2, SACS, MRE11, KCNC3 and DARS2. The overall diagnostic yield was 18%, 
which supported an effectiveness of targeted exome sequencing in a clinical setting. 
Another example of a successful application of targeted exome sequencing is the 
identification of an inherited retinal degeneration (IRD) panel enabling the capture of 
exons from 73 IRD genes and 1 deep intronic splice site known to be associated with 
IRD (Shanks et al., 2013). The authors performed targeted exome sequencing on 50 
patients (36 “unknowns” and 14 positive controls) with IRD and found pathogenic 
mutations in 25% of patients in the “unknowns” group in a total of 6 genes, namely: 
RHO, ABCA4, PDE6B, GUCY2D, CRX and CRB1T.  
Targeted exome sequencing has several advantages. It is argued that a well-defined 
number of genes being sequenced with a panel would reduce the final data output, 
enabling clinicians to reduce the time and cost of diagnosis (Rehm et al., 2013). A pre-
defined gene portfolio, hence, would reduce the amount of data input, enabling the use 
of less-time-consuming sequencing technology. This would therefore enable more 
patient samples to be analysed, compared to WGS and WES (Rehm et al., 2013). The 
possibility to customise and update a panel is also beneficial. However, despite obvious 
advantages, targeted exome sequencing has several disadvantages over whole exome 
sequencing. Firstly, a panel has a set portfolio of genes; therefore identification of novel 
disease genes is not possible. Secondly, unusual clinical presentations might result in 
selecting the wrong panel. Currently we are witnessing a stream of reports describing 
novel presentations of established neurological diseases (Pfeffer et al., 2015). Such 
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knowledge will eventually lead to updating existing panels. However, until then, the one 
should bear in mind the potential pitfalls of the current panels in use. 
1.4.2. Whole exome sequencing 
Whole exome sequencing targets the whole protein-coding part of the genome without 
prioritising any gene. WES does not rely on any postulation of involvement of 
particular genes in the given phenotype and therefore might be a less biased approach 
than targeted exome sequencing. In the past, numerous studies reported successful 
application of whole exome sequencing to various inheritable and complex neurological 
disorders enabling clinicians to establish their cause. Examples of neurological 
disorders and putative causative variants identified by whole exome sequencing are 
shown in Table 1.1.   
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Table 1.1: Neurological disorders and their putative causative variants, as 
identified by whole exome sequencing. 
The table shows a selection of recent studies on various types of neurological disorders 
that used whole exome sequencing to identify putative causative variants. AD, 
Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; EOAD, early-onset 
Alzheimer’s disease; FALS, familial amyotrophic lateral sclerosis; LOAD, late-onset 
Alzheimer’s disease; PD, Parkinson’s disease; SCA, spinocerebellar ataxias; MS, 
multiple sclerosis (adapted and updated from Jiang et al., 2014) 
 
 
Disease Reference Subtype Gene 
AD (Guerreiro et al., 2012) EOAD NOTCH3 
 (Pottier et al., 2012) EOAD SORL1 
 (Pottier et al., 2013) EOAD TREM2 
 (Guerreiro et al., 2013) LOAD TREM2 
 (Sassi et al., 2014) EOAD Presenilin 1 
PD (Koroglu et al., 2013) Juvenile parkinsonism DNAJC6 
 (Nuytemans et al., 
2013) 
 VPS35 
 (Nuytemans et al., 
2013) 
 EIF4G1 
 (Ruiz-Martinez et al., 
2015) 
Late-onset Parkinson's disease 
with cognitive impairment. 
GIGYF2 
Epilepsy (Heron et al., 2012) Autosomal dominant nocturnal 
frontal lobe epilepsy 
KCNT1 
 (Barcia et al., 2012) Malignant migrating partial 
seizures of infancy 
KCNT1 
 (Andrade et al., 2012) Teenage-onset progressive 
myoclonus epilepsy 
CLN6 
 (Zhou et al., 2012) Autosomal-recessive spinal 
muscular atrophy associated 
with progressive myoclonic 
epilepsy 
ASAH1 
 (Saitsu et al., 2012b) Ohtahara syndrome CASK 
 (Saitsu et al., 2012a) Ohtahara syndrome KCNQ2 
 (Berger et al., 2012) Intractable epilepsy of infancy EFHC1 
 (Lemke et al., 2012) Various types of epilepsy SCN1A; 
SCN2A; 
STXBP1; 
KCNJ10; 
KCTD7; 
KCNQ3; 
ARHGEF9; 
SMS; TPP1; 
MFSD8 
 (Karkheiran et al., 
2013) 
Progressive myoclonus 
epilepsy syndrome 
COL6A2 
 (Hallmann et al., 2014) Progressive myoclonus 
epilepsy syndrome 
CARS2 
 (Blanchard et al., 2015) Early-infantile epileptic 
encephalopathy 
SCN8A 
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Table 1.1: Continued 
Disease Reference Subtype Gene 
MS (Ramagopalan et al., 
2011) 
 CYP27B1 
 (Dyment et al., 2012)  TYK2 
 (Granstrom et al., 2014)  EDNRB 
Stroke (Cole et al., 2012) Ischemic stroke CSN3 
 (Kim et al., 2014) Ischemic stroke Paraoxonase-1 
ALS (Wu et al., 2012b) FALS SOD1 
 (Williams et al., 2012) FALS UBQLN2 
 (Gonzalez-Perez et al., 
2012) 
FALS VCP 
 (Wu et al., 2012a) FALS PFN1 
 (Daoud et al., 2012) Juvenile ALS SPG11 
 (Smith et al., 2014) FALS TUBA4A 
 (Johnson et al., 2014) FALS MATR3 
SCA (Doi et al., 2011) Autosomal-recessive SCA STY14 
 (Sailer et al., 2012) Autosomal dominant SCA PRKCG 
 (Lee et al., 2012) Autosomal dominant SCA KCND3 
 (Duarri et al., 2012) Autosomal dominant SCA KCND3 
 (Huang et al., 2012) Autosomal dominant SCA ITPR1 
 (Dundar et al., 2012) Autosomal-recessive infantile 
onset SCA 
C10orf2 
 (Li et al., 2013) Autosomal dominant SCA TGM6 
 (Sun et al., 2013) Autosomal-recessive SCA TPP1 
 (Heimdal et al., 2014) Autosomal-recessive SCA STUB1 
 (Mallaret et al., 2014) Autosomal-recessive SCA WWOX 
 (Mancini et al., 2015) Autosomal-recessive SCA CLN5 
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Recent data also suggest that whole exome sequencing could not only be a useful tool 
for the discovery of novel disease genes, but also enable the revision of diagnosis. For 
example, Dixon-Salazar at co-workers performed whole exome sequencing in 118 
patients with paediatric-onset neurodevelopmental disorder and identified new disease 
genes in 19% of the cohort (Dixon-Salazar et al., 2012). Notably, in 8% of the cohort 
putative causative mutations were discovered in genes known to cause diseases that 
were different from those previously diagnosed. This led to revision of the diagnosis 
and a change of management in these patients.  
Applying whole exome sequencing to highly heterogeneous cohorts of patients, with 
neurological disorders, revealed that the diagnostic yield could be high. For example, 
Fogel and co-workers applied whole exome sequencing to a cohort of 76 patients who 
presented with predominantly adult- and sporadic-onset cerebellar ataxia (Fogel et al., 
2014). The researchers were able to find a definitive cause of disease in 21% of the 
patients and identified a further 40% of cases with potentially pathogenic mutations, 
bringing the overall diagnostic yield to 61%. In a similar study, whole exome 
sequencing was employed in order to establish a molecular cause of disease in a highly 
heterogeneous cohort of 35 patients with suspected inherited ataxia (Pyle et al., 2014). 
The study reported identification of confirmed pathogenic variants in 41% of the 
patients and identified a possible cause of the disease in a further 23% of the patients, 
meaning that the overall likely molecular diagnosis was defined in 64% of the patients. 
The latter two studies highlighted the impact of whole exome sequencing on patients, 
which are difficult to diagnose by traditional means. As recent studies show, whole 
exome sequencing could also link known disease genes with unusual presentations 
broadening the phenotypic spectrum of the disease, for example SPG7, SACS (Pyle et 
al., 2014) and ELOVL4 (Ozaki et al., 2015). 
1.4.3. Basic steps of exome sequencing 
The basic steps of exome sequencing are: fragmentation of genomic DNA, ligation of 
adaptors to DNA fragments, capturing the fragments containing exons via 
hybridization, washing out the uncaptured DNA, elution of the captured DNA 
fragments, polymerase chain reaction (PCR) amplification and massively parallel 
sequencing followed by alignment and variant calling (Figure 1.4). 
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Figure 1.4: The basic steps required for exome sequencing. 
The basic steps required for exome sequencing involve fragmentation of genomic DNA, 
constructing an in vitro shotgun library, flanking the library fragments by adaptors (not 
shown), enriching the library for sequences corresponding to exons (dark blue 
fragments) by hybridization of the fragments to biotinylated DNA or RNA baits (orange 
fragments), and recovery of the hybridized fragments by biotin–streptavidin-based pull-
down. Finally, amplification and massively parallel sequencing of the enriched, 
amplified library is performed and mapping and calling of candidate causal variants 
follows (adapted from Bamshad et al., 2011).  
Construct)
shotgun)library) Hybridiza4on)
Genomic)DNA) Fragments)
Pulldown)
Wash))))
Mapping,)alignment,)
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)
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1.4.4. Prioritising of variants (filtering process) 
Whole exome sequencing of an individual yields on average 20,000 variants (Bamshad 
et al., 2011). In order to establish which of these variants account for the individual’s 
phenotype, the variants are prioritized through a filtering process. In this Thesis the 
filtering process is described in detail in Chapter 3. Briefly, the variants are Compared 
to public databases such as 1000 genomes (Abecasis et al., 2010), dbSNP (Sherry et al., 
2001) and Exome Variant Server (the latest release available at 
http://evs.gs.washington.edu/EVS/). This interrogation enables the filtering out of 
common variants with minor allele frequencies above 1% in these databases. This step 
considerably reduces the number of putative pathogenic variants, bringing it down to 
approximately 600 (Bamshad et al., 2011). The variants are further filtered based on the 
mode of inheritance and involvement of the putative disease gene in the biological 
processes or known diseases, which would fit the phenotype. Of note, at the time this 
work commenced the Exome Aggregation Consortium (ExAC) data was not available 
and was not used. However, this has been subsequently reviewed and included in 
Chapter 4 of this Thesis. The latest release of ExAC data is available at 
http://exac.broadinstitute.org/ . 
1.4.5. Establishing causality of filtered variants 
After filtering of variants, as described in the previous section, the list of variants could 
still be long and contain dozen(s) of variants. Therefore each variant should be assessed 
manually and prioritized based on certain criteria, as recommended by the recent 
guidelines (MacArthur et al., 2014; Richards et al., 2015). There are numerous 
pathogenicity criteria that are considered before a variant could be called pathogenic, 
benign or classified as uncertain significance. These criteria are outlined in Table 1.2. 
The filtered variants are confirmed with Sanger sequencing. The pathogenicity of the 
variants is further investigated by a segregation study, where the available affected and 
unaffected relatives of the individual are investigated (segregation of the variant with 
the disease supports its pathogenicity). Following this, various pathogenicity prediction 
programs are employed in order to check how the putative causative mutation might 
impact on the function of the encoded protein (for example cause truncation or affect a 
functional domain in the protein) (Adzhubei et al., 2010; Schwarz et al., 2010). The 
variant of interest is then cross- examined in a cohort of unrelated controls of matched 
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ethnic background (pathogenicity of the variant is supported if the variant is not 
detected in the control population). 
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1.4.6. Strategies for finding disease-causing rare variants using exome sequencing  
 
Sequencing of multiple unrelated affected individuals  
If exomes of unrelated individuals with a similar phenotype have been sequenced, then 
their data could overlap. This would aid in reducing the number of candidate genes 
because more distantly related individuals would share less variants (Figure 1.5 a). Ng 
and colleagues used this approach to identify a nonsense mutation or frameshift 
insertions and deletions in myeloid/lymphoid or mixed-lineage leukemia 2 gene MLL2 
as a cause of Kabuki syndrome in ten unrelated individuals (Ng et al., 2010a). 
 
Sequencing the extremes  
To identify rare variants involved in common disease the strategy of sequencing the 
extremes could be employed, as described in previous sections. This strategy is suitable 
for quantitative phenotypes. It involves sequencing of candidate genes relevant to the 
study, or whole exome sequencing, in the individuals from the both ends of the 
phenotype. Individuals with an excess of rare variants in the same gene are expected to 
fall into a “high end” of the phenotype and this particular gene is hypothesised to be a 
prime suspect for causing the observed phenotype (Figure 1.5 b). Using exome 
sequencing in this setting will accelerate the study considerably.  
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Figure 1.5: Several strategies where exome sequencing could be used for finding 
disease causing rare variants. 
a – exome sequencing of multiple unrelated individuals exhibiting similar phenotypes is 
used to identify causative variants within the same gene, as outlined in the shaded 
region shared by all three individuals in this figure. b – for the quantitative phenotypes 
strategy “sequencing of the extremes” could be employed. It involves exome 
sequencing in individuals from the both ends of the phenotype. Individuals with an 
excess of rare variants in the same gene are expected to fall into the “high end” of the 
phenotype and this particular gene is hypothesised to be a prime suspect for causing the 
observed phenotype (adapted from Bamshad et al., 2011).   
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Sequencing of multiple affected individuals within the same pedigree 
It is important to decide which samples to sequence in an exome sequencing project 
because the cost of this technique is still prohibitive in comparison with other methods. 
The mode of inheritance of a monogenic disease will affect the study design and the 
way the analysis is undertaken (Bamshad et al., 2011). Based on the original study’s 
logic (Ng et al., 2009), it is clear that analysing rare recessive diseases will be easier 
than dominant ones because there are far fewer genes in each exome that are 
homozygous or compound heterozygous for rare non-synonymous changes (i.e. genes 
with two rather than one rare protein altering allele per gene). That is why when 
analysing pedigrees with a recessive mode of inheritance of rare Mendelian traits, 
sequencing the exome of just one affected individual might be informative enough. If 
the family is consanguineous, then homozygosity mapping of this patient could be 
performed as well. The data are then combined in order to reduce the number of 
candidate genes.  
For dominantly inherited traits it is necessary to exome sequence a minimum of two 
affected individuals from a studied pedigree and then to overlap the data in order to find 
the shared variants.  
It is preferable that the exomes of most distantly related affected individuals are 
sequenced because in this case they would share fewer variants (Figure 1.6). Wang and 
co-workers sequenced exomes of four affected members in one four-generation Chinese 
family with autosomal dominant spinocerebellar ataxia and found that they all shared a 
missense mutation in a novel ataxia transglutaminase 6 gene TGM6 (Wang et al., 2010).  
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Figure 1.6: A theoretical example of how the degree to which two affected 
individuals are related could affect the outcome of exome sequencing data. 
It is estimated, that, on the average, each sequenced exome will result in approximately 
20,000 variants. When exomes of two affected siblings are intersected, the number of 
variants shared between them will be reduced to 1/2th of the genome. Comparing the 
exomes of 1st cousins and 2nd cousins will reduce the number of candidate variants to 
roughly an 1/8th and 1/32th of the genome, respectively. This example assumes that all 
but 2% of variants will be identified in public databases such as dbSNP and 1000 
genomes and the number of novel variants predicted to be deleterious will be 
approximately 20%. (reproduced from Brunham and Hayden, 2013).   
16/06/2015 02:52PubMed Central, Fig. 2: Hum Genet. 2013 Jun; 132(6): 603–617. Published online 2013 Mar 17. doi:  10.1007/s00439-013-1286-3
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Fig. 2
Theoretical example of filtering steps used to limit number of variants identified by exome sequencing. The
three examples indicate two affected individuals who are related to different degrees. Comparing the
exomes of siblings, 1st cousins or 2nd cousins will limit candidate variants to the roughly 1/2th, 1/8th or
1/32nd of the genome, respectively, that is shared by two such individuals. Additional discrete filtering and
bioinformatics steps c n further reduce the number of candidate variants. Exampl s assume that all but 2 %
of variants will be identifi d in public databases such as dbSNP a d 1000 Ge omes Project and that
approximately 20 % of nov l variants ill be predicted to be deleterious to the fu ction of the encoded
protein
HUMAN GENETICS
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Sequencing parents-child trios for de novo mutations  
If a de novo mutation is suspected to be responsible for the phenotype, then exomes of 
parent-child trios should be sequenced. In this case only the child would be affected and 
excluding all variants shared between parents and their offspring would give a list of 
variants that are unique to the child and thus could be causative. This strategy was used 
in such complex traits as autism spectrum disorder (Neale et al., 2012; O'Roak et al., 
2012), schizophrenia (Girard et al., 2011), and mental retardation (Vissers et al., 2010). 
Exome sequencing of parent-child trios was also proved to be effective in such common 
neurodegenerative disorders such as amyotrophic lateral sclerosis (Steinberg et al., 
2015) and multiple sclerosis (Dyment et al., 2012). 
1.4.7. Establishing number of cases needed for an exome sequencing study 
There are several aspects to consider before undertaking an exome sequencing study. 
The most important step is to establish the number of cases which would be optimal for 
the particular exome sequencing study. 
Mendelian diseases 
It is anticipated that for Mendelian diseases, where disease-specific alleles have a large 
effect size, exome sequencing of as little as one individual will be needed for successful 
identification of causative variants (Figure 1.7).  
 
Sporadic diseases 
For sporadic and occasionally familial clustering cases only tens to hundreds of 
individuals might be enough to elucidate rare causative variants with moderate effect 
size (Tsuji, 2010).  
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Figure 1.7: The estimated number of individuals needed for identification of 
disease causing variants in different groups of diseases employing whole genome 
sequencing and whole exome sequencing. 
For Mendelian diseases, where disease-specific alleles have a large effect size, only 
several individuals are needed for successful identification of causative variants. For 
sporadic and occasionally familial clustering cases only tens to hundreds of individuals 
might be enough for elucidating rare causative variants with moderate effect size. For 
common diseases, where disease-causing common variants have small effect size, 
hundreds to thousands of individuals are needed (adapted from Tsuji, 2010).  
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Common diseases 
To associate rare variants with common, complex diseases would require a large 
number of cases because for most human genes the power to detect associations is low 
(Tennessen et al., 2012). It is estimated that for common diseases, where disease-
causing common variants have a small effect size, hundreds to thousands of individuals 
are needed in order to identify causative variants (Tsuji, 2010). 
1.4.8. Application of exome sequencing in different settings 
Ng and colleagues were the first to use exome sequencing to find a cause of Miller 
syndrome, a rare recessive Mendelian disorder (Ng et al., 2010b). This study pioneered 
the approach for identification of a cause of rare disorders in situations where large 
families are not available for linkage analysis and only a very small number of affected 
individuals are accessible for the study. Since then exome sequencing has proved to be 
useful in very different settings. 
Combining exome sequencing with linkage analysis 
Combining exome sequencing with linkage analysis, in multi-generation families with 
multiple affected and unaffected individuals, could aid in narrowing down a list of 
candidate genes. For example, in a study of spinocerebellar ataxia, combining exome 
sequencing and linkage analysis in three unrelated families of different ethnicity helped 
to identify the cause of the disease as mutations in the voltage-gated potassium channel 
Kv4.3-encoding gene KCND3 (Lee et al., 2012). In a more recent study of 
spinocerebellar ataxia type 21, in a large French family with 11 affected members, the 
addition of 12 family members enabled the authors to reconsider previous linkage 
analysis and map the disorder to chromosome 1 instead of chromosome 7, as previously 
proposed (Delplanque et al., 2014). Furthermore, the subsequent whole exome 
sequencing of the affected members enabled the authors to identify the causative 
mutation in the transmembrane protein gene TMEM240. The combination of linkage 
analysis and whole exome sequencing enabled the authors to establish that a mutation in 
KCTD17 was a cause of autosomal dominant myoclonus-dystonia in a British pedigree 
consisting of 7 affected subjects (Mencacci et al., 2015). Finally, in a recent study of a 
consanguineous Palestinian Arab family, with recessive progressive myoclonus 
epilepsy with early ataxia, the combination of linkage analysis and WES led to the 
discovery of a novel homozygous missense mutation in LMNB2 as a cause of the 
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observed phenotype (Damiano et al., 2015). 
 
Exome sequencing and homozygosity mapping 
In situations where traditional approaches could be used (for example, homozygosity 
mapping), exome sequencing may simply accelerate the study. For example, Doi and 
co-workers, in their study of a Japanese family with autosomal recessive cerebellar 
ataxia, combined homozygosity mapping with exome sequencing and identified a 
homozygous missense mutation in synaptotagmin XIV (SYT14) as a cause of the 
disease (Doi et al., 2011). 
 
Exome sequencing in diseases with locus and phenotypic heterogeneity 
When a conventional approach could not be successfully applied, exome sequencing 
becomes the method of first choice. For example, for diseases characterised by locus 
heterogeneity, it would be very laborious and expensive to screen all candidate genes 
for the casual mutation via PCR and Sanger sequencing. Exome sequencing could be a 
cost- and time-efficient approach in this setting. For example, in a recent study of three 
unrelated Tunisian families, diagnosed with autosomal recessive cerebellar ataxia 
(ARCA), exome sequencing was performed alongside homozygosity mapping and a 
new mutation in the SACS gene, as well as a known mutation in the SPG11 gene, were 
identified. This study also identified a mutation in APOB, a gene previously associated 
with ataxia (Hammer et al., 2012). Likewise, exome sequencing may prove very useful 
in dissecting diseases with phenotypic heterogeneity where only the most likely disease 
genes are routinely prioritised for screening (Ku et al., 2012). 
 
Exome sequencing in complex diseases 
Complex neurological diseases are very difficult to dissect at present. Nevertheless, the 
application of exome sequencing for these scenarios was recently shown to be very 
promising. De novo mutations are the most deleterious form of rare genetic variations 
and are more damaging than inherited variants. This is because, being private, they have 
not been subjected to purifying selection (Brunham and Hayden, 2013). Until recently it 
was not possible to investigate the involvement and role of these mutations in the 
disease.  
Exome sequencing of parent-child trios made it possible to realize that de novo 
mutations are the main contributors to complex forms of neurodevelopmental disorders 
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with severely reduced fitness, such as autism, intellectual disability and schizophrenia 
(Veltman and Brunner, 2012). Girard and colleagues, for example, sequenced exomes 
of 14 schizophrenia patients and their unaffected parents and demonstrated that de novo 
mutations occur at a much higher frequency than expected by chance (Girard et al., 
2011). Recent pilot studies of autistic-spectrum disorders (Neale et al., 2012; O'Roak et 
al., 2012; Sanders et al., 2012) and intellectual disability (Vissers et al., 2010) also 
suggested that de novo mutations are a major cause of sporadic cases of these diseases. 
This also highlighted the mechanism by which de novo mutations could contribute to 
these diseases being frequent in the human population. Interestingly, de novo mutations 
were not bound to a single gene, but rather were found in different genes with a role in 
neurodevelopment. It is anticipated that de novo mutations may also play a significant 
role in many other common diseases (Veltman and Brunner, 2012).  
Complex neurological disorders, such as Parkinson’s disease, Alzheimer’s disease and 
amyotrophic lateral sclerosis are relatively common, with both common and rare 
variants contributing to their pathogenesis (Foo et al., 2012). Over recent years, 
multiple studies reported successful application of exome sequencing to identify 
causative rare mutations in familial forms of complex neurological disorders.  
In 2011 two research groups simultaneously published their studies identifying a 
mutation in VPS35 as a cause of autosomal dominant late onset Parkinson’s disease 
(PD) in several unrelated pedigrees. The first group (Vilarino-Guell et al., 2011) applied 
whole exome sequencing to a Swiss kindred and three unrelated families who presented 
with late onset PD and a sporadic case. A mutation in VPS35 (c.1858G>A; 
p.Asp620Asn) was found in all affected individuals but was absent in 3,309 controls. 
Similarly, the second group (Zimprich et al., 2011) employed whole exome sequencing 
in 16 affected individuals from an autosomal dominant Austrian family who presented 
with late onset PD and found that a mutation in VPS35 (c.1858G>A; p.Asp620Asn) 
segregated with the disease. 
Whole exome sequencing was also successfully applied in recent studies on the 
pathogenesis of unexplained cases of Alzheimer’s disease. (AD) For example Guerreiro 
and co-workers employed whole exome sequencing in order to find a genetic cause of 
AD in an early onset Turkish patient from a consanguineous family (Guerreiro et al., 
2012). The patient was found to have the same mutation in NOTCH3 that was 
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previously linked to cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy.  
Similar success of the application of whole exome sequencing in complex neurological 
disorders was reported recently in amyotrophic lateral sclerosis  (ALS). Familial ALS 
cases constitute about 10% of all ALS cases (Dion et al., 2009). Of all familial cases, 
about 50% still remain unsolved (Jiang et al., 2014). For example, in one study whole 
exome sequencing was applied to a large Chinese family who presented with autosomal 
dominant ALS. A novel SOD1 p.Cys146X mutation was found to segregate with the 
disease (Wu et al., 2012b). In a more recent study, whole exome sequencing was 
employed to find a cause of ALS and dementia in a Caucasian family and found a 
MATR3 mutation p.Phe115Cys in all affected individuals, but not in 27, 666 control 
chromosomes (Johnson et al., 2014). Exome sequencing of an additional 108 cases with 
familial ALS led to the identification of a  MATR3 p.Thr622Ala mutation in a Sardinian 
family. These findings prompted re-sequencing of the entire MATR3 gene in 96 British 
ALS cases and resulted in the identification of a MATR3 mutation p.Pro154Ser in an 
individual who presented with sporadic ALS.  
Studies in sporadic neurological diseases supported the causative role of de novo 
mutations in these diseases. For example, Rosewich and co-workers sequenced exomes 
of three parent-child trios and identified three heterozygous de novo mutations in the 
ATP1A3 gene as a cause of alternating hemiplegia of childhood (Rosewich et al., 2012). 
Interestingly, ATP1A3 has been previously associated with rapid-onset dystonia. This 
and other studies highlighted the importance of the observation of de novo mutations in 
a gene previously reported to be involved in the phenotype. 
Exome sequencing for mosaic variant discovery 
Recent studies imply that exome sequencing could be applied in the identification of 
mosaic mutations. In order to find a cause of hypomyelination with atrophy of basal 
ganglia and cerebellum (H-ABC), Simons and co-workers performed exome sequencing 
in 10 families (5 trios, 2 quartets and 3 single probands) (Simons et al., 2013). One of 
the quartets consisted of asymptomatic parents and severely affected siblings. 
Seemingly sporadic presentation and severity of H-ABC in an affected individual would 
normally indicate that the disease is caused by a de novo mutation. However, in the case 
of this quartet, exome sequencing showed that the father was homozygous wild-type 
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and the mother shared a TUBB4A c.745G>A; p.Asp249Asn mutation with both siblings. 
Detailed investigation of exome sequencing reads revealed that in the mother the ratio 
of wildtype to mutant allele was 3.6:1, which was considerably higher than in all other 
affected heterozygous individuals included in the study (1.0:1 – 1.4:1). This finding 
suggested mosaicism in the mother. Deep sequencing of DNA from blood, saliva and 
buccal cells confirmed the mosaicism in the asymptomatic mother. Overall, this study 
indicated that de novo mutations in asymptomatic mosaic individuals could cause 
disease in offspring, if inherited. 
 
Mitochondrial exome sequencing 
Calvo and colleagues used the principal of exome sequencing to identify the genetic 
cause of a mitochondrial disease in 42 unrelated infants with clinical and biochemical 
evidence of mitochondrial OXPHOS disease (Calvo et al., 2012). Inherited defects in 
OXPHOS could be caused by mutations in either mitochondrial DNA (mtDNA) or 
nuclear DNA. Therefore, researchers performed “MitoExome” sequencing of the 
mtDNA as well as approximately 1000 nuclear genes encoding proteins targeted to 
mitochondria. They further prioritized rare variants disrupting protein function. Their 
choice of mitochondrial nuclear genes was based on the MitoCarta inventory (Pagliarini 
et al., 2008). The approach by Calvo and co-workers enabled the identification of novel 
nuclear-encoded mitochondrial genes NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 3 (NDUFB3) and acylglycerol kinase (AGK), which previously were not 
linked to disease. 
1.5. Neurological disorders: the importance of a diagnosis 
Neurological disorders represent a vast group of diseases which manifest as a range of 
diverse phenotypes. Most neurological disorders are highly heterogeneous and 
individually very rare. Furthermore, many neurological diseases exhibit phenotypic 
overlap. This substantial clinical spectrum, together with immense genetic 
heterogeneity, makes precise molecular diagnosis difficult. For patients with 
neurological phenotypes, establishing the diagnosis involves stepwise testing, which is 
expensive and time consuming (Warman Chardon et al., 2015). Many patients, who 
present with a rare neurological phenotype, may never receive a molecular diagnosis 
(Shashi et al., 2014). Accurate and timely diagnosis is crucial because for some 
neurological diseases treatment could be available (Toscano and Schoser, 2013). 
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Correct molecular diagnosis could also assist in patient management and limit 
unnecessary and invasive tests. For example, identifying mutations in the SLC2A1 gene 
in patients presented with Glucose transporter type 1 deficiency syndrome enables 
implementation of the ketogenic diet. The latter treatment result in reduction of seizure 
frequency for up to 50% (Klepper, 2015; Schoeler et al., 2015). Precise molecular 
diagnosis of rare neurological disorders is vital because it would eventually define the 
pathways involved in the disease. This would potentially result in identifying new 
therapeutic targets. Exome sequencing is gradually establishing itself as an excellent 
tool to elucidate causative mutations in various neurological diseases. 
1.6. Research project structure 
The research presented in this study aims to evaluate the application of whole-exome 
sequencing for the molecular diagnosis of unexplained neurological disorders. General 
materials and methods (Chapter 2) are followed by the investigation of approaches to 
filtering of exome sequencing data from large cohorts (Chapter 3). To investigate the 
use of whole exome sequencing for the molecular diagnosis of neurological disorders 
we performed whole exome sequencing in a heterogeneous cohort of patients with 
suspected inherited ataxia as an example of a neurological disorder (Chapter 4). We 
then move on to performing molecular genetic analysis to determine pathogenicity of a 
heterozygous splice site mutation in ZFYVE27 in an autosomal dominant pedigree 
(Chapter 5) and TUBB4A mutations in an autosomal dominant pedigree and a sporadic 
case (Chapter 6). Finally, we evaluate the pathogenicity of mutations in ZFYVE26, 
FASTKD2 and KCNB2. 
1.6.1. Research Aims 
• To assess the use of whole exome sequencing for diagnostic purposes in 
neurological disorders 
• To identify novel ataxia genes 
• To investigate the pathogenicity of mutations in novel ataxia genes  
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Chapter 2 
Materials and Methods  
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Chapter 2. Materials and Methods 
2.1. Ataxia patient cohort 
We have collected 22 randomly selected families of white European origin with 
unexplained ataxia and no known consanguinity. All subjects studied gave written 
informed consent. The cohort consisted of 35 affected individuals identified through 
routine referrals to the regional neurogenetics service at Newcastle upon Tyne. 25/35 
had a family history, suggestive of autosomal dominant inheritance (11/25) or 
autosomal recessive inheritance (14/25). All treatable and most common inherited 
causes of ataxia were excluded on routine clinical investigations. Clinical presentation 
and all routine clinical investigations performed on these patients were previously 
published and are summarised in Table 4.5 (Pyle et al., 2014).   
2.1.2. Control group for case-control study 
In order to exclude variants commonly found in specific ethnic groups this study 
collected DNA from 302 healthy individuals with the same ethnic background as the 
cohort presented here.  
2.1.3. In-house control panel for exome sequencing 
An in-house control panel of 286 exomes derived from unrelated individuals was used 
to filter for rare variants below a designated MAF (typically MAF<=0.01). 
2.2. Patient DNA 
Patients DNA was extracted from various tissues as described below. For some patients 
DNA samples were provided by Northern Genetics Service (The Newcastle upon Tyne 
Hospitals NHS Foundation Trust, Newcastle upon Tyne). All patient DNA samples 
were stored at -20oC. 
2.2.1. Genomic DNA extraction from blood 
Genomic DNA was extracted from blood using a Nucleon® Genomic DNA Extraction 
Kit (Hologic Gen-Probe Incorporated, San Diego, USA) following the manufacturer’s 
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protocol. 
2.2.2. Genomic DNA extraction from Buccal swabs 
Genomic DNA was extracted from Sterilin buccal swabs (Copan, Brescia, Italy) using 
QIAamp® DNA Mini Kit (QIAGEN, Manchester, UK) as per manufacturer’s protocol. 
2.2.3. Genomic DNA extraction from hair root cells 
Genomic DNA was extracted from hair root cells using QIAamp® DNA Mini Kit 
(QIAGEN, Manchester, UK) following manufacturer’s protocol. 
2.2.4. Genomic DNA extraction from cultured fibroblasts 
Genomic DNA was extracted from cultured fibroblasts using QIAamp® DNA Mini Kit 
(QIAGEN, Manchester, UK) as per manufacturer’s protocol. 
2.2.5. Genomic DNA amplification 
In order to increase the amount of patient DNA available for sequencing studies, whole 
genome was amplified from patient DNA samples using a REPLI-g Mini Kit 
(QIAGEN, Manchester, UK) following the manufacturer’s protocol. 
2.3. Control DNA 
Control DNA was extracted from anonymous blood samples from healthy individuals 
using a Nucleon® Genomic DNA Extraction Kit (Hologic Gen-Probe Incorporated, San 
Diego, USA) following the manufacturer’s protocol. 
2.4. Whole exome analysis 
2.4.1. Whole exome sequencing 
Whole-exome sequencing was performed on one or several individuals from each 
pedigree depending on the mode of inheritance of the disease. Whole-exome 
sequencing was outsourced to AROS (AROS Applied Biotechnology A/S, Aarhus, 
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Denmark). Genomic DNA was subjected to a library preparation using TruSeqTM DNA 
Sample Preparation Kit (Illumina Inc., San Diego, USA) and the targeted regions were 
captured using the TruSeqTM 62 Mb Exome Enrichment Kit (Illumina Inc., San Diego, 
USA). The captured fragments were sequenced on an Illumina HiSeq2000 platform 
(Illumina Inc., San Diego, USA) producing 100 bp paired-end reads. 
2.4.2. Bioinformatics 
Bioinformatic analysis was performed using an in-house algorithm incorporating the 
published tools. The following was performed by Dr. Helen Griffin (Newcastle 
University): the reads were aligned to the human reference genome (UCSChg19) using 
Burrows-Wheeler Aligner (Li and Durbin, 2010), PCR duplicates were removed with 
Picard v1.85 (available at http://broadinstitute.github.io/picard/), single base variants 
(SBV) and insertions/deletions (indels) were identified with Varscan v2.2 (Koboldt et 
al., 2009) and Dindel v1.01 (Albers et al., 2011) respectively.. 
2.5. Sanger sequencing validation of prospective variants 
In order to verify that the gene variants identified by exome sequencing were not 
artefacts, Sanger sequencing was performed to confirm the mutations. 
2.5.1. Primer design 
Primer oligonucleotide sequences specific for the genes of interest were designed using 
Primer 3 (v.0.4.0) software (available at http://frodo.wi.mit.edu). Primer 3 specifies 
product size as well as melting temperature of the designed primers and their GC 
content (%). Target DNA sequences were uploaded into the online software and primer 
sequences selected to span the region of interest. The generated primer sequences were 
checked for specificity using the online program Basic Local Alignment Search Tool 
(BLAST) (available from http://blast.ncbi.nlm.nih.gov/Blast.cgi). This program is 
provided by the National Centre for Biotechnology Information (NCBI) (available from 
http://www.ncbi.nlm.nih.gov). BLAST identifies homologous regions in sequences by 
comparing nucleotide sequences to sequence databases and calculates statistical 
significance of matches. All primers used in this study to date are listed in Table 2.1. 
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Table 2.1: Primer sequences, annealing temperatures and amplicon sizes 
Gene Variant Forward Primer Sequence 5'-3' 
Reverse Primer Sequence 
5'-3' 
Anneal
temp 
(˚C) 
PCR 
product 
size (bp) 
ABCB7   
GCAGTGTGAAAGGCAG
AGGAAAGT 
TCTTTTGACCGAGATTT
GCTGTTGTGT 65 400 
AKAP4   
GGGCTGCCCCATCGTTG
CTA 
GGAGGTGGCCAAAGTG
CCAA 65 
 
400 
ATP1A3   
CTGGCACCCCAGGCCTT
CAC 
CGCCACCTCGCAGGAC
AAGA 65 
 
394 
ATXN7 1 
TGGCTCACCATTCACCT
GGGGG 
CACACACACACACTCA
TGCTCT 65 520 
ATXN7 2 
CCCTACCCCTCAACGGT
AACA 
CTTGTGCCCCTGGGAT
GGTG 65 
 
400 
 
C12ORF65   
GCATAATCTTGAGGGCA
GATG 
GGCCCAAGCCAGAAA
AATA 
 
65 486 
CACNA1A   
ACCACCCCCACTGCTTC
CCA 
ACCAATAGCAGGTACC
CATTCCA 
61, 
DMSO 346 
 
CEP68   
TCTCCCTTCCCCTGTTTT
GTAGGA 
GGCAGGCCACTGAGTG
CAGG 65 
 
376 
CIT   
CAGGCGGCTGTAGTCCC
AG 
GCAAACATCTCTGCCC
TTGTGG 
 
63 600 
COL1CA1   
ACAGTAAAAGCAGACA
CAGGCATT 
GGCCCAGCAGGAGCA
AAGGG 65 
 
395 
CSTB   
CTCTCACGGCCACAGCC
CG 
ACGATACCAGCCCCGG
GAGG 65 
 
499 
DACH2   
TTTTGAAATTAGAGGCA
GCTGGAGAA 
ACCCTGTCAAGGTACA
GGAAATGACA 65 
 
443 
FASTKD2 1 
GAAGCGCAGCTTCTCGG
GGA 
CGGCCGAACCCAGACC
ATCA 
 
65 
 
373 
FASTKD2 2 
AGCCATTTGGAAGTGTT
TCAGTGGAG 
GTGCTTATGCCCTTTGT
TTGAAAGCCA 
 
65 
 
274 
FASTKD2 3, 4 
CCCCTACAGGAAAACG
ACAGCACG 
AGGGCTGTTAGAGTGC
TTATGCC 65 
 
361 
FASTKD2 5 
TGAGCCTGGGAGGTTG
AGGCT 
TGGTACTGGAGGTCTT
TGCAGGA 65 
 
479 
FASTKD2 6 
ACCAACTGTCCAGAATG
ATGTGTG 
TCCACAGCAACACCTG
CTCTGC 65 
 
427 
FASTKD2 7 
ACATGAAGAATGCTTAC
AAGCTGCATA 
GGCCAGTTCCAGAGGC
AATGCTG 65 
 
338 
FASTKD2 8 
AGCTTTCTTAAACCCTA
GCATGTAGTC 
TGTGTGCTTTGCACATT
TACAGCAG 65 
 
296 
HSPG2 1,2 
CACCATCGGCTGAGTCG
GGC 
GTCCCCAGGATGTGGC
ACAGG 
65, 
DMSO 484 
HSPG2 3 
GCAGCGCCTGGAGACC
TCTG 
CCAGGGGTGGGGAGTA
CGGG 65, Bet 470 
HSPG2 4 
GCCTTCGACCCACCCTC
CCA 
GGGAGACAGGTGCCCA
CCCA 
65 
DMSO 458 
HSPG2 5,6 
CTGGGGCCAAAGGGGC
AGAG 
GCTTCCACCAGCCCTA
CCAGC 
65, 
DMSO 370 
HSPG2 7 
GCGCCACTTGTCTGTAC
CCCC 
GGCCACTGAGGAGGCA
AGGC 65, Bet 
 
295 
HSPG2 8 
GTGTGACGGGAAGGCG
GTGG 
GCTGGAGGGGCTGGAT
GGGA 
65, 
DMSO 366 
HSPG2 9 
TCGAGTGTTTGCCCTTC
TGT 
TAATATTGGCCCTGCA
CCTG 
65, 
DMSO 397 
HSPG2 10 
GGGCGTGAAGGGGGAG
GGAA 
TTGTGCCGAGCCCACA
GCAG 
65, 
DMSO 363 
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Table 2.1 continued 
Gene Variant Forward Primer Sequence 5'-3' 
Reverse Primer Sequence 
5'-3' 
Anneal
temp 
(˚C) 
PCR 
product 
size (bp) 
HSPG2 11 
CCCCACCCCTCTGCTCC
CAG 
TTCAGCCCCAGCCTGG
CTCA 
65, 
DMSO 333 
IGDCC3 1 
CCACATCTTTACACAGG
AGGACCC 
GTCCCCAGAGGCTGGG
TGTT 
 
65 
 
364 
IGDCC3 2 
GGTGGGCAGGGGAGTG
TGAA 
GGAGTCCCAGTTCCAC
CACCA 
 
65 
 
579 
JPH2   
ACCCTCCACACTGTGCT
CCA 
CGATATCGACGCCACC
ACCA 
58, 
DMSO 
 
274 
KCNA1   
TTCTTCGCCTGCCCCAG
CAA 
ACACCACCGCCCACCA
GAAA 65 
 
388 
KCNB2 1 
TGCCTTCGCTCGAAGTA
TGGAACT 
GGCCAGCTGCTCCTGT
GGAC 65 394 
KCNB2 2 
CCAGCACAGCCAGGCC
ACTG 
TCCTGCGGGGAGGAAG
AGCC 
65, 
DMSO 382 
KCNC3   
GGTCGTCATGGTGACCA
CAGCCCA 
TGGAGGTGGAGACGG
AGCCCT 
65, 
DMSO  491 
KCNH8   
AGCACCTCTGTGTGTCC
CTCC 
GCTGAAATGGACTGCA
GAGGCGT 65 
 
350 
KIAA0196   
CTTAGGGTACTGACTCT
TCCTTGGGA 
AACATGGAGTGGGTAT
TGCCTTCT 
 
58 
 
444 
LAMP3   
GCAAGGCAACCTCCACT
CAGACT 
GGCCACACCCAACAAC
TCACACA 
 
65, Bet 498 
MICALCL 1 
AACTGCTATTTTTGCCC
ATCCCA 
TGGGGTGTGGGTCTCT
GTGGT 65 
 
299 
MICALCL 2 
TAGGGCAGCAGGAGAG
CCCC 
TGGGCAAACTGTGGGT
GCGG 65 
 
350 
MLL2   
CATGGTGAGCCCTGCCC
TGC 
CCAGCCTTGGAACCCA
GTGCC 65 
 
296 
MYH14   
CAGGCTCTGTGCTATGC
GTGTG 
TCCGCTCTCACCTACCT
GGTCT 
 
65 
 
346 
NEFH   
AAATCCCCAGCCGAAG
TC 
TGGAGTCTTGGCTTCT
GGAG 65 693 
NPC1 1 
GCTCTGACAAATGAAA
GCTCAA 
AGGACGAAGCAGCAA
AACAT 
 
65 
 
494 
NPC1 2 
CCTGGTCTTAAGCAATT
CTCTTG 
TCTCTGTTCGTGCCCTT
AGTTAG 
 
65 
 
447 
OBFC2A   
ATGGGACATAATCATTT
GGGAAGTTTTTG 
ACTCAGCACACCACAA
AGTGCAA 65 
 
447 
SACS 1 
ACTTGTTCAAGCTGTTC
TTGTGGACC 
CCATTCTTATGTCCTGA
GCGGGC 
 
65 
 
247 
SACS 2 
GTGGTGAGCTGAGATTG
TGCC 
GTGTTCCGTGGAATAT
TCACTTCTCC 
61, 
DMSO 
 
390 
SLC18A2   
TGTGCGGTCTTGGACCC
CCT 
AACAGGCCAGCTCCGG
GGAA 65 
 
365 
SLC1A3   
TGCAGTTGGTAGATACG
GCGAAC 
ACATCTTGGTTTCACT
GTCGATGGGT 65 
 
328 
 
SLC22A16   
GTGTCCCAAGAAAACC
AGATAGGAAA 
AGCAGGAATAAGAGG
GAGAACACA 65 
 
300 
SPG7   
CGCGGATCACGCAGGC
GCGG 
TGCTACGCCGGAAACC
GTTACTGGAT 
61, 
DMSO 542 
SPG7 1 
CAAAGCCACCGTCACTT
GT 
GATCTTGGCTCACCAC
AACC 
57, 
DMSO 
 
483 
SPG7 2 
TGGTTTTTGTTTTGCTTT
GG 
CATCTCCCCATTTTCCA
GAC 
 
63 
 
297 
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Table 2.1 continued 
Gene Variant Forward Primer Sequence 5'-3' 
Reverse Primer Sequence 
5'-3' 
Anneal
temp 
(˚C) 
PCR 
product 
size (bp) 
SPG7 3 
ACGAGGTAGACGGGCT
CAG 
CAGACGGGTTGGGAAA
GTC 
 
59 
 
600 
SRRM4 1 
TCGGGAGGGATGGTGA
CCAGTG 
ACCGCACCCAGGCTCT
CCAG 
65, 
DMSO 391 
SRRM4 2 
AGCCCCTCCTCATCCGG
CAG 
AAGAAGGCGGGGAGG
GCAGG 67, Bet 348 
TDP1   
GCACAGCCAGCAGAAT
TATGGGC 
GGGTATCATCTGCGGA
ATGCAGAGC 58 528 
TNNT2   
CACCCACAGCAGCTGG
GAATCT 
CAGCCCAGAATCAGGG
TTTCCA 
 
65 
 
299 
TPP1   
TCCGACACAGCCTGCAC
CAG 
ACAGACTGCCCCCTTC
CCCA 65 
 
385 
TTBK2   
ACAGGGACACACATGC
ATCAGGTT 
TCGCAGGAGTCCCAGT
GCCT 
65, 
DMSO 363 
TUBB4A 1 
GATCCACTCCACGAAGT
AGCTG 
GAGGCACTCTACGACA
TCTGTTT 
 
65 
 
423 
TUBB4A 2 
GGTCATTCATGTTGCTC
TCGGCCT 
AACATGATGGCGGCGT
GCGA 
 
65 
 
361 
USH2A 1 
TGGCTTGGATGGTGGTT
GCC 
AGGCCTCGTGAACTTC
AATTGCT 65 
 
388 
USH2A 2 
AGCCTTTCTGATGGGTT
CTAAATGGA 
ACGGGTTTTACCAGGA
ACAGTAGT 65 
 
478 
VARS2 1 
CTCTTGGCAGGTTCCCC
CTG 
GCCCCCACTCCCCTCT
CAC 
 
66 
 
300 
VARS2 2 
CACCTGTCAGCTGTTCT
TCCTCAC 
CCCAGAGACCAGGGCT
GTCC 
 
66 
 
298 
WNK1 1 
TGCTGTTTCCCTTACTC
CTCAGGTGG 
GCAGACTATCCATTGG
CTCTCATTGT 65 480 
WNK1 2 
ACTGGCCAATAGGAAG
CCCAGA 
CCCCAAAGATGGGGAA
ACTCTACTGA 65 400 
ZFYVE26 3 
TGCTCCCAGGTGGCTCT
GGT 
CCCAAAGAAGGTAGTT
GGCACTTAGCA 65 448 
ZFYVE26 4 
TCCCTTCTCCCAGCTAA
AATCTGGC 
AGCCCACCCTTTGCCT
TTGGT 65 398 
ZFYVE27   
CTTCAACCACTGTGCGA
TGT 
GGCTCAACCAGAAACA
GGAG 65 481 
ZKSCAN4   
GTCTTAAAATACAGCTC
TCTGTGATGAGT 
GGATCCGGGCCACATC
TCCG 65 
 
461 
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2.5.2. Standard polymerase chain reaction (PCR) 
PCR was performed in a final reaction volume of 25 µL containing 1U Immolase™ 
DNA Polymerase (Bioline, London, UK), 0.2mM dNTPs (VHBio, Gateshead, UK), 1x 
ImmoBuffer (160mM (NH4)2SO4, 1M Tris-HCl pH 8.3; Bioline, London, UK), 4mM 
MgCl2 (Bioline, London, UK), 0.25µM of each forward and reverse primers and 1 µL 
of total genomic DNA extract containing on average 25ng DNA. Where GC-rich 
primers affected amplification efficiency, addition of 1M Betaine (Sigma-Aldrich, 
Dorset, UK) or 10% dimethylsulphoxide (DMSO) (Sigma-Aldrich, Dorset, UK) was 
required in order to reduce the formation of secondary structures in GC-rich regions 
(Sun et al., 1993; Henke et al., 1997). PCR reactions were performed in a Veriti® 96-
well Thermal Cycler (Life Technologies Ltd., Paisley, UK). PCR conditions involved a 
hot start at 95oC for 10 minutes, followed by 30 cycles of denaturation at 95oC for 1 
minute, annealing at the relevant primer annealing temperature (Table 2.1) for 1 minute, 
extension at 72oC for 1 minute. The final extension step was performed at 72oC for 10 
minutes, followed by cooling the reaction to 4oC. The PCR reactions were stored at -
20oC. 
2.5.3. Agarose gel electrophoresis 
Agarose gel electrophoresis allows visualisation of PCR products and is used for 
determining the amount, purity and amplicon sizes of amplified DNA fragments. 2% 
agarose gel was prepared with molecular grade agarose (Helena Biosciences Europe, 
Gateshead, UK) and 1x TAE buffer (0.04M Tris acetate, 0.001M EDTA; Severn 
Biotech Ltd., Worcestershire, UK) and contained 0.4 µg/ml Ethidium Bromide (Sigma-
Aldrich, Dorset, UK) to aid the visualisation of DNA. 5µL of each amplified PCR 
product was mixed with 5µL of Orange G loading buffer (50% glycerol (Sigma-
Aldrich, Dorset, UK), 50% H2O, Orange G (Sigma-Aldrich, Dorset, UK)), loaded onto 
the agarose gel, along with 5µL of Hyperladder IV (Bioline, London, UK) DNA 
marker. These were electrophoretically separated (Scie-Plas, Severn Biotech Ltd., 
Worcestershire, UK ) in 1x TAE buffer at a constant voltage of 65 V. The PCR products 
were visualised by exposure to the UV light using GelDoc-It®2 Imager (UVP, LLC, 
Cambridge, UK)  
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2.5.4. Exonuclease I/FastAP treatment 
The clean-up reaction removes unincorporated primers and degrades unincorporated 
nucleotides, which would otherwise interfere with the sequencing reaction. In order to 
clean-up the PCR product prior to sequencing, 10 U of Exonuclease I (Thermo Fisher 
Scientific Inc., Leicestershire, UK) and 1 U of Thermo Scientific FastAP 
Thermosensitive Alkaline Phosphatase (Thermo Fisher Scientific Inc., Leicestershire, 
UK) were mixed with 20 ng of the PCR amplicon in a 96-well plate (Greiner Bio-One 
Ltd., Gloucestershire, UK). The enzymatic reaction was performed in a Veriti® 96-well 
Thermal Cycler (Life Technologies Ltd., Paisley, UK) and involved incubation at 37oC 
for 15 minutes, followed by enzyme inactivation at 85oC for 15 minutes.  
2.5.5. BigDye® Terminator sequencing 
Sequencing of the PCR amplicons was performed using the BigDye® Terminator v3.1 
Cycle Sequencing Kit (Life Technologies Ltd., Paisley, UK). This kit contains all 
reagents required for the sequencing reaction. Following the Exonuclease I/FastAP 
treatment, a mastermix of 1 µL of BigDye® Terminator v3.1 Ready Reaction Mix, 2 µL 
of BigDye® Terminator v1.1/v3.1 5X Sequencing Buffer and 0.5 µM of appropriate 
forward or reverse gene specific primer was added to the enzymatic reaction mix and 
made up to 20 µL with dH2O. The BigDye® Terminator cycle sequencing was 
performed in a Veriti® 96-well Thermal Cycler (Life Technologies Ltd., Paisley, UK). 
The reaction conditions involved an initial denaturing step at 96oC for 1 minute, 
followed by 25 cycles of 96oC for 10 seconds, 50oC for 5 seconds and 60oC for 4 
minutes. 
2.5.6. Ethanol/EDTA/sodium acetate precipitation 
Unincorporated dye-labelled terminators in the sequencing reaction interfere with the 
downstream sequencing process and therefore should be completely removed prior to 
electrophoresis. In order to do this, ethanol-aided precipitation of the cycle sequencing 
product was performed. A mixture of 2 µL of 125mM EDTA (Sigma-Aldrich, Dorset, 
UK), 2 µL of 3M sodium acetate (Sigma-Aldrich, Dorset, UK), and 70 µL of 100% 
ethanol (VWR International Ltd., Leicestershire, UK) was added to each cycle 
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the plate was centrifuged at 2000 g for 30 minutes. The supernatant was removed by 
inverting the plate on tissue and centrifuging briefly at 100 g. Following this, 70 µL of 
70% ethanol (VWR International Ltd., Leicestershire, UK) was added and the sample 
centrifuged at 1650 g for 15 minutes. The supernatant was removed by inverting the 
plate on tissue and briefly centrifuging at 100 g. The sample was then air dried for 10 
minutes in the dark to allow the evaporation of the remaining ethanol. 
2.5.7. Capillary electrophoresis sequencing 
The precipitated pellets were resuspended in 10 µL highly de-ionized formamide       
(Hi-Di™, Life Technologies Ltd., Paisley, UK) and incubated for 2 minutes at 95oC in a 
Veriti® 96-well Thermal Cycler (Life Technologies Ltd., Paisley, UK). Following the 
incubation, the plate was briefly chilled on ice and then loaded into the ABI PRISM® 
3100 Genetic Analyser (Life Technologies Ltd., Paisley, UK) to allow capillary 
electrophoresis sequencing. 
2.5.8. Sequence analysis 
The generated sequence data (electropherograms) were analysed using SeqScape® v2.6 
Software (Life Technologies Ltd., Paisley, UK). This software allows mutation 
detection and analysis by comparing nucleotide sequences to manually uploaded 
chromosome reference sequences from Ensembl Genome Browser (available at 
http://www.ensembl.org/index.html). 
2.6. Cloning from extracted PCR fragments and plasmid DNA sequencing 
2.6.1. PCR and extraction of DNA fragments 
PCR amplicons were generated as described in Section 2.5.2 and electrophoretically 
separated on 1-3% agarose gel as described in Section 2.5.3. The percentage of the 
agarose gel was dependent on the size of the amplicon of interest (i.e. 1% gels for 1kb 
amplicons) and the size difference between amplicons of interest (i.e. 3% gels for 
amplicons differing 15 bp in size). Following separation, the bands were excised from 
the gel and DNA was extracted using QIAquick® gel extraction Kit (QIAGEN, 
Manchester, UK) as per manufacturer’s protocol. The elution of DNA from the column 
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was performed using 30µL of water. 
2.6.2. Ligation  
The pGEM®-T easy vector system (Promega, Southampton, UK) was used for ligation 
of the extracted DNA fragment. Ligation reaction was performed in a final reaction 
volume of 10µL containing 5ng of pGEM®-T easy vector, 3 Weiss units of T4 DNA 
ligase, approximately 30ng of DNA fragment preparation and 1x ligation buffer. The 
ligation was incubated at room temperature for at least 16 hours. 
2.6.3. Transformation 
5 µL of the ligation reaction was added to 50µL of JM109 competent cells (Promega, 
Southampton, UK) and incubated for 20 minutes on ice followed by heat shock at 42oC 
for 45 seconds. The cells were then put on ice and incubated for 2 minutes. 800 µL of 
sterile 2YT broth containing 16 g/L tryptone (Sigma-Aldrich, Dorset, UK), 10 g/L yeast 
extract (Sigma-Aldrich, Dorset, UK) and 5 g/L sodium chloride (Sigma-Aldrich, 
Dorset, UK) was added to the cells and incubated for 90 minutes at 37oC. The cells 
were plated out on 2YT agar plates containing 15g/L agar (Sigma-Aldrich, Dorset, UK) 
and supplemented with 100 µg/mL Ampicillin (Sigma-Aldrich, Dorset, UK), 0.5 mM 
IPTG (Promega, Southampton, UK) and 75 µg/mL X-GAL (Promega, Southampton, 
UK) to allow blue/white selection of recombinants. The plates were incubated overnight 
at 37oC. Successful incorporation of the DNA fragment interrupts the α-peptide coding 
region of β-galactosidase enabling identification of recombinants by white/blue colour 
screening on the plates. 
2.6.4. Extraction of plasmid DNA (minipreps) 
Single colonies were transferred from the agar plates into 15mL Falcon tubes (Greiner 
Bio-One, Stonehouse, UK) containing 5mL of sterile 2YT broth supplemented with 
100 µg/mL Ampicillin (Sigma-Aldrich, Dorset, UK). The tubes were incubated 
overnight at 37oC in a rotary incubator. Following incubation the cultures were 
centrifuged at 3000 g for 10 minutes and the supernatant was discarded. Plasmid DNA 
was extracted using QIAprep® Spin Miniprep Kit (QIAGEN, Manchester, UK) as per 
manufacturer’s protocol. DNA was eluted in 50µL of dH2O. The plasmid DNA yield 
was determined using a NanoDrop 2000 Spectrophotometer (Fisher Scientific, 
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Leicestershire, UK). 
2.6.5. Sequencing of plasmid DNA constructs 
Sequencing of the plasmid DNA was performed using the BigDye® Terminator v3.1 
Cycle Sequencing Kit (Life Technologies Ltd., Paisley, UK). The cycle sequencing 
reaction was performed in a final reaction volume of 20 µL containing approximately 
200 ng of plasmid DNA, 1 µL of BigDye® Terminator v3.1 Ready Reaction Mix, 2 µL 
of BigDye® Terminator v1.1/v3.1 5X Sequencing Buffer and 0.5µM of forward or 
reverse pUC/M13 sequencing primers (Promega, Southampton, UK) as outlined in 
Table 2.2. The BigDye® Terminator cycle sequencing was performed in a Veriti® 96-
well Thermal Cycler (Life Technologies Ltd., Paisley, UK) as described in Section 
2.5.5.  
Table 2.2: pUC/M13 sequencing primers 
Forward primer Reverse  primer 
5´-TCACACAGGAAACAGCTATGAC-3´ 5´-CGCCAGGGTTTTCCCAGTCACGAC-3´ 
2.7. Segregation Analysis 
If multiple affected and unaffected individuals’ DNA was available from a pedigree, 
segregation analysis was performed. Each family member, where DNA was available, 
was analysed for the mutation of interest. The screening was performed using Sanger 
sequencing as described in Section 2.5. Segregation of the putative pathogenic variant 
with the disease supported pathogenicity of the mutation. 
2.7.1. Pedigrees with family history 
In the pedigrees with a dominant mode of inheritance we searched for genes with a 
single heterozygous variant which were shared between multiple affected and absent in 
unaffected individuals.   
In the families with a suspected recessive mode of inheritance we searched for 
compound heterozygous variants shared between affected individuals. In the recessive 
families, where only one affected individual was available for the analysis, we 
sequenced DNA of unaffected parents, if available. In such cases we only considered 
!! 48!
the compound heterozygous mutations in the affected individual if one of the variants 
was shared with the mother and the other one with father.  
2.7.2. Pedigrees with no family history 
For cases in which there was only one affected individual and no family history, we 
considered both single heterozygous variants (to fit a dominant inheritance model) and 
compound heterozygous variants (to fit a recessive mode of inheritance). Sequencing 
both unaffected parents, if available, enabled the discovery of de novo variants. In 
sporadic cases with a putative causative compound heterozygous mutation, where the 
parent’s DNA was not available for screening, segregation of alleles was confirmed 
with sequencing of the cloned alleles. Compound heterozygous variants, which 
occurred in trans, supported a recessive mode of inheritance.  
 
Cloning of genomic DNA for allelic cis-trans study 
Cloning of genomic DNA from extracted PCR fragments was performed as described in 
Section 2.6.  
 
Sanger sequencing validation of plasmid DNA clones for allelic cis-trans study 
Plasmid DNA Sanger sequencing was performed as outlined in Section 2.6. 
2.8. Cell culture 
Control fibroblasts were obtained from the Newcastle BioBank (Newcastle University) 
from anonymous healthy individuals. Patient’s fibroblasts were obtained from the 
Newcastle BioBank (Newcastle University). Informed consent was obtained from all 
probands before skin biopsies were performed. 
The cells were incubated in in a humidified incubator at 37°C with an atmosphere of 
5% CO2, in minimum essential media (MEM) (Life Technologies Ltd., Paisley, UK) 
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, Dorset, UK), 2mM 
L-glutamine (Life Technologies Ltd., Paisley, UK), 50 units/mL penicillin (Life 
Technologies Ltd., Paisley, UK), 50µg/mL streptomycin (Life Technologies Ltd., 
Paisley, UK), 110 mg/L sodium pyruvate (Sigma-Aldrich, Dorset, UK), Minimum 
Essential Medium vitamins at 1x (Life Technologies Ltd., Paisley, UK), non-essential 
amino acids at 1x (Life Technologies Ltd., Paisley, UK), and 50mg/L uridine (Life 
!! 49!
Technologies Ltd., Paisley, UK).  
2.8.1. Media change and passaging 
The cells were initially grown on the surface of conventional tissue culture plastic 
25cm2 flasks (Greiner Bio-One, Stonehouse, UK) and then transferred into 75cm2 flasks 
(Greiner Bio-One, Stonehouse, UK). Media was changed every 48 hours. Cells were 
passaged every 2-3 days when 80% confluent. In order to split cells, they were detached 
from the flask surface using trypsin-EDTA solution (Life Technologies Ltd., Paisley, 
UK) at 1x and incubated for 5 minutes at 37°C, followed by neutralization with the 
growth media. Cells were harvested by centrifugation at 200 x g for 5 minutes. The 
pellet was washed in Oxoid™ Phosphate Buffered Saline (PBS) (Thermo Fisher 
Scientific Inc., Leicestershire, UK), resuspended in growth media and seeded. 
2.8.2. Freezing 
In order to freeze cells, they were removed from the flask surface and pelleted, as 
described above, before resuspending in freezing media containing 90% FBS and 10% 
DMSO (Sigma-Aldrich, Dorset, UK). Cells were transferred to a  -80°C freezer in an 
isopropanol filled container enabling slow cooling. After a minimum of 24 hours cells 
were transferred to liquid nitrogen for long-term storage. 
2.8.3. Thawing 
A cryovial, containing the relevant frozen cells, was removed from liquid nitrogen, 
thawed quickly in a 37°C water bath and transferred into a 75cm2 flask with 11mL of 
supplemented growth media as described above. After pelleting at 200 x g for 5 minutes 
cells were washed in Oxoid™ Phosphate Buffered Saline (Thermo Fisher Scientific 
Inc., Leicestershire, UK), resuspended in growth media and seeded. 
2.9. Sanger sequencing of complementary DNA (cDNA) 
2.9.1. Total RNA extraction from cultured fibroblasts 
Cultured fibroblast cells were harvested as described in Section 2.8 and the pelleted 
cells were washed in Oxoid™ PBS (Thermo Fisher Scientific Inc., Leicestershire, UK). 
Total RNA was extracted from the pelleted cultured cells using RNeasy® Mini Kit 
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(QIAGEN, Manchester, UK) as per manufacturer’s protocol. The total RNA yield was 
determined using a NanoDrop 2000 Spectrophotometer (Fisher Scientific, 
Leicestershire, UK). 
2.9.2. Generating first strand DNA (RT step) 
Single-strand copy DNA (cDNA) was generated from total RNA extract using High 
Capacity cDNA Reverse Transcription (RT) Kit (Life Technologies Ltd., Paisley, UK) 
as per manufacturer’s protocol. This Kit contains all reagents needed for reverse 
transcription of total RNA to single-stranded cDNA. The reverse transcription step was 
performed in a final reaction volume of 20µL containing 1x RT buffer, 4mM dNTPs, 
50U MultiScribe™ Reverse transcriptase, 1x RT Random Primer and 10µL of total 
RNA extract containing approximately 1 µg of total RNA. RT reactions were carried 
out in Veriti® 96-well Thermal Cycler (Life Technologies Ltd., Paisley, UK). Reverse 
transcription conditions involved annealing at 25oC for 10 minutes, followed by cDNA 
synthesis at 37oC for 120 minutes and termination of reaction at 85oC for 5 minutes. 
The RT reactions were stored at -20oC 
2.9.3. Reverse transcription PCR (RT-PCR) 
The first-strand cDNA obtained at the RT step was amplified directly with PCR. PCR 
was performed in a final reaction volume of 25µL containing 2.5µL of the first-strand 
reaction, 2.5U GoTaq® DNA Polymerase (Promega, Southampton, UK), 0.2mM dNTPs 
(VHBio, Gateshead, UK), 1 x GoTaq® Reaction Buffer containing MgCl2 at a 
concentration of 7.5mM for a final concentration of 1.5mM in the 1x reaction; pH 8.5 
(Promega, Southampton, UK) and 0.2µM of each forward and reverse primer. Where 
GC-rich primers affected amplification efficiency, addition of 10% DMSO (Sigma-
Aldrich, Dorset, UK) was required in order to reduce the formation of secondary 
structure in GC-reach regions  (Sun et al., 1993). PCR reactions were performed in a 
Veriti® 96-well Thermal Cycler (Life Technologies Ltd., Paisley, UK). PCR conditions 
involved a hot start at 95oC for 4 minutes, followed by 30-40 cycles of denaturation at 
95oC for 30 seconds, annealing at primer annealing temperature for 30 seconds, and 
extension at 72oC. The final extension step was performed at 72oC for 10 minutes, 
followed by cooling the sample to 4oC. The PCR reactions were stored at -20oC. 
2.9.4. Cloning and sequencing of RT-PCR fragments 
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DNA fragments generated in RT-PCR step (Section 2.9.3) were extracted from an 
agarose gel as described in Section 2.6. DNA fragments were cloned and sequenced as 
described in Section 2.6. 
2.10. Microscopy 
2.10.1. Inverted microscopy for tissue culture samples 
Images of cells were taken using DS-Fi2 camera mounted on inverted microscope 
Nikon Eclipse TS100 (Nikon UK Limited, Surrey, UK) and NIS-Elements D-3.2 
microscope imaging software (Nikon UK Limited, Surrey, UK). 
2.10.2. Upright microscopy for IHC 
Images were captured using AxioCam HRc camera (Zeiss, Cambridge, UK) mounted 
on upright microscope Axio plan 2 (Zeiss, Cambridge, UK) and Axiovision microscope 
imaging software v.4.6.3 (Zeiss, Cambridge, UK). 
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Chapter 3. Approaches to filtering exome data from large cohorts 
3.1. Introduction 
3.1.1. Principle of filtering 
Whole exome sequencing produces about 10 GB of final data and it is a real challenge 
to distinguish novel variants for Mendelian or complex traits against a background of 
non-pathogenic polymorphisms and sequencing errors. Moreover, a recent study of 
2,440 exomes of European and African ancestry demonstrated that out of 13,595 single 
nucleotide variants (SNVs), which each person carried on average, around 2.3% were 
predicted to alter protein function of approximately 313 genes per genome. Also, 95.7% 
of SNVs, predicted to be functionally significant, were rare (Tennessen et al., 2012). In 
a similar independent study Nelson and co-workers sequenced 202 genes encoding drug 
targets in 14,002 individuals. They found that rare variants, many of which are 
deleterious, are abundant and geographically clustered (Nelson et al., 2012). These 
studies hypothesised that an excess of rare deleterious variants is due to the recent 
explosion of population growth and weak purifying selection. These findings highlight 
potential difficulties researchers might confront when interpreting exome sequencing 
data. In order to prioritize candidate genes and to reduce their number, step-wise 
filtering is applied. 
The main idea behind the filtering process is that in order to find rare or novel alleles, 
which are shared between affected individuals in one pedigree or several unrelated 
pedigrees, exome sequences of a small number of affected individuals are compared 
with a set of polymorphisms that are available in public databases (Ng et al., 2010). The 
majority of exome sequencing studies use public databases such as dbSNP (Sherry et 
al., 2001) (available at http://www.ncbi.nlm.nih.gov/SNP/), 1000 Genomes Project 
(Abecasis et al., 2010) (April 2012 release), and Exome Variant Server (May 2012 
release) (the latest release available at http://evs.gs.washington.edu/EVS/). The novelty 
of the variant is based on the assumption that, being rare, this variant will be absent in 
public databases (Bamshad et al., 2011). Rare variants might be present in those 
databases, albeit at a very low frequency (normally not more than 1% of the 
population).  
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3.1.2. Filtering steps 
It is suggested that there is no optimal universal filtering pipeline and variant cut-off. 
This is because characteristics of functional variants will differ between genes, 
depending on the importance of the gene for the effective functioning of the human 
species and lack of purifying selection (Do et al., 2012). 
Functional annotation of all detected variants using ANNOVAR 
In order to identify causal mutations, bioinformatic analysis, which utilises online tools, 
is performed. ANNOVAR is a tool which is used for functional annotation of identified   
novel variants (Wang et al., 2010). ANNOVAR incorporates algorithms allowing       
the identification of protein-altering mutations. ANNOVAR also enables filtering out 
common variants that are present in dbSNP137 database (Sherry et al., 2001), 1000 
Genomes  Project (Abecasis et al., 2010) and Exome Variant Server (the latest release 
available at http://evs.gs.washington.edu/EVS/). Provided with the list of variants and 
their chromosomal positions, obtained from exome sequencing raw data, ANNOVAR is 
capable of creating a user-friendly output in the form of an Excel spread sheet. The 
output data created by ANNOVAR is arranged in columns, which contain information 
such as protein coding change, gene annotation and variant pathogenicity scores 
calculated by various pathogenicity prediction programs (Table 3.1).  
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Functional data for each variant are presented in columns “Function”, “Gene” and 
“Exonic variant function” (Table 3.1). Column “Function” contains values that specify 
whether the variant is positioned in the exon or intron or hits a region within a splicing 
junction etc. Possible values in column “Function” are summarized in Table 3.2. 
Column “Gene” provides the name of a gene where the variant resides. Column 
“Exonic variant function” shows functional consequences of the amino acid change as a 
result of the exonic variant. Only exonic and splice site (those situated ± 2bp from an 
exon boundary) variants are annotated in this column. All possible annotation values 
and their explanation are given in Table 3.3. 
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Table 3.2: Possible values in column “Function” and their explanations presented 
in ANNOVAR output (adapted from ANNOVAR website, available at 
http://annovar.openbioinformatics.org )  
Value Explanation 
exonic variant overlaps a coding region 
splicing variant is within 2-bp of a splicing junction  
ncRNA variant overlaps a transcript without coding annotation in the gene 
definition  
UTR5 variant overlaps a 5' untranslated region 
UTR3 variant overlaps a 3' untranslated region 
intronic variant overlaps an intron 
upstream variant overlaps 1-kb region upstream of transcription start site 
downstream variant overlaps 1-kb region downtream of transcription end site  
intergenic variant is in intergenic region 
 
Table 3.3: Possible annotation values in column “Exonic variant function” and 
their explanations presented in ANNOVAR output (adapted from ANNOVAR 
website, available at http://annovar.openbioinformatics.org )  
Annotation Explanation 
frameshift 
insertion 
an insertion of one or more nucleotides that cause frameshift 
changes in protein coding sequence 
frameshift deletion a deletion of one or more nucleotides that cause frameshift changes 
in protein coding sequence 
frameshift block 
substitution 
a block substitution of one or more nucleotides that cause frameshift 
changes in protein coding sequence 
stopgain a nonsynonymous SNV, frameshift insertion/deletion, nonframeshift 
insertion/deletion or block substitution that lead to the immediate 
creation of stop codon at the variant site.  
stoploss a nonsynonymous SNV, frameshift insertion/deletion, nonframeshift 
insertion/deletion or block substitution that lead to the immediate 
elimination of stop codon at the variant site 
nonframeshift 
insertion 
an insertion of 3 or multiples of 3 nucleotides that do not cause 
frameshift changes in protein coding sequence 
nonframeshift 
deletion 
a deletion of 3 or multiples of 3 nucleotides that do not cause 
frameshift changes in protein coding sequence 
nonframeshift 
block substitution 
a block substitution of one or more nucleotides that do not cause 
frameshift changes in protein coding sequence 
nonsynonymous 
SNV 
a single nucleotide change that cause an amino acid change 
synonymous SNV a single nucleotide change that does not cause an amino acid change 
unknown unknown function (due to various errors in the gene structure 
definition in the database file) 
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ANNOVAR output also incorporates data from Online Mendelian Inheritance in Man 
(OMIM®, available at https://omim.org) and Gene Ontology (GO, available at 
http://www.geneontology.org), which provide data about gene associated diseases and 
gene product’s biological properties, respectively. The latter two databases are linked by 
ANNOVAR to the identified variants enabling a quick genotype/phenotype 
interrogation. 
Variant pathogenicity scores predicted by various pathogenicity prediction programs are 
presented in the ANNOVAR output in separate columns. Pathogenicity prediction 
programs that were incorporated in ANNOVAR at the time of writing this Thesis are 
outlined below.  
• MutationTaster (Schwarz et al., 2010) makes predictions on the basis of 
evolutionary conservation, loss of protein function and splice site changes 
(scores between 0 and 1 with the larger scores suggesting a higher probability to 
cause a disease).  
• Sorting Intolerant from Tolerant (SIFT) algorithm (Kumar et al., 2009) predicts 
the effect of the amino acid change (scores between 0 and 1 reflect the 
probability of being pathogenic: 0 = highest; 1 = lowest).  
• Polymorphism Phenotyping 2 (PolyPhen2 ) (Adzhubei et al., 2010) predicts the 
effect of the amino acid change (scores between 0 and 1 with the larger scores 
suggesting a higher probability to be damaging).  
• Likelihood Ratio Test (LRT) method (Knudsen and Miyamoto, 2001) predicts 
pathogenicity of variants based on conservation of protein residues (scores 0 to 1 
high score indicating a large deleterious effect).  
• Phylogenetic p-values (PhyloP) (Pollard et al., 2010) algorithm estimates the 
probability of observed variation under the hypothesis of neutral evolutionary 
rate and assigns conservation p-values (Conserved =>0.95, Non-Conserved 
<0.95).  
• Genomic Evolutionary Rate Profiling (GERP) (Cooper et al., 2005) measures 
base conservation via estimating probability of the observed substitution under 
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the hypothesis of neutral evolutionary rate (range from -12.3 to 6.17, with 6.17 
being the most conserved).  
Most of the programs outlined above use conservation of the affected residue and 
information about structure of the protein for prediction. Although using prediction 
programs may be successful in some cases (Brunham et al., 2005), one should 
remember, that these programs might not be sensitive enough in other cases and thus 
should be used with great caution and only as a guide (Flanagan et al., 2010; Ng et al., 
2010). Also, a poor agreement among different programs has been reported (Tennessen 
et al., 2012).  
Focusing on deleterious variants 
The majority of exome sequencing studies only focus on deleterious variants such as 
exonic, protein altering and splice site alterations. The latter is defined as within 2 bp of 
the intron-exon boundary (Calvo et al., 2010). Such approach is justified because the 
majority of protein altering variants are predicted to affect protein function and to be 
deleterious (Kryukov et al., 2007). Also, most of the variants known to cause 
Mendelian disorders disrupt protein-coding regions of the genome (Stenson et al., 
2009).  
The range of pathogenicity predicting programs is being used to predict the 
pathogenicity of variants, as outlined above.  
Setting Minor Allele Frequency (MAF) restrictions 
Minor allele frequency (MAF) is the frequency at which the less common allele occurs 
in a population. If, for example, the minor allele occurs in 5% of a given population, 
then this would mean that the MAF value for this allele is 0.05. Alleles with a MAF less 
than 0.01 are considered rare (Bamshad et al., 2011). In order to filter out putative 
causative variants, MAF restrictions should be clearly set for the exome sequencing 
study.  
Previously many groups ruled out any variant found in public databases such as dbSNP 
(Sherry et al., 2001), 1000 Genomes Project (Abecasis et al., 2010), and in-house 
exome databases. This is based on the assumption that, because causative variants are 
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very rare, any individual, who has a rare variant, will be affected. However, this is true 
only for fully penetrant variants (Brunham and Hayden, 2013). Also, as more whole 
exome and whole genome studies are undertaken, more data will be deposited in the 
public databases. This means that with time more rare variants will be accounted for and 
excluding them from sequencing studies could be very restrictive (Bamshad et al., 
2011). That is why many groups allow the minor allele frequency for variants found in 
public databases to be as high as 0.01 (McDonald et al., 2012). 
Consider mode of inheritance 
A filtering workflow, used to prioritise putative causative gene variants in a pedigree, 
depends on mode of inheritance. For example, for dominant diseases only single 
heterozygous variants, which are shared between affected members, are considered. For 
recessive pedigrees, homozygous (for consanguineous families) or compound 
heterozygous (for non-consanguineous families) variants are considered. However, such 
approach should be used with a caution because an apparent homozygosity in a non-
consanguineous recessive family could, for example, indicate a large genomic deletion 
on the other chromosome (Pyle et al., 2013). For sporadic cases with no family history 
both single heterozygous and compound heterozygous mutations are considered in order 
to fit presumed dominant or recessive models, respectively. For suspected de novo 
mutations parent-child trios should be filtered for mutations absent in both parents (Ku 
et al., 2012).  
 
Select variants based on a gene or gene product function 
Candidate gene variants can be prioritised based on a corresponding gene or protein 
function. This approach has been shown to be successful for some disorders. For 
example, in exome sequencing studies of mitochondrial disorders the genes could be 
stratified by their involvement with mitochondria (Calvo et al., 2012). Recent studies 
suggest that using a list of key words may also be beneficial in prioritising putative 
causative mutations (Fogel et al., 2014). Key words could be based on the best 
definition of the phenotype of the patient and should be used to search additional 
databases that are incorporated into ANNOVAR. For example, in a recent exome 
sequencing study of a highly heterogeneous cohort of ataxia patients the authors 
successfully used the key word “ataxia” to filter in variants in known ataxia genes 
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(Fogel et al., 2014). The latest literature proposes that when prioritising the filtered 
variants, researchers should start from focusing on known or novel variants in known 
disease genes, followed by considering novel rare variants in “likely novel candidate 
genes” (Gonzaga-Jauregui et al., 2015). It is also recommended that in order to link 
genomic data with a clinical phenotype, the list of filtered out genes should be reviewed 
by at least one neurologist. This would allow a review of the variants based on the latest 
literature and diagnostic criteria (Fogel et al., 2014). 
 
Average coverage of consensus coding sequence (CCDS) bases 
The quality of exome sequencing data could be assessed by coverage of CCDS bases. In 
exome sequencing, sequence coverage (depth) is the average number of times the base 
is covered in a given experiment (Rizzo and Buck, 2012). Low coverage could result in 
misinterpreting the sequencing data and could result in potentially missing causative 
variants (Rehm et al., 2013). Low coverage could also lead to a false-positive or false-
negative variant call because variant calling algorithms take into consideration the 
number of times the base is seen as a reference as opposed to being seen as a variant. It 
is anticipated that it is impossible to impose a CCDS base coverage threshold, which 
would be universal for all laboratories. This is because the coverage would differ 
amongst different sequencing platforms, enrichment kits and analytical algorithms used 
by the laboratories for acquisition and interpretation of exome sequencing data (Rehm 
et al., 2013). 
 
Coverage analysis of genes previously linked to the disease  
As recommended by the recent guidance for interrogation of putative causative variants 
in human disease (MacArthur et al., 2014), the study on ascribing pathogenicity to the 
prospective variants should start from investigating genes, which were previously 
linked to that phenotype. Therefore it is necessary to assess the coverage of CCDS bases 
in those known disease genes along with the coverage of total CCDS bases. The list of 
genes for such study could be generated based on the latest published data. For 
example, gene panels designed for targeted exome sequencing in mitochondrial disease 
(Calvo et al., 2012) and ataxia (Nemeth et al., 2013) could be used in patients with 
these phenotypes. 
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3.2. Materials and methods 
3.2.1. Functional annotation of variants using ANNOVAR 
The study cohort consisted of 35 affected individuals (P1-P35) from 22 randomly 
selected families of white European descent with no known consanguinity. Whole 
exome sequencing was performed on 30 patients enrolled in this study In-house 
bioinformatic analysis was based on previously published tools and performed, as 
described in Section 2.4.2. All variants were functionally annotated by Dr. Helen 
Griffin (Newcastle University) using ANNOVAR (Wang et al., 2010), which enabled 
identification of protein altering mutations along with their functional annotation. The 
ANNOVAR output file was presented as an Excel spread sheet containing a list of 
variants for each proband along with columns containing values for each variant. The 
values were as follows: chromosome position of the variants, reference and variant 
sequences, name of the gene in which the variant was recorded, OMIM® and Gene 
Ontology data linked to each variant, MAF value for each identified variant recorded in 
dbSNP137, 1000 genomes (April 2012 data release) and Exome Variant Server NHLBI-
ESP6500 databases (May 2012 release). The in-house pipeline was modified in order to 
include MAF values for a control panel of 286 unrelated in-house exomes. The 
ANNOVAR output file also incorporated pathogenicity prediction programs presented 
in separate columns, which ascribed each variant a pathogenicity score (as described in 
Section 3.1.2). Finally, the ANNOVAR output file contained functional data for each 
variant presented in columns “Function” and “Gene” (as described in detail in Section 
3.1.2).  
3.2.2. Filtering for deleterious variants 
In order to identify causal mutations, the list of variants annotated with ANNOVAR  (as 
described in Section 3.2.1) was obtained from Dr. Helen Griffin (Newcastle University) 
and further manually filtered as outlined in Figure 3.1. This study only focused on 
deleterious variants (protein altering variants, nonsense mutations, exonic 
insertions/deletions (indels) and splice site variants) and excluded all synonymous 
variants. A range of bioinformatic programs for predicting pathogenicity of variants was 
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employed (MutationTaster (Schwarz et al., 2010), SIFT (Kumar et al., 2009), PolyPhen 
(Adzhubei et al., 2010), PhyloP (Pollard et al., 2010), LRT (Knudsen and Miyamoto, 
2001), GERP (Cooper et al., 2005)). However, due to the possible disagreement 
between these programs (Tennessen et al., 2012) the current study used them with 
caution and only as a guide.  
 
Figure 3.1: Overview of the filtering process to prioritise putative causative gene 
variants. 
3.2.3. Setting MAF cut off 
Minor allele frequency (MAF) cut off was set at 1% in dbSNP137, 1000 genomes 
(April 2012 data release) and Exome Variant Server NHLBI-ESP6500 databases (May 
2012 release) as well as in 286 unrelated in-house controls (Figure 3.1). For families 
with a suspected recessive mode of inheritance or sporadic cases we set up a MAF cut 
off at <0.05 to accommodate for compound heterozygous mutations. Variants with 
MAF values above this cut off were excluded. 
Focus&on&deleterious&variants&(protein&altering&
variants,&nonsense&muta5ons,&exonic&
inser5ons/dele5ons&(indels)&and&splice&site&
variants)&and&exclude&synonymous&variants&&
Select&only&rare&variants&below&a&designated&
MAF&from&in@house&control&MAF,&1000&
Genomes&and&Exome&Variant&Server&(typically&
MAF<=0.01)&&
Select&variants&based&on&a&gene&func5on&(key&words)&
Variants&absent&in&
&both&parents&
Genes&with&two&mutated&
&alleles&
Variants&shared&between&
mul5ple&affected&
De#novo# Recessive& Dominant&
Select&variants&based&on&mode&of&inheritance&&&
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3.2.4. Selection of variants based on mode of inheritance 
Selection of the remaining variants was based on mode of inheritance, as reflected in 
(Figure 3.1). Depending on the mode of inheritance we filtered for genes with 
compound heterozygous mutations (for suspected autosomal recessive and sporadic 
cases), genes with a single heterozygous mutation shared between multiple affected 
family members (for autosomal dominant traits) or variants absent in both parents of the 
affected individual (for suspected de novo cases). 
3.2.5. Selection of variants based on gene function (using key words) 
The variants were prioritized for brain and nerve cell expression and for connection 
with known neurological disease, which could fit the phenotype in the subjects being 
studied (Figure 3.1). Following the suggestions in the latest guidance for investigating 
putative causative variants in human disease (MacArthur et al., 2014), this study started 
exploring variants in genes known to be associated with ataxia. For this key words were 
used (cerebellum, ataxia) and prioritized genes based on clinical information in OMIM® 
and Gene Ontology as described in Section 3.2.1. The filtered in variants were cross-
referenced with the latest literature in order to identify known and novel variants in 
genes previously associated with ataxia or related neurological diseases. The variants 
were considered sequentially as follows: 
• known variants in known ataxia and related neurological diseases genes; 
• novel variants in known ataxia and related neurological diseases genes; 
Following this, the current study investigated rare variants in genes linked to 
neurological disorders that could fit the phenotype in the affected individuals. Such 
genes are potentially novel genes associated with ataxia. This study further prioritised 
genes matching OMIM® and Gene Ontology terms brain, neuro, nerve (to aid in 
prioritizing genes expressed in the tissue relevant to the ataxia phenotype); spastic, 
cephal, lysosome (to prioritize genes linked to diseases with possible phenotype 
overlap). In order to determine the possible link between the variants and the patient’s 
phenotype, two neurologists reviewed the list of putative causative mutations.  
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3.2.6. Average coverage of consensus coding sequence (CCDS) bases 
Coverage was calculated for all Consensus Coding Sequence (CCDS) bases 
(31,935,069 bp), by Dr. Helen Griffin (Newcastle University), using custom scripts and 
following a protocol outlined below in Section 3.2.7. The percentage of bases that 
mapped to target regions (Illumina Truseq 62Mb targets +/-500bp) was also calculated 
(mean target base coverage). 
3.2.7. Coverage analysis of ataxia genes from recent publications 
In order to check if all known ataxia genes were covered in this study’s patients by 
exome sequencing, a recently published list of genes used for a targeted capture in a 
similar ataxia cohort study was employed (Nemeth et al., 2013). This list (Table 3.4) 
consisted of 118 genes and included known ataxia genes (42 genes, 786 exons), genes 
causing ataxia in mouse models (18 genes, 514 exons), transfer RNA synthetase genes 
(35 genes, 580 exons), genes associated with other neurological disorders with ataxia as 
a part of phenotype (6 genes, 79 exons), speculative genes based on function (7 genes, 
167 exons) and genes associated with Joubert syndrome (10 genes, 243 exons). The 
latter is a specific ataxia disorder. Coverage was calculated for CCDS bases for genes 
studied by Nemeth and colleagues (386,444 bp). Coverage analysis was performed by 
Dr. Helen Griffin (Newcastle University) using custom scripts. For this the list of genes 
(Table 3.4) was uploaded by Dr. Helen Griffin (Newcastle University) into online 
formatting software SAMtools (available at http://samtools.sourceforge.net). SAMtools 
software allows alignment of sequence reads against large reference sequences, 
including the human genome, in a common alignment format (Li et al., 2009). Per base 
files of coverage depth (pileup files) were created for each patient using files of aligned 
sequence reads and the 'mpileup' command in SAMtools formatting software. Custom 
Perl scripts were then used to calculate the mean per target base read depth and the 
number of target bases which were covered to a minimum depth of 20-, 10-, 5- and 1-
fold. This was done for consensus coding sequence (CCDS) target bases and also 
specifically for all coding bases of genes selected for targeted capture by Nemeth and 
colleagues. 
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Table 3.4: List of genes selected for targeted capture by Nemeth and colleagues 
(taken from Nemeth et al., 2013) 
 
Autosomal 
Dominant 
Autosomal 
Recessive 
Ataxia in 
mouse 
models 
tRNA 
synthetase 
genes 
Other 
disorders 
associated 
with 
Ataxia 
Speculative Joubert 
ATXN1 APTX AARS AARS2 PRPS1 AIFM1 AHI1 
ATXN2 SACS CHD6 CARS GAN EN1 ARL13B 
ATXN3 ABCB7 A2BP1 CARS2 SLC6A19 EN2 CC2D2A 
PLEKHG4 ATM ATP2B2 DARS TINF2 KLHL1 CEP290 
SPTBN2 MRE11A AGTPBP1 DARS2 PSAP RAB3A INPP5E 
CACNA1A TTPA DNAJC19 EARS2 SCN1A SYNE2 NPHP1 
ATXN7 ATCAY DST EPRS   EEF2 OFD1 
ATXN8OS FXN GRID2 FARS2     RPGRIP1L 
ATXN10 SIL1 HERC1 FARSA     TMEM216 
TTBK2 TDP1 KCNJ6 FARSB     TMEM67 
KCNC3 CABC1 MYO5A GARS       
PRKCG SETX RELN HARS       
ITPR1 SYNE1 RORA HARS2       
TBP MARS2 SLC12A6 IARS       
FGF14 GRM1 SNAP25 IARS2       
AFG3L2 KIAA0226 TRPC3 KARS       
BEAN1 DARS2 USP14 LARS       
KCNA1 KCNJ10 AFF1 LARS2       
CACNB4 AAAS   MARS       
SLC1A3 VLDLR   NARS       
ATN1     NARS2       
PPP2R2B     PARS2       
      QARS       
      RARS       
      RARS2       
      SARS       
      SARS2       
      TARS       
      TARS2       
      VARS       
      VARS2       
      WARS       
      WARS2       
      YARS       
      YARS2       
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3.2.8. Sanger sequencing validation and segregation study 
In order to confirm putative pathogenic variants, Sanger sequencing was performed as 
described in Section 2.5. Where possible, multiple affected and unaffected family 
members were Sanger sequenced in order to segregate putative pathogenic mutations, as 
described in Section 2.7. 
3.3. Results  
3.3.1. Coverage and depth statistics 
Coverage and depth statistics analysis for 30 patients was performed for CCDS bases, 
as described in Section 3.2.6, and the result was previously published (Pyle et al., 
2014). The mean target base coverage for all exomes was 72-fold. On average, 85% of 
all CCDS bases were covered 20-fold, 91% of all CCDS bases were covered 10-fold 
and 93% of all CCDS bases were covered 5-fold. Coverage and depth statistics for each 
patient is presented in Table 3.5.  
 
! !68!T
ab
le
 3
.5
: C
ov
er
ag
e 
an
d 
de
pt
h 
st
at
is
tic
s. 
C
ov
er
ag
e 
ca
lc
ul
at
ed
 fo
r C
on
se
ns
us
 C
od
in
g 
Se
qu
en
ce
 (C
C
D
S)
 b
as
es
 (3
1,
93
5,
06
9 
bp
). 
Ta
rg
et
 b
as
es
 - 
ba
se
s 
‘o
n-
ta
rg
et
’ t
o 
Ill
um
in
a 
Tr
us
eq
 6
2M
b 
ta
rg
et
s +
/-5
00
bp
. A
da
pt
ed
 fr
om
 P
yl
e 
et
 a
l.,
 2
01
4.
 
 
Pa
tie
nt
 ID
 
M
ea
n 
ta
rg
et
 
ba
se
 
co
ve
ra
ge
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
20
-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
20
-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
10
-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
10
-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
5-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
5-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
1-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
1-
fo
ld
 
P1
 
51
.2
 
19
16
02
85
 
60
.0
 
22
42
95
50
 
70
.2
 
24
72
29
18
 
77
.4
 
27
70
13
24
 
86
.7
 
P2
 
43
.3
 
18
65
57
73
 
58
.4
 
22
18
81
63
 
69
.5
 
24
57
02
41
 
76
.9
 
27
57
45
58
 
86
.3
 
P3
 
48
.2
 
19
32
05
91
 
60
.5
 
22
74
11
13
 
71
.2
 
25
01
76
36
 
78
.3
 
27
83
61
53
 
87
.2
 
P5
 
72
.7
 
29
22
34
16
 
91
.5
 
30
55
82
12
 
95
.7
 
30
97
61
57
 
97
.0
 
31
33
69
61
 
98
.1
 
P7
 
40
.5
 
24
73
75
79
 
77
.5
 
29
11
40
27
 
91
.2
 
30
34
02
08
 
95
.0
 
31
09
80
22
 
97
.4
 
P9
 
63
.1
 
28
16
35
68
 
88
.2
 
30
06
67
23
 
94
.1
 
30
72
97
68
 
96
.2
 
31
28
14
41
 
98
.0
 
P1
0 
83
.7
 
29
40
54
77
 
92
.1
 
30
51
72
61
 
95
.6
 
30
92
52
25
 
96
.8
 
31
32
86
06
 
98
.1
 
P1
1 
80
.8
 
29
27
50
24
 
91
.7
 
30
46
31
83
 
95
.4
 
30
86
92
66
 
96
.7
 
31
28
07
00
 
98
.0
 
P1
2 
80
.9
 
29
29
02
00
 
91
.7
 
30
45
30
08
 
95
.4
 
30
86
23
32
 
96
.6
 
31
27
54
73
 
97
.9
 
P1
3 
85
.2
 
29
41
91
13
 
92
.1
 
30
51
91
56
 
95
.6
 
30
89
01
97
 
96
.7
 
31
28
96
82
 
98
.0
 
P1
4 
65
.0
 
28
82
11
17
 
90
.2
 
30
40
31
09
 
95
.2
 
30
86
83
27
 
96
.7
 
31
26
89
83
 
97
.9
 
P1
5 
74
.4
 
29
23
31
08
 
91
.5
 
30
48
29
29
 
95
.5
 
30
89
52
99
 
96
.7
 
31
28
52
48
 
98
.0
 
P1
6 
11
1.
8 
29
44
64
26
 
92
.2
 
30
12
48
45
 
94
.3
 
30
49
42
61
 
95
.5
 
31
02
37
82
 
97
.1
 
P1
7 
11
1.
2 
29
56
87
33
 
92
.6
 
30
31
80
16
 
94
.9
 
30
68
75
74
 
96
.1
 
31
19
02
12
 
97
.7
 
! !69!T
ab
le
 3
.5
: c
on
tin
ue
d 
Pa
tie
nt
 ID
 
M
ea
n 
ta
rg
et
 
ba
se
 
co
ve
ra
ge
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
20
-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
20
-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
10
-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
10
-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
5-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
5-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
1-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
1-
fo
ld
 
P1
8 
62
.2
 
28
63
46
67
 
89
.7
 
30
35
04
64
 
95
.0
 
30
86
69
22
 
96
.7
 
31
28
36
71
 
98
.0
 
P2
0 
77
.3
 
29
18
56
21
 
91
.4
 
30
48
44
59
 
95
.5
 
30
88
73
62
 
96
.7
 
31
29
54
67
 
98
.0
 
P2
1 
79
.8
 
29
22
14
44
 
91
.5
 
30
46
36
39
 
95
.4
 
30
86
28
72
 
96
.6
 
31
26
83
74
 
97
.9
 
P2
2 
10
2.
7 
29
60
20
38
 
92
.7
 
30
41
13
80
 
95
.2
 
30
75
38
78
 
96
.3
 
31
22
31
81
 
97
.8
 
P2
3 
95
.3
 
29
82
43
44
 
93
.4
 
30
65
74
87
 
96
.0
 
30
97
64
91
 
97
.0
 
31
35
69
31
 
98
.2
 
P2
5 
75
.9
 
29
06
81
10
 
91
.0
 
30
42
10
50
 
95
.3
 
30
89
06
06
 
96
.7
 
31
31
76
31
 
98
.1
 
P2
6 
79
.0
 
29
20
68
79
 
91
.5
 
30
47
82
80
 
95
.4
 
30
91
52
48
 
96
.8
 
31
35
65
40
 
98
.2
 
P2
7 
77
.6
 
29
18
96
39
 
91
.4
 
30
53
67
70
 
95
.6
 
30
95
93
69
 
96
.9
 
31
35
61
38
 
98
.2
 
P2
8 
68
.4
 
29
03
85
81
 
90
.9
 
30
46
54
82
 
95
.4
 
30
90
08
00
 
96
.8
 
31
28
73
62
 
98
.0
 
P2
9 
79
.8
 
29
19
79
44
 
91
.4
 
30
37
90
82
 
95
.1
 
30
79
38
88
 
96
.4
 
31
23
71
88
 
97
.8
 
P3
0 
83
.4
 
29
41
07
02
 
92
.1
 
30
58
11
33
 
95
.8
 
30
98
64
64
 
97
.0
 
31
37
52
68
 
98
.2
 
P3
1 
39
.9
 
25
28
33
05
 
79
.2
 
29
44
32
10
 
92
.2
 
30
52
80
49
 
95
.6
 
31
17
89
79
 
97
.6
 
P3
2 
78
.2
 
29
13
45
84
 
91
.2
 
30
48
45
42
 
95
.5
 
30
95
35
70
 
96
.9
 
31
37
87
02
 
98
.3
 
P3
3 
38
.6
 
18
02
54
93
 
56
.4
 
21
90
76
41
 
68
.6
 
24
49
30
70
 
76
.7
 
27
61
33
77
 
86
.5
 
 
! !70!T
ab
le
 3
.5
: c
on
tin
ue
d 
Pa
tie
nt
 ID
 
M
ea
n 
ta
rg
et
 
ba
se
 
co
ve
ra
ge
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
20
-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
20
-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
10
-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
10
-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
5-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
5-
fo
ld
 
N
um
be
r 
 
C
C
D
S 
ba
se
s 
co
ve
re
d 
1-
fo
ld
 
%
 C
C
D
S 
ba
se
s 
co
ve
re
d 
1-
fo
ld
 
P3
4 
53
.6
 
19
08
03
57
 
59
.7
 
22
29
57
09
 
69
.8
 
24
59
29
72
 
77
.0
 
27
65
93
25
 
86
.6
 
P3
5 
66
.5
 
26
84
96
88
 
84
.1
 
29
58
85
59
 
92
.7
 
30
56
84
20
 
95
.7
 
31
30
50
79
 
98
.0
 
   
!! 71!
3.3.2. Coverage of ataxia genes and bases (based on the list studied by Nemeth et al., 
2013) 
Coverage of ataxia genes included in the recently published ataxia panel (Nemeth et al., 
2013) was calculated for the patients with ataxia studied here, as described in Section 
3.2.7, and the result was previously published (Pyle et al., 2014). Coverage calculated 
for total CCDS bases for the genes studied by Nemeth and colleagues. A total of 118 
known and putative ataxia genes had 2,369 exons (386,444 bp). The mean target base 
coverage for all exomes was 64-fold. On average, 89% of all ataxia CCDS bases were 
covered 20-fold, 93% of CCDS bases were covered 10-fold and 95% of CCDS bases 
were covered 5-fold. These data are in line with findings by Nemeth and colleagues and 
the similar studies (Taylor et al., 2014). Coverage and depth statistics for each patient is 
presented in Table 3.6. 
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3.3.3. Filtering for putative causative variants 
On average each individual had approximately 60,000 on target (within targets of 
Illumina Truseq 62Mb +/-500bp) single-nucleotide variants (SNV) and 6,000 on target 
indels (insertion/deletion). This study’s filtering strategy yielded a list of prospective 
variants, all of which were verified with Sanger sequencing using custom designed 
primers (Chapter 2, Table 2.1). Population frequency data and pathogenicity scores for 
variants found in 27 patients from the ataxia cohort presented here were used in Pyle et 
al., 2014 and are presented in Table 3.7. 
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3.4. Discussion  
This study presents 35 individuals with unexplained ataxia from 22 randomly selected 
families of white European descent with no known consanguinity. Whole exome 
sequencing was performed on 30 patients enrolled in this study. In order to prioritize 
candidate genes, the raw data was carefully filtered. After filtering in prospective 
candidate genes, the putative causative variants were confirmed with Sanger sequencing 
in the patient and multiple affected and unaffected members of the family, if available. 
As outlined in previous sections, many groups in earlier studies ruled out variants found 
in public databases such as dbSNP, the 1000 Genomes Project, and in in-house exome 
databases (Sherry et al., 2001). Excluding rare variants, which were previously found in 
public databases, from the sequencing study could be very restrictive. This is because as 
more data are deposited in the public databases, more rare variants will be accounted for 
(Bamshad et al., 2011). Also, rare pathogenic mutations could be deposited in the 
public databases because younger individuals with low penetrant neurological disorders 
have not yet presented with the phenotype (Keogh and Chinnery, 2013). In the more 
recent studies many groups would allow the minor allele frequency for variants found in 
public databases to be as high as 0.01 (McDonald et al., 2012). The current study 
employed similar tactics. However, this study realize that a MAF cut off of 1% is 
arbitrary and should only be used as a guide. This is true for several reasons. Firstly, 
MAF values for rare variants could differ between public databases, as demonstrated in 
this study by an NPC1 mutation c.709C>T:p.Pro237Ser in patients P15 and P16 
(MAF=0.0153 in US-based ESP6500; MAF=0.0064 in UK-based 1000 Genomes 
project; MAF=0.0052 in an in-house panel of 286 unrelated exomes). The latter data 
was previously published (Pyle et al., 2014; Pyle et al., 2015) and presented here in 
Table 3.4. Secondly, MAF cut off values vary depending on different modes of 
inheritance and availability of the family history in the patients being studied. The 
current study filtered out all variants with MAF>=0.01 in presumed dominant 
pedigrees, but allowed MAF>0.01 for compound heterozygous variants in presumed 
recessive cases. The latter was considered only when the other allele was very rare. One 
example of such approach is compound heterozygous FASTKD2 mutations, which was 
identified in patient P21 (Table 3.4). While mutation c.-66A>G has a MAF>0.01 in one 
of the databases, when taken together with the other mutation, it would cause disease 
with an incidence of approximately 1:17,000. This is well below recently suggested 
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incident rate of 1:10,000 for rare recessive disorders (Stranneheim and Wedell, 2015). 
Likewise, compound heterozygous WFS1 mutations identified in patient P20 (Table 
3.4) would be expected to cause a disease with an incidence rate of about 1:14,000. This 
is despite the p.Arg456His mutation having MAF=0.04 in ESP6500 database.  
In order to prioritise putative causative variants, this study used keywords, as described 
in Section 3.2.5, to filter for variants in known ataxia and related neurological disorder 
genes. This enabled a significant reduction in the variant numbers (selected examples 
are presented in Figure 3.2). Three examples are highlighted here. Firstly, patient P7 
had 1,649 rare/novel variants (Figure 3.2, a), out of which 396 variants were both 
heterozygous and protein altering. 43 of these variants contained the terms “nerv” or 
“neuro” in Gene Ontology and only one variant contained the term “ataxia” in OMIM 
database. Secondly, patients P9 and P10 had 1,419 and 1,609 rare/novel variants, 
respectively (Figure 3.2, b). Out of these, patient P9 had 522 and patient P10 had 510 
rare/novel protein altering variants. The two patients shared 25 compound heterozygous 
protein altering variants, out of which only one variant had terms “nerv” or “neuro” or 
“brain” or “ataxia” in Gene Ontology or OMIM database. And finally, patient P17 had 
1,421 rare/novel variants (Figure 3.2, c), out of which 624 were both heterozygous and 
protein altering. Three of these variants contained the terms “nerv” or “neuro” or 
“brain” or “ataxia” in Gene Ontology or OMIM database.  
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Figure 3.2: Genetic variant numbers identified in selected patients following exome 
sequencing and bioinformatic analysis pipeline. Variant numbers identified in 
patients P7 (a), P9 and P10 (b) and P17 (c). SNV=single-nucleotide variants; 
indel=insertion/ deletion variants. (*) Variants with position within targets (Illumina 
Truseq 62Mb) +/-500bp, observed on both (forward and reverse) strands and (SBVs 
only) variant allele frequency >24%. (**) Rare/novel variants (MAF<=0.01) with 
exclusion of common variants found to be shared with an in-house panel of 286 
individuals, dbSNP137, 1000 genomes (April 2012 data release) and Exome Variant 
Server NHLBI-ESP6500 databases (May 2012 release). 
After filtering with keywords and identifying putative candidate genes, an extensive 
literature search was performed. Following this, current variants associated with ataxia 
and related neurological disorders were identified. The study then cross-referenced the 
published variants with the variants filtered with the pipeline described here. The 
current study first concentrated on the known variants in the known ataxia and related 
neurological disorder genes. Following this the study searched for novel variants in the 
known ataxia and related neurological disorder genes. Finally, this study considered rare 
variants in potential novel ataxia genes, which would fit the phenotype in the patients 
from the cohort. Studies by other research groups, which were published after this study 
was performed, employed a similar approach (Fogel et al., 2014; Gonzaga-Jauregui et 
al., 2015). This study eventually was able to identify known pathogenic variants in 
genes associated with ataxia and related neurological disorders in two families. First, a 
dominant KCNC3 c.1259G>A:p.Arg420His mutation in patient P7 (Table 3.4), which 
Number of genes with rare variants 
Patient ID/ 
inheritance  Variant type On target (*) 
Rare/novel 
variants (**) 
Heterozygous 
protein altering  
Contains 
"neuro" or 
"nerv" in Gene 
Onthology 
Contains 
"ataxia" in 
OMIM 
P7/dominant 
SNV 65,662 1,649 396 43 1 Indel 7,538 
Number of shared genes with rare variants 
Patient ID/ 
inheritance  Variant type On target (*) 
Rare/novel 
variants (**) 
Rare/novel 
protein 
altering 
variants  
Compound 
heterozygous  
protein altering  
 Compound heterozygous  
protein altering and contains 
"neuro" or "nerv" or "brain" or 
"ataxia" in Gene Onthology or 
OMIM 
P9/recessive 
SNV 63,999 1,419 522 
25 1 
Indel 7,508 
P10/recessive 
SNV 67,390 1,609 510 Indel 7,902 
Number of Genes with Rare Variants 
Patient ID/ 
inheritance  Variant type On target (*) 
 Rare/novel 
variants (**)  
Heterozygous  
protein altering  
Single heterozygous  protein 
altering and contains "neuro" 
or "nerv" or "brain" or 
"ataxia" in Gene Onthology or 
OMIM 
P17/dominant SNV 70,573 1,421 624 3 Indel 7,004 
a"
c"
b"
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was previously associated with ataxia (Waters et al., 2006; Figueroa et al., 2011). In the 
current study this mutation segregated with the disease (confirmed by a segregation 
study in patient P8 and unaffected members of this family). Second, compound 
heterozygous SPG7 mutations in patients P9 and P10 (c.1529C>T:p.Ala510Val and 
c.1715C>T:p.Ala572Val) (Table 3.4), which were previously described in patients with 
ataxic features (Casari et al., 1998; Pfeffer et al., 2015). A novel mutation in a known 
ataxia gene SLC1A3 (de Vries et al., 2009) was identified in patient P17 
(c.1361G>A:p.Arg45Gln) (Table 3.4). The latter mutation segregated with the disease 
in this family (it was also present in patient P18 and absent in the unaffected family 
members). This study also identified novel mutations in a known ataxia gene SACS in 
three unrelated families (Table 3.4). 
In this study the variants have been chosen according to the inheritance mode in each 
family. For example, in families with a presumed dominant inheritance model this study 
primarily filtered for genes with a single heterozygous change (shared between multiple 
exomes, where available). Likewise, in families with a presumed recessive mode of 
inheritance the current study selected genes with at least two mutated alleles (for non-
consanguineous families). None of the families, included in this study, were 
consanguineous, therefore the majority of the homozygous changes were excluded. 
However, one family (patients P3 and P4) presented with a seemingly homozygous 
SACS stop-codon mutation c.13048G>T:p.Glu4350*, which was present in the mother, 
but not in the father (Pyle et al., 2013). The comparative genomic hybridisation study 
identified a 0.7 Mb deletion on chromosome 13q12.12, which includes the SACS gene, 
in both brothers. The deletion was heterozygous in the asymptomatic father. This 
example shows that in non-consanguineous families seemingly homozygous variants 
could, in fact, be hemizygous, indicating chromosomal rearrangements. The latter are 
increasingly recognised as a cause of late-onset neurological disease (Pyle et al., 2013). 
In conclusion, this study demonstrates that a stepwise filtering algorithm is an effective 
tool for interpretation of exome sequencing data. Filtering significantly reduces the 
number of putative causative variants from tens of thousands down to just about a dozen 
per individual. Such a tremendous reduction of data makes it easier to evaluate 
prospective variants. This aids in establishing a prompt molecular diagnosis in a highly 
heterogeneous group of patients with a neurological disorder. 
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Chapter 4. Whole exome sequencing for molecular diagnosis of 
neurological disorders using undiagnosed inherited and sporadic 
ataxias as a model 
4.1. Introduction 
4.1.1. Hereditary ataxia overview 
Clinical manifestation 
Ataxia is defined as a disturbance of balance and movement coordination (Shakkottai 
and Fogel, 2013). Hereditary ataxias are a group of progressive neurological disorders, 
which are highly heterogeneous both clinically and genetically. Phenotypically, 
hereditary ataxias are characterized by incoordination of gait (ataxic gait) and 
disturbance of hand and eye movements and speech (Jayadev and Bird, 2013). In most 
cases, patients with ataxia are presented with atrophy of the cerebellum. Additionally, 
patients may present with neuropathy, spasticity, seizures and cognitive damage 
(Shakkottai and Fogel, 2013). 
Ataxias can be subdivided on the basis of inheritance mode into autosomal dominant, 
autosomal recessive, X-linked, and mitochondrial (Bird, 1993 - ). Ataxias are also 
categorized by a gene or chromosomal locus, which contain the causative mutation(s). 
The full phenotypic spectrum of ataxias is not fully established; new types of ataxia and 
new ataxia genes are still being discovered. (Fogel et al., 2014a). Therefore, the ataxia 
nomenclature is a work in progress. Also, there is a substantial overlap between ataxias 
and some other neurological disorders, which makes precise diagnosis difficult. It is 
estimated that, when taken together, prevalence of all ataxias could be 15-20:100,000 
(Smeets and Verbeek, 2014). 
Establishing the diagnosis 
The first step in establishing the diagnosis is a clinical examination of the patient 
involving neurological tests, detailed family history and magnetic resonance imaging 
(MRI) of the brain (Fogel et al., 2014a). The aim of the first step is to rule out common 
non-genetic (acquired) causes of ataxia. Acquired conditions causing ataxia are 
represented by an array of disorders including toxic, inflammatory, nutritional, 
neoplastic and infectious disorders (Shakkottai and Fogel, 2013). Hereditary nature of 
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ataxia in the patient is supported by positive family history, recognizing a phenotype 
previously linked to hereditary ataxia and identification of ataxia-causing mutation(s) 
(Jayadev and Bird, 2013). Distinguishing between hereditary and acquired ataxias is 
important because for some acquired ataxias a specific treatment may be available 
(Shakkottai and Fogel, 2013).  
After ruling out acquired causes of ataxia, genetic investigations are concentrated on the 
most common ataxia causing genes (Fogel et al., 2014a). Firstly, the patient is subjected 
to genetic tests for the repeat expansion disorders. Dominant cases are investigated for 
repeat expansions in genes ATXN1, ATXN2, ATXN3, CACNA1A, ATXN7, which cause 
spinocerebellar ataxias (SCA) SCA1, SCA2, SCA3, SCA6 and SCA7, respectively. 
Dominant cases also could be investigated for repeat expansions in genes ATXN8 / 
ATXN80S, ATXN10, PPP2R2B, TBP, and ATN1, which cause SCA8, SCA10, SCA12, 
SCA17 and dentatorubral-pallidoluysian atrophy (DRPLA), respectively. It is estimated 
that up to 60% of hereditary dominant ataxias could be identified with testing for repeat 
expansion disorders (Jayadev and Bird, 2013). Patients with recessive family history are 
investigated for repeat expansions in FXN, which cause Friedreich ataxia. Male patients 
with suspected X-linked hereditary ataxia cases are investigated for repeat expansions in 
FMR1, which cause fragile X-associated tremor/ataxia syndrome. Secondly, the patient 
is investigated for the most common types of ataxia caused by non-repeat mutations 
(Fogel et al., 2014b). Cases with dominant family history could be investigated for 
mutations in SPTBN2, KCNC3, PRKCG, ITPR1, FGF14 and AFG3L2, which cause 
SCA5, SCA13, SCA14, SCA15, SCA27 and SCA28, respectively. Cases with recessive 
family history could be considered for genetic tests in ATM, APTX, SETX and TTPA, 
which cause ataxia-telangiectasia, ataxia with oculomotor apraxia type 1 (AOA1), 
ataxia with oculomotor apraxia type 2 (AOA2) and ataxia with vitamin E deficiency 
(AVED), respectively. 
If the patient is tested negative for all the above investigations, then advanced 
diagnostic tests, such as clinical exome or genome sequencing, is recommended (Fogel 
et al., 2014b).  
Autosomal Dominant Cerebellar Ataxia 
Prevalence of autosomal dominant cerebellar ataxias (ADCA) varies between countries, 
possibly due to a founder effect (Gasser et al., 2010). In the Netherlands it is estimated 
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to be around 3:100,000 (van de Warrenburg et al., 2002). More recent meta-analysis of 
the global ADCA prevalence was estimated to be 1-5:100,000 (Ruano et al., 2014). 
ADCA are further subdivided into spinocerebellar ataxias (SCA), episodic ataxias (EA), 
dentatorubral-pallidoluysian atrophy (DRPLA), autosomal dominant cerebellar ataxia 
with deafness and narcolepsy (ADCADN), hypomyelinating leukoencephalopathy and 
spastic ataxia (SPAX1) (Bird, 1993 - ). SCAs represent the most numerous group of 
ADCAs. The most common cause of dominantly inherited ataxias is repeat expansion 
within the coding or noncoding regions of the corresponding genes (Duenas et al., 
2006). Out of these, CAG repeat expansions are the most common. (Durr, 2010). CAG 
codes for glutamine, therefore disorders caused by expansion of CAG repeat are 
referred to as polyglutamine disorders. Besides CAG repeat mutations, there are 
numerous conventional mutations in associated genes, which cause ADCA. In a recent 
study of French ataxias, the authors estimated that repeat expansions account for 45% of 
all dominant ataxias, whereas conventional mutations account for only 6% with the 
remaining 48% of all dominant ataxias remaining genetically undiagnosed (Durr, 2010). 
The nomenclature for the inheritable ataxias is still being updating due to phenotypic 
overlap between ataxia subtypes. The latest data for ADCA are presented in Table 4.1.  
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Table 4.1: Molecular genetics of autosomal dominant cerebellar ataxias. 
This table depicts the molecular genetics of autosomal dominant cerebellar ataxias. 
Chromosomal locus is given only when the gene is unknown. For SCA9 there is no 
information published to date (adapted from (Bird, 1993 - )).  
 
Disease 
Name 
Gene Symbol or 
Chromosomal 
Locus  
Type of Mutation Reference 
SCA1 ATXN1 CAG repeat (Subramony and Ashizawa, 
1993-) 
SCA2 ATXN2 CAG repeat (Pulst, 1993--a) 
SCA3 ATXN3 CAG repeat (Paulson, 2009) 
SCA4 16q22.1 --- (Flanigan et al., 1996; 
Hellenbroich et al., 2003; 
Edener et al., 2011) 
SCA5 SPTBN2 Non-repeat 
mutations 
(Ikeda et al., 2006) 
SCA6 CACNA1A CAG repeat (Gomez, 1993-) 
SCA7 ATXN7 CAG repeat (Garden, 1993-) 
SCA8 ATXN8 / 
ATXN80S 
CAG/CTG (Ikeda et al., 1993-) 
SCA10 ATXN10 ATTCT repeat (Matsuura and Ashizawa, 
1993-) 
SCA11 TTBK2 Non-repeat 
mutations 
(Houlden, 1993-) 
SCA12 PPP2R2B CAG repeat (Margolis et al., 1993-) 
SCA13 KCNC3 Non-repeat 
mutations 
(Pulst, 1993--b) 
SCA14 PRKCG Non-repeat 
mutations 
(Chen et al., 1993-) 
SCA15 ITPR1 Deletion of the 5' 
part of the gene 
(Storey, 1993-) 
SCA16 CNTN4 Non-repeat mutation (Miura et al., 2006) 
SCA17 TBP CAA/CAG repeat 
mutation 
(Toyoshima et al., 1993-) 
SCA18 7q22-q32 --- (Brkanac et al., 2002; 
Brkanac et al., 2009) 
SCA19/22 KCND3 Non-repeat 
mutations 
(Verbeek et al., 2002; Chung 
et al., 2003; Schelhaas et al., 
2004; Duarri et al., 2012; Lee 
et al., 2012) 
SCA20 11q12.2-11q12.3 260-kb duplication (Storey, 1993-) 
SCA21 TMEM240 Non-repeat 
mutations 
(Delplanque et al., 2014)  
SCA23 PDYN Non-repeat 
mutations 
(Verbeek et al., 2004; 
Bakalkin et al., 2010) 
SCA25 2p21-p13 --- (Stevanin et al., 2003) 
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Table 4.1: continued 
 
Disease 
Name 
Gene Symbol 
or 
Chromosomal 
Locus  
Type of Mutation Reference 
SCA26 EEF2 Non-repeat mutations (Yu et al., 2005; Hekman et 
al., 2012) 
SCA27 FGF14 Non-repeat mutations (van Swieten et al., 2003) 
SCA28 AFG3L2 Non-repeat mutations (Cagnoli et al., 2006; 
Mariotti et al., 2008) 
SCA29 ITPR1 Non-repeat mutations (Dudding et al., 2004) 
SCA30 4q34.3-q35.1 --- (Storey et al., 2009) 
SCA31  BEAN1 TGGAA Intronic 
repeat expansion 
(Sato et al., 2009; Sakai et 
al., 2010; Edener et al., 2011) 
SCA34 ELOVL4 Non-repeat mutations (Cadieux-Dion et al., 2014) 
SCA35 TGM6 Non-repeat mutations (Wang et al., 2010) 
SCA36 NOP56 GGCCTG Intronic 
repeat expansion 
(Kobayashi et al., 2011) 
SCA37 1p32 --- (Serrano-Munuera et al., 
2013) 
SCA38 ELOVL5 Non-repeat mutations (Di Gregorio et al., 2014) 
SCA40 CCDC88C Non-repeat mutations (Tsoi et al., 2014) 
DRPLA ATN1 CAG repeat (Tsuji, 1993-) 
ADCADN DNMT1 Non-repeat mutations (Klein et al., 2013) 
Hypo-
myelinating 
leukoen-
cephalopathy 
TUBB4A Non-repeat mutations (Hamilton et al., 2014; 
Miyatake et al., 2014) 
EA1 KCNA1 Non-repeat mutation (D'Adamo et al., 1993-) 
EA2  CACNA1A Non-repeat mutations (Spacey, 1993-) 
EA3  1q42 --- (Cader et al., 2005) 
EA4  --- --- (Steckley et al., 2001) 
EA5 CACNB4 Non-repeat mutation (Jen et al., 2007) 
EA6 SLC1A3 Non-repeat mutation (Winter et al., 2012) 
EA7 19q13 --- (Kerber et al., 2007) 
SPAX1 VAMP1 Non-repeat mutations (Meijer et al., 2002; Bourassa 
et al., 2012) 
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Autosomal Recessive Cerebellar Ataxia 
Similarly to ADCAs, the prevalence of autosomal recessive cerebellar ataxias (ARCA) 
varies greatly between countries. The recent estimation of the global ARCA prevalence 
was 3:100,000 (Ruano et al., 2014). The most common forms of ARCAs in Europe are 
Friedreich ataxia (FRDA), ataxia telangiectasia (AT), and ataxia with oculomotor 
apraxia type 1 and type 2 (AOA1 and AOA2, respectively). Prevalence of FRDA is 
estimated to be 1:50,000 in Europe (Gasser et al., 2010). The most recent autosomal 
recessive hereditary ataxia nomenclature is outlined in Table 4.2. The table is divided 
into two parts with the first part listing more prevalent autosomal recessive ataxias 
(reported in more than 5 families worldwide) or treatable types. There are several types 
of recessive ataxia, for which a treatment is available. These include cerebrotendinous 
xanthomatosis (CTX) (treated with chenodeoxycholic acid), Refsum disease (treated 
with dietary phytanic acid), Brown-Vialetto-Van Laere syndrome 2 (treated with 
riboflavin), ataxia with vitamin E deficiency (AVED) (treated with vitamin E) and 
primary coenzyme Q10 deficiency-4 (COQ10D4), also known as autosomal recessive 
spinocerebellar ataxia-9 (SCAR9) (treated with coenzyme Q10 supplement). The first 
part of Table 4.2 also contains autosomal recessive ataxias more often found in a 
specific ethnic group, for example, autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS), which is found in French-Canadians (Ogawa et al., 2004). The 
second part of Table 4.2 lists less common autosomal recessive ataxias (reported in 1-5 
families worldwide) (Musselman et al., 2014).  
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Table 4.2:  Molecular genetics of Autosomal Recessive Cerebellar Ataxias. 
This table depicts the molecular genetics of Autosomal Recessive Cerebellar Ataxias 
(adapted from Bird, 1993 - ). *More common - reported in >5 families; **treatable – 
types of ataxia with treatment available; ***less common – reported in 1-5 families 
 
Gene / 
Locus  
Disease References  
More common* and/or treatable** 
ANO10 Autosomal recessive spinocerebellar ataxia 10 
(SCAR10) 
(Vermeer et al., 2010; 
Renaud et al., 2014)  
APTX Ataxia with oculomotor apraxia type 1 
(AOA1) 
(Coutinho and Barbot, 
1993-) 
ATM Ataxia-telangiectasia (AT) (Gatti, 1993-) 
C10orf2 Infantile-onset spinocerebellar ataxia (IOSCA) (Nikali and Lonnqvist, 
1993-) 
CYP27A1 Cerebrotendinous xanthomatosis (CTX) (Kim et al., 1994) 
FXN Friedreich ataxia (FRDA) (Bidichandani and 
Delatycki, 1993-) 
PHYH 
PEX7 
Refsum disease (Wanders et al., 1993-) 
PNPLA6 Boucher-Neuhäuser syndrome (Tarnutzer et al., 2015) 
SACS Autosomal recessive spastic ataxia of 
Charlevoix-Saguenay (ARSACS) 
(Vermeer et al., 1993-) 
SETX Ataxia with oculomotor apraxia type 2 
(AOA2) 
(Moreira and Koenig, 
1993-) 
SIL1 Marinesco-Sjögren syndrome (Anttonen and 
Lehesjoki, 1993-) 
SLC52A2 Brown-Vialetto-Van Laere syndrome 2 (Fogel et al., 2014a; 
Foley et al., 2014)  
TTPA Ataxia with vitamin E deficiency (AVED) (Schuelke, 1993-) 
WFS1 Wolfram syndrome (Chaussenot et al., 
2011; Fogel et al., 
2014a)  
Less common*** 
ABHD12 Polyneuropathy, hearing loss, ataxia, retinitis 
pigmentosa, and cataract (PHARC) 
(Fiskerstrand et al., 
2010; Chen et al., 
2013) 
ACO2 Infantile cerebellar- retinal degeneration 
(ICRD) 
(Spiegel et al., 2012) 
ADCK3 
(CABC1) 
Autosomal recessive spinocerebellar ataxia 9 
(SCAR9) 
(Lagier-Tourenne et 
al., 2008; Mollet et al., 
2008) 
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Table 4.2: continued 
 
Gene / 
Locus  
Disease References  
Less common 
ATCAY Cayman ataxia (Bomar et al., 2003) 
ATP8A2 Cerebellar ataxia, mental retardation, and 
dysequilibrium syndrome 4 (CAMRQ4) 
(Onat et al., 2013) 
STUB1 
(CHIP) 
Autosomal recessive spinocerebellarataxia16 
(SCAR16) 
(Shi et al., 2013; 
Depondt et al., 2014; 
Synofzik et al., 2014)  
CLCN2 Leukoencephalopathy with ataxia (LKPAT) (Depienne et al., 2013) 
CLN5 Adult-onset autosomal 
recessive ataxiaassociated with neuronal ceriod-
lipofuscinosis 5 (CLN5 disease) 
(Mancini et al., 2015) 
CWF19L1 Autosomal recessive ataxia (Turkish) (Burns et al., 2014) 
FLVCR1 Posterior column ataxia with rentinitis 
pigmentosa (AXPC1) 
(Ishiura et al., 2011) 
GOSR2 Ramsay Hunt syndrome (Corbett et al., 2011) 
GRID2 Autosomal recessive spinocerebellar ataxia 18 
(SCAR18) 
(Hills et al., 2013; Van 
Schil et al., 2014)  
GRM1 Autosomal recessive spinocerebellar ataxia 13 
(SCAR13) 
(Guergueltcheva et al., 
2012) 
KCNJ10 SeSAME syndrome (Scholl et al., 2009) 
KIAA0226 Autosomal recessive spinocerebellar ataxia 15 
(SCAR15) 
(Assoum et al., 2013) 
LAMA1 Cerebellar dysplasia (Aldinger et al., 2014) 
PNKP Ataxia with oculomotor apraxia type 4 (AOA4) (Bras et al., 2015) 
POLG Mitochondrial recessive ataxiasyndrome 
(MIRAS) 
(Mignarri et al., 2015) 
PTF1A Pancreatic and cerebellar agenesis (PACA) (Sellick et al., 2004) 
RNF216 Gordon Holmes syndrome (Santens et al., 2015) 
SLC9A1 Lichtenstein-Knorr syndrome (Guissart et al., 2015) 
SPTBN2 Autosomal recessive spinocerebellarataxia14 
(SCAR14) 
(Lise et al., 2012; 
Elsayed et al., 2014) 
SYNE1 SYNE1-related autosomal recessive 
cerebellar ataxia 
(Gros-Louis et al., 
2007) 
SYT14 Autosomal recessive spinocerebellar ataxia 11 
(SCAR11) 
(Doi et al., 2011) 
TDP1 Spinocerebellar ataxia with axonal neuropathy 
(SCAN1) 
(Takashima et al., 
2002) 
TPP1 Autosomal recessive spinocerebellar ataxia 7 
(SCAR7) 
(Breedveld et al., 2004; 
Sun et al., 2013) 
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Table 4.2: continued 
 
Gene / 
Locus  
Disease References  
Less common 
VLDLR VLDLR-associated cerebellar 
hypoplasia(CAMRQ1) 
(Ali et al., 2012) 
WWOX Autosomal recessive spinocerebellar ataxia 12 
(SCAR12) 
(Mallaret et al., 2014) 
ZNF592 Autosomal recessive spinocerebellar ataxia 5 
(SCAR5) 
(Mallaret et al., 2014) 
9q34-qter Autosomal recessive spinocerebellar ataxia 2 
(SCAR2) 
(Delague et al., 2001) 
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X-Linked Hereditary Ataxias 
X-linked hereditary ataxias are uncommon (Bird, 1993 - ), several types have been 
described to date with fragile X tremor ataxia syndrome (FXTAS) being the most 
common (Zanni and Bertini, 2011). FXTAS is caused by the expansion of a CGG-
trinucleotide repeat in the fragile X mental retardation 1 gene (FMR1) (Leehey, 2009). 
The latest nomenclature for X-linked hereditary ataxias is presented in Table 4.3  
 
 
Table 4.3:  Molecular genetics of X-linked hereditary ataxias. This table depicts the 
molecular genetics of X-linked hereditary ataxias (adapted from Bird, 1993 - ).  
 
Gene / 
Locus  
Disease References  
ABCB7 X-linked sideroblastic anemia and ataxia 
(XLSA/A) 
(Allikmets et al., 1999)  
CASK CASK-related disorders (Moog et al., 2011) 
FMR1 fragile X-associated tremor/ataxia syndrome 
(FXTAS) 
(Hagerman et al., 
2001) 
OPHN1 X-linked mental retardation with cerebellar 
hypoplasia and distinctive facial appearance 
(Zanni et al., 2005)  
SLC9A6 Syndromic X-linked mental retardation, 
Christianson type 
(Garbern et al., 2010)  
Xq25-
q27.1 
X-linked spinocerebellar ataxia 5 (Zanni et al., 2008)  
 
Spastic ataxias 
Spastic ataxias represent a group of disorders which combine spasticity with features of 
cerebellar ataxia (Bird, 1993 - ). There are five disorders, which are designated spastic 
ataxia (SPAX1 through to SPAX5) with SPAX1 being inherited dominantly and the 
other four exhibiting an autosomal recessive inheritance. Spastic paraplegia type 7 
(SPG7) is an autosomal recessive disorder caused by mutations in SPG7, which encodes 
paraplegin (Roxburgh et al., 2013). Recently, mutations in SPG7 were described as a 
major cause of unexplained ataxia with adult-onset presentation (Pfeffer et al., 2015). 
Spastic ataxia types are presented in Table 4.4.  
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Table 4.4:  Molecular genetics of disorders with spasticity and cerebellar ataxia. 
This table depicts the molecular genetics of spastic ataxias (adapted from Bird, 1993 - ).  
 
Disease Gene / Locus  References  
SPAX1 VAMP1 (Bourassa et al., 2012)  
SPAX2 KIF1C (Dor et al., 2014) 
SPAX3 MARS2 (Bayat et al., 2012) 
SPAX4 MTPAP (Crosby et al., 2010) 
SPAX5 AFG3L2 (Pierson et al., 2011) 
SPG7 SPG7 (Pfeffer et al., 2015)  
 
Mitochondrial Ataxias 
Ataxia phenotype can associate with mutations in the mitochondrial DNA (mDNA). For 
example, mutations in ATP synthase 6 gene (MTATP6) were found to cause childhood 
and adult-onset cerebellar ataxia (Pfeffer et al., 2012). Ataxia may also associate with 
mitochondrial disorders such as myoclonic epilepsy with ragged red fibres (MERRF), 
neuropathy, ataxia, and retinitis pigmentosa (NARP) and Kearns-Sayre syndrome 
(Rowland, 1983; Finsterer, 2009). Furthermore, mutations in nuclear-encoded genes, 
which regulate mitochondrial biogenesis, could result in hereditary ataxia (Table 4.2, 
POLG1). 
4.1.2. Whole exome sequencing in ataxia 
Precise diagnosis of hereditary ataxias is important because it leads to accurate genetic 
counselling and aids in diagnosis for families or patients with similar phenotypes. 
Correct diagnosis could also alter patient management as treatments are available for 
certain types of ataxia (Dixon-Salazar et al., 2012). The current diagnostic laboratory 
approach for dissecting heterogeneous monogenic disorders, such as ataxia, is stepwise 
genetic testing, which is expensive and time consuming. After exclusion of common 
acquired causes of ataxia, the majority of inherited ataxias arise as a result of repeat 
expansions (Hersheson et al., 2012). These mutations are usually detected on a routine 
diagnostic test, which  provides a diagnosis for up to 60% of cases with a positive 
family history (Anheim et al., 2010). The remaining 40% of inherited ataxias are 
individually rare (<1%). The diagnostic approach for the latter is screening for 
individual genes, which is a lengthy and expensive procedure. The current cost of the 
diagnosis of a neurological disorder could exceed £6,500 per individual 
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(Kingsmore and Saunders, 2011).  
Targeted next generation sequencing was recently shown to dramatically improve 
diagnostic outcome in ataxia patients. Hoischen and co-workers performed a pilot study 
using autosomal recessive ataxia as a model neurological disorder to assess the 
application of next generation sequencing in diagnostic settings (Hoischen et al., 2010). 
Coding and noncoding regions of seven known autosomal recessive ataxia genes were 
targeted in five patients with known mutations and two unaffected controls. On average 
80% of the targeted region was covered 25-fold per base. Six out of seven known 
mutations were successfully identified. In another study, 58 known ataxia genes were 
captured in 50 highly heterogeneous ataxia patients without diagnosis (Nemeth et al., 
2013). The authors were able to establish diagnosis in only 18% of the patients, 
explaining this by the limited portfolio of genes included in the panel. An additional 
challenge in targeted next generation sequencing is unusual clinical presentation, which 
might lead a clinician to choose an incorrect gene panel for screening. Whole exome 
sequencing could overcome this challenge. 
The aim of this study was to evaluate the use of whole exome sequencing for diagnostic 
purposes in neurological disorders. A heterogeneous cohort of patients with suspected 
inherited ataxia was used as an example of a neurological disorder and whole exome 
sequencing was applied with the aim to identify candidate gene mutations.  
4.2 Materials and methods 
4.2.1. Inclusion criteria  
This study presents a cohort of 35 affected individuals with unexplained ataxia, as 
described in  Section 2.1. The main inclusion criterion was ataxia as a predominant 
clinical feature. All common sporadic, inherited and metabolic causes were excluded on 
routine clinical investigations prior to inclusion in this study.  
4.2.2. Molecular genetics and bioinformatics 
All samples were prepared and sequenced, as described in Section 2.4.1. Bioinformatic 
analysis was performed as described in Section 2.4.2. Variant filtering was performed as 
described in Section 3.2. Coverage analysis of CCDS bases and known ataxia genes 
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was performed as described in Sections 3.2.6 and 3.2.7, respectively.  
4.2.3. Variant definition 
Variants were defined as previously described (Pyle et al., 2014). Definition criteria 
were as follows: 
1) Confirmed pathogenic variant – a previously described pathogenic variant or a 
variant in a known ataxia gene where the variant was predicted to affect protein 
structure and function, and segregated with at least one affected family member. 
2) Possible pathogenic variant – a variant in a known disease gene where the 
variant was predicted to alter protein structure and function, but not fulfilled all 
criteria for confirmed pathogenic variants. 
3) Variants of uncertain significance or no candidate variants found. 
4.2.4. In silico mutation pathogenicity study (splice prediction using Alamut software) 
Pathogenicity of the variants was assessed with mutation interpretation software Alamut 
(http://www.interactive-biosoftware.com/), which incorporates five splice prediction 
methods, namely: SpliceSiteFinder-like (Zhang, 1998), MaxEntScan (Yeo and Burge, 
2004), NNSPLICE (Reese et al., 1997), GeneSplicer (Pertea et al., 2001) and Human 
Splicing Finder (Desmet et al., 2009). Alamut software also has a capacity to predict 
exonic splicing enhancers (ESEs), which are short sequences within exons that enhance 
pre-mRNA splicing (Blencowe, 2000). Two programs are incorporated within Alamut 
in order to aid this, namely ESEfinder (Cartegni et al., 2003) and RESCUE_ESE 
(Fairbrother et al., 2004). An additional utility incorporated into Alamut in order to aid 
in determining which exonic variant has the highest chance to skip this exon is program 
EX-SKIP (available at http://ex-skip.img.cas.cz/).  
4.3 Results 
4.3.1. Clinical presentation, laboratory investigations and exome sequencing results 
for 35 patients with suspected inherited ataxia 
Clinical presentation, comprehensive laboratory investigations and exome sequencing 
results for 35 patients with suspected inherited ataxia studied here were previously 
published (Pyle et al., 2014) and are presented in Table 4.5. Additional clinical data and 
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segregation analysis results for cases with confirmed and possibly pathogenic mutations 
were previously published (Pyle et al., 2014) and are presented in Appendix 1.
! !
97!
T
ab
le
 4
.5
. C
lin
ic
al
 p
re
se
nt
at
io
n,
 la
bo
ra
to
ry
 in
ve
st
ig
at
io
ns
 a
nd
 e
xo
m
e 
se
qu
en
ci
ng
 r
es
ul
ts
 fo
r 
35
 p
at
ie
nt
s w
ith
 su
sp
ec
te
d 
in
he
ri
te
d 
at
ax
ia
 
A
bb
re
vi
at
io
ns
: M
 =
 m
al
e,
 F
 =
 fe
m
al
e;
 H
om
 =
 h
om
oz
yg
ou
s;
 H
et
 =
 h
et
er
oz
yg
ou
s;
 '+
' =
 p
re
se
nt
; '
-' 
= 
ab
se
nt
, n
ot
 a
pp
lic
ab
le
 (t
es
t n
ot
 c
ar
rie
d 
ou
t);
 s
ib
 =
  
si
bl
in
g;
 a
ff
 =
 a
ff
ec
te
d;
 N
or
m
al
 =
 a
ll 
re
su
lts
 n
or
m
al
/n
eg
at
iv
e;
 M
R
I =
 m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
  s
Se
gr
eg
at
io
n 
an
al
ys
is
 p
er
fo
rm
ed
 in
 th
e 
fa
m
ily
 tw
o 
ha
ve
 b
ee
n 
re
po
rte
d 
pr
ev
io
us
ly
 (P
yl
e 
et
 a
l.,
 2
01
2;
 P
yl
e 
et
 a
l.,
 2
01
3)
 
Th
is
 ta
bl
e 
in
cl
ud
ed
 in
 P
yl
e 
et
 a
l.,
 2
01
4.
 
A
bb
re
vi
at
io
ns
: 
M
 =
 m
al
e,
 F
 =
 f
em
al
e;
 H
om
 =
 h
om
oz
yg
ou
s;
 H
et
 =
 h
et
er
oz
yg
ou
s;
 '+
' =
 p
re
se
nt
; 
'-'
 =
 a
bs
en
t, 
no
t 
ap
pl
ic
ab
le
 (
te
st
 n
ot
 c
ar
rie
d 
ou
t);
   
   
   
  
si
b 
= 
 s
ib
lin
g;
 a
ff
 =
 a
ff
ec
te
d;
 N
or
m
al
 =
 a
ll 
re
su
lts
 n
or
m
al
/n
eg
at
iv
e;
 M
R
I =
 m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
  s
Se
gr
eg
at
io
n 
an
al
ys
is
 p
er
fo
rm
ed
 in
 th
e 
fa
m
ily
 
tw
o 
ha
ve
 b
ee
n 
re
po
rte
d 
pr
ev
io
us
ly
 (P
yl
e 
et
 a
l.,
 2
01
2;
 P
yl
e 
et
 a
l.,
 2
01
3)
 
A
da
pt
ed
 fr
om
 P
yl
e 
et
 a
l.,
 2
01
4.
 
 Co
nf
irm
ed
 p
at
ho
ge
ni
c 
 
ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 
at
 o
ns
et
 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
s 
Cerebellar a ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P1
, M
 
te
en
s 
af
f s
ib
 
(P
2)
 
Le
ar
ni
ng
 
di
ff
ic
ul
tie
s  
+ 
- 
- 
- 
- 
- 
+ 
+ 
- 
+ 
- 
SA
C
S 
c.
20
76
de
lG
:p
.T
hr
69
2T
hr
 
fs
*7
13
; 
c.
39
65
_3
96
6d
el
A
C
:p
. 
G
ly
13
22
V
al
fs
*1
34
3s
 
! !
98!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Co
nf
irm
ed
 p
at
ho
ge
ni
c 
 
ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 
at
 o
ns
et
 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
s 
Cerebellar a ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P2
, F
 
26
 
af
f s
ib
 
(P
1)
 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
- 
- 
- 
+ 
+ 
+ 
- 
+ 
+ 
 
 
P3
, M
 
te
en
s 
af
f s
ib
 
(P
4)
 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
  
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
- 
- 
SA
C
S 
he
m
iz
yg
ou
s c
.1
30
48
G
>T
: 
p.
G
lu
43
50
*;
 0
.7
M
b 
de
le
tio
n 
on
 C
hr
13
q1
2.
12
s  
P4
, M
 
C
hi
ld
 
ho
od
 
af
f s
ib
 
(P
3)
 
W
al
ki
ng
 
de
la
y 
+ 
+ 
+ 
- 
+ 
+ 
- 
- 
+ 
+ 
+ 
P5
, M
 
40
 
af
f s
ib
 
(P
6)
 
G
ai
t 
di
st
ur
ba
nc
e 
 
+ 
- 
- 
- 
- 
- 
- 
+ 
- 
- 
+ 
SA
C
S 
c.
15
80
C
>G
:p
.S
er
52
7*
 
c.
67
81
C
>A
:p
.L
eu
22
61
Ile
s  
! !
99!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Co
nf
irm
ed
 p
at
ho
ge
ni
c 
 
ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 a
t 
on
se
t 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
s 
Cerebellar a ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P6
, F
 
40
 
af
f s
ib
 
(P
5)
 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
+ 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
 
 
P7
, F
 
23
 
af
f s
ib
 
(P
8)
 
Sp
ee
ch
, 
B
al
an
ce
 
+ 
+ 
- 
- 
+ 
- 
- 
- 
- 
+ 
- 
K
C
N
C
3 
he
t. 
c.
12
59
G
>A
:p
.A
rg
42
0H
is
s  
P8
, F
 
57
 
af
f s
ib
 
(P
7)
 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
- 
- 
+ 
- 
- 
- 
- 
+ 
- 
P9
, M
 
30
 
af
f s
ib
 
(P
10
) 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
+ 
- 
+ 
+ 
- 
- 
+ 
- 
+ 
SP
G
7 
c.
15
29
C
>T
:p
.A
la
51
0V
al
; 
c.
17
15
C
>T
:p
.A
la
57
2V
al
 
!100!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Co
nf
irm
ed
 p
at
ho
ge
ni
c 
 
ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 a
t 
on
se
t 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
s 
Cerebellar a ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P1
0,
 F
 
29
 
af
f s
ib
 
(P
9)
 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
- 
+ 
- 
- 
+ 
- 
- 
+ 
+ 
- 
 
 
P1
1,
 F
 
in
fa
nc
y 
af
f s
ib
 
(P
12
), 
m
ot
he
r 
(P
13
) 
D
el
ay
ed
 
m
ot
or
 a
nd
 
sp
ee
ch
 
de
ve
lo
pm
en
t 
+ 
- 
+ 
- 
+ 
+ 
- 
- 
- 
+ 
- 
TU
BB
4A
 
he
t 
c.
90
0C
>A
:p
.M
et
30
0I
le
s  
P1
2,
 F
 
in
fa
nc
y 
af
f s
ib
 
(P
11
), 
m
ot
he
r 
(P
13
) 
D
el
ay
ed
 
m
ot
or
 a
nd
 
sp
ee
ch
 
de
ve
lo
pm
en
t 
+ 
- 
+ 
+ 
+ 
+ 
- 
- 
- 
+ 
- 
P1
3,
 F
 
30
 
af
f 
ch
ild
re
n 
(P
11
, 
P1
2)
 
G
ai
t 
di
st
ur
ba
nc
e,
 
sl
ur
re
d 
sp
ee
ch
 
+ 
- 
+ 
- 
+ 
+ 
- 
- 
+ 
+ 
- 
m
os
ai
c 
c.
90
0C
>A
:p
.M
et
30
0I
le
s  
! !
101!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Co
nf
irm
ed
 p
at
ho
ge
ni
c 
 
ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 a
t 
on
se
t 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
s 
Cerebellar a ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P1
4,
 
F 
5 
N
on
e 
Le
ar
ni
ng
 
di
ff
ic
ul
tie
s, 
ga
it 
di
st
ur
ba
nc
e 
+ 
- 
- 
+ 
- 
+ 
- 
- 
+ 
- 
- 
TU
BB
4A
 
he
t 
c.
10
91
C
>A
:p
.A
la
36
4A
sp
s  
P1
5,
 
F 
21
 
af
f s
ib
  
(P
16
) 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
- 
- 
+ 
- 
+ 
- 
- 
+ 
- 
- 
N
PC
1 
c.
46
7T
>C
: p
.M
et
15
6T
hr
 
c.
70
9C
>T
:p
.P
ro
23
7S
er
s  
P1
6,
 
F 
21
 
af
f s
ib
 
 (P
15
) 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
- 
+ 
- 
+ 
- 
- 
+ 
- 
- 
! !
102!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Co
nf
irm
ed
 p
at
ho
ge
ni
c 
 I
D
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 a
t 
on
se
t 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
s 
Cerebellar a ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P1
7,
 
M
 
30
 
af
f 
m
ot
he
r, 
au
nt
, 
co
us
in
 
(P
18
) 
Sp
ee
ch
 
di
st
ur
ba
nc
e 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
- 
+ 
- 
+ 
- 
- 
- 
- 
- 
SL
C
1A
3 
he
t 
c.
13
61
G
>A
:p
.A
rg
45
4G
ln
s  
P1
8,
 
F 
39
 
af
f 
m
ot
he
r, 
co
us
in
 
(P
17
) 
Sp
ee
ch
 
di
st
ur
ba
nc
e 
+ 
+ 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
 
 
! !
103!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Po
ss
ib
ly
 p
at
ho
ge
ni
c 
 I
D
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 
at
 o
ns
et
 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
 
 Cerebellar Ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P1
9,
 
M
 
32
 
N
on
e 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
- 
- 
- 
- 
- 
+ 
- 
- 
- 
+ 
ZF
YV
E2
6 
c.
23
38
C
>T
:p
.A
rg
78
0*
 
c.
24
50
de
lT
:p
.L
eu
81
7C
ys
fs
*1
2 
P2
0,
 F
 
40
 
N
on
e 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
- 
- 
- 
+ 
+ 
- 
- 
- 
- 
- 
W
FS
1 
c.
57
7A
>C
:p
.L
ys
19
3G
ln
; 
c.
13
67
G
>A
:p
.A
rg
45
6H
is
 
P2
1,
 F
 
in
fa
nc
y 
N
on
e 
W
al
ki
ng
 
de
la
y 
+ 
- 
+ 
- 
+ 
+ 
- 
- 
- 
- 
- 
FA
ST
K
D
2 
c.
-6
6A
>G
; 
c.
14
9A
>G
:p
.L
ys
50
A
rg
s  
! !
104!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Po
ss
ib
ly
 p
at
ho
ge
ni
c 
 I
D
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 
at
 o
ns
et
 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
 
 Cerebellar Ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P2
2,
 
M
 
37
 
af
f s
on
 
(P
23
) 
U
pp
er
 
lim
b 
cl
um
si
ne
ss
 
+ 
- 
+ 
- 
- 
+ 
- 
- 
- 
+ 
- 
ZF
YV
E2
7 
c.
80
5-
2A
>G
s  
P2
3,
 
M
 
35
 
af
f 
fa
th
er
 
(P
22
) 
+ 
- 
- 
- 
- 
+ 
- 
- 
+ 
+ 
- 
P2
4,
 
M
 
25
 
af
f 
fa
th
er
 
(P
22
) 
af
f h
al
f-
br
ot
he
r 
(P
23
) 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
+ 
- 
! !
105!
T
ab
le
 4
.5
: c
on
tin
ue
d 
Po
ss
ib
ly
 p
at
ho
ge
ni
c 
 ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 
at
 o
ns
et
 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
 
 Cerebellar Ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P2
5,
 
F 
11
 
N
on
e 
U
pp
er
 
lim
b 
cl
um
si
ne
ss
 
+ 
- 
+ 
- 
- 
+ 
- 
- 
+ 
- 
- 
W
N
K
1 
c.
19
94
C
>T
:p
.T
hr
66
5I
le
s  
c.
32
72
C
>T
:p
.T
hr
10
91
Ile
s  
! !
106!
T
ab
le
 4
.5
: c
on
tin
ue
d 
U
nc
er
ta
in
 si
gn
ifi
ca
nc
e 
or
 n
o 
ca
nd
id
at
e 
va
ria
nt
s f
ou
nd
 
 
ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 a
t 
on
se
t 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
 
Cerebellar Ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P2
6,
 F
 
13
 
N
on
e 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
- 
- 
K
C
N
B2
 
c.
15
89
C
>T
: p
.S
er
53
0P
he
; 
c.
23
51
T>
C
:p
.L
eu
78
4P
ro
   
   
  
P2
7,
 M
 
20
 
2 
af
f 
ch
ild
re
n 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
+ 
+ 
- 
- 
+ 
- 
- 
- 
+ 
- 
AB
C
B7
 
PO
LG
 
 
W
FS
1 
ho
m
 (h
em
i) 
c.
81
8G
>A
:p
.A
rg
27
3G
ln
s   
 
c.
22
43
G
>C
:p
.T
rp
74
8S
er
;  
c.
34
28
A
>G
:p
.G
lu
11
43
G
ly
   
   
   
   
he
t c
.1
29
4C
>G
:p
.L
eu
43
2V
al
 
P2
8,
 F
 
ch
ild
 
ho
od
 
af
f 
co
us
in
 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
+ 
- 
N
o 
ca
nd
id
at
e 
va
ria
nt
s 
P2
9,
 F
 
40
 
af
f 
ch
ild
 
(P
30
) 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
+ 
! !
107!
T
ab
le
 4
.5
: c
on
tin
ue
d 
U
nc
er
ta
in
 si
gn
ifi
ca
nc
e 
or
 n
o 
ca
nd
id
at
e 
va
ria
nt
s f
ou
nd
 
 ID
, 
Se
x 
Ag
e 
of
 
on
se
t 
(y
) 
Fa
m
ily
 
H
ist
or
y 
Sy
m
pt
om
 a
t 
on
se
t 
Cl
in
ic
al
 si
gn
s 
In
ve
sti
ga
tio
ns
 
G
en
e 
Va
ria
nt
 
Cerebellar Ataxia 
Ey
es
 
Cerebellar dysarthria 
El
ec
tro
ph
ys
io
lo
gy
 
M
RI
 
Jerky ocular pursuit 
Gaze evoked nystagmus 
Hypometric saccades 
Optic atrophy 
Axonal sensorimotor 
neuropathy 
Demyelinating 
sensorimotor neuropathy 
Normal 
Cerebellar atrophy 
Generalised atrophy 
P3
0,
 
M
 
21
 
af
f m
ot
he
r 
(P
29
) 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
+ 
- 
- 
- 
- 
+ 
- 
- 
+ 
- 
N
o 
ca
nd
id
at
e 
va
ria
nt
s 
P3
1,
 
F 
46
 
N
on
e 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
+ 
- 
- 
- 
+ 
- 
- 
- 
- 
- 
P3
2,
 
M
 
31
 
N
on
e 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
+ 
- 
- 
+ 
- 
- 
- 
+ 
+ 
P3
3,
 
M
 
te
en
s 
af
f s
ib
 
(P
34
) 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
- 
+ 
- 
- 
+ 
- 
- 
+ 
+ 
- 
P3
4,
 
M
 
11
 
af
f s
ib
 
(P
33
) 
U
pp
er
 li
m
b 
cl
um
si
ne
ss
 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
- 
P3
5,
 
F 
20
 
M
ot
he
r 
ha
s 
hy
po
to
ni
a 
G
ai
t 
di
st
ur
ba
nc
e 
+ 
+ 
+ 
- 
+ 
- 
- 
- 
- 
+ 
- 
!! 108!97!
4.3.2. Population frequency data and pathogenicity scores for variants found in 27 
patients with ataxia 
Population frequency data and pathogenicity scores for variants found in 27 patients 
with ataxia were previously published (Pyle et al., 2014) and are presented in Chapter 3 
of this Thesis (Table 3.4). 
4.3.3. Confirmed pathogenic variants 
Confirmed pathogenic variants were found in 9 out of 22 families (41% of families) 
(Pyle et al., 2014) (presented in Table 4.5 and Appendix 1, and Chapter 3 (Table 3.4)). 
SACS 
Novel compound heterozygous SACS mutations were identified in three unrelated 
families (Appendices 1 and 2). Each family had a pair of affected siblings who shared 
mutations. Patients P1 and P2 were compound heterozygous for p.Thr692Thr fs*713 
and p.Gly1322Val fs*1343 (Pyle et al., 2012), patients P3 and P4 shared p.Glu4350* 
and a 0.7Mb deletion on Chr13q12.12, which included SACS (Pyle et al., 2013) and 
finally, patients P5 and P6 shared mutations p.Ser527* and p.Leu2261Ile. 
 
KCNC3 
A known dominant KCNC3 mutation p.Arg420His (Waters et al., 2006; Figueroa et al., 
2010) was found to segregate with ataxia in four members of a three-generation 
autosomal dominant pedigree (patients P7 and P8), making this family the 5th 
worldwide to date with a p.Arg420His mutation. 
 
SPG7 
Previously reported compound heterozygous SPG7 mutations (p.Ala510Val and 
p.Ala572Val) (Casari et al., 1998) were found in two affected siblings from a family 
with no spasticity (patients P9 and P10). 
 
 
TUBB4A  
Likely de novo dominant TUBB4A mutations (Simons et al., 2013) were found in two 
families. In one family, siblings P11 and P12 were heterozygous for p.Met300Ile, 
whereas their affected mother (P13) was mosaic for this mutation. In the other family, 
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the affected individual (P14) had a p.Ala364Asp mutation. Detailed investigations of 
pathogenicity of these mutations are presented in Chapter 6. 
 
NPC1  
Two siblings (P15 and P16) presenting with adult onset ataxia had compound 
heterozygous mutations in NPC1 (p.Met156Thr and p.Pro237Ser). Subsequent 
oxysterol analysis confirmed pathogenicity of these mutations (Table 4.6; performed by 
Kim Barlett, Newcastle upon Tyne Foundation Hospitals NHS Trust) (Carstea et al., 
1997).  
 
Table 4.6: Plasma oxysterol measurements in P15 and P16. Reproduced from Pyle et 
al., 2014 
 
Patient 7 alpha (ng/ml) 7 beta (ng/ml) 7 keto (ng/ml) 
P15 21.3 12.9 33.9 
P16 77.1 60.6 167.4 
Normal Range 2.6-53.6 2.9-10.8 2.4-29.1 
 
 
SLC1A3 
A novel dominant p.Arg454Gln mutation, in a known ataxia gene SLC1A3, segregated 
with ataxia in two members of a family (P17 and P18) (de Vries et al., 2009). Patient 
P17 had an affected mother.  
4.3.4. Possible pathogenic variants  
Possible pathogenic variants were found in 5 out of 22 families (23% of families) (Pyle 
et al., 2014) and the result is presented in Appendices 1, 2 and Chapter 3 (Table 3.4). 
ZFYVE26 
One patient (P19) had a compound heterozygous mutation (p.Leu817Cysfs*12 and 
p.Arg780*) in ZFYVE26 (SPG15). The p.Arg780* mutation occurs in a highly 
conserved residue and is predicted to be disease causing or damaging by three 
prediction programmes. The parental samples were unavailable for analysis. However, 
we were able to show, via cloning, that the variants were inherited in trans, supporting a 
recessive inheritance model (this investigation is presented in Chapter 7). This led the 
clinicians to re-assess the neuroimaging and confirm the thin corpus callosum, which is 
a characteristic of SPG15 (Goizet et al., 2009). 
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WFS1 
Previously described compound heterozygous WFS1 mutations (p.Lys193Gln and 
p.Arg456His) were identified in one family (patient P20) (Cryns et al., 2003). Both 
mutations occur at conserved residues and have been previously linked to Wolfram 
syndrome. 
 
FASTKD2 
One patient (P21) had compound heterozygous FASTKD2 mutations (p.Lys50Arg, 
which is conserved among species, and c.-66A>G predicted to affect normal splicing of 
exon 1) (Ghezzi et al., 2008). Sanger sequencing revealed segregation of the variants 
with the disease. Splice predictions for FASTKD2 (NM_001136194.1):c.-66A>G - [c.-
165 (Exon 1c) - c.-51+85 (Intron 1c)] show a gain of acceptor site at  c.-65 by one 
program and loss of acceptor site at –c.64 by another program (Alamut v2.4, Interactive 
Biosoftware, Rouen, France) (Figure 4.1 A). The in silico splice-site prediction for the 
c.-66A>G mutation was validated with sequencing analysis of cDNA clones (this 
investigation is presented in Chapter 7). 
. 
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ZFYVE27 
A predicted splice site mutation (c.805-2A>G) was detected in three members of an 
autosomal dominant pedigree (P22, P23 and P24) in the ZFYVE27 gene, which was 
previously described in connection with spasticity, but not ataxia (Mannan et al., 2006). 
Splice predictions for ZFYVE27 c.805-2A>G show loss of acceptor site of exon 7 in 
five splice prediction programs (Alamut v2.4, Interactive Biosoftware, Rouen, France) 
(Figure 4.1 B). Detailed investigation of the possible pathogenicity of this mutation is 
presented in Chapter 5. 
 
WNK1 
Novel compound heterozygous mutations (p.Thr665Ile and p.Thr1091Ile) were found in 
WNK1 in one patient (P25). The parents were both asymptomatic, each carrying an 
alternative or different allele, supporting the recessive inheritance model. The 
p.Thr665Ile mutation occurs in a highly conserved residue and is predicted to be 
pathogenic by four pathogenicity prediction programs. WNK1 is a known disease gene, 
which has not been previously associated with ataxia. Mutations in WNK1 were 
previously reported in cases with hereditary sensory and autonomic neuropathy type II 
(Lafreniere et al., 2004; Shekarabi et al., 2008). 
4.3.5. Variants of uncertain significance or no candidate variants found 
Variants of uncertain significance were found in 2 families (patients P26 and P27) and 
no candidate variant was found in 6 families (8 patients). This study, therefore, was not 
able to identify likely causative variants in 8 families (36% of families). The potential 
candidate variants are presented in Table 4.5 and Appendix 1. A list of variants in 
patients where we were not able to confidently identify likely candidates was previously 
published (Pyle et al., 2014) and is presented in Appendix 2. 
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4.4. Discussion 
4.4.1. Diagnostic yield 
This exome sequencing study identified confirmed pathogenic variants in 9 out of 22 
families (41%). Possible pathogenic variants were found in 5 out of 22 families (23%). 
Taken together, this accounts for a likely molecular diagnosis in 14 of 22 families 
(64%). These findings agree with whole exome sequencing studies in ataxia cohorts 
performed by other groups. Ohba and co-workers assessed patients with childhood-
onset cerebellar ataxia and were able to define a molecular cause of the disease in 9 out 
of 23 families (39%) (Ohba et al., 2013). Another study assessed the diagnostic yield of 
whole exome sequencing in 28 families with paediatric ataxia patients without a 
molecular diagnosis (Sawyer et al., 2014). Molecular cause of the disease was 
established in 13 out of 28 families (46%). Of note, the lower diagnostic yield in the 
latter two studies might be due to lack of family history in some cases. Fogel and 
colleagues (Fogel et al., 2014b) applied WES to a heterogeneous cohort of 76 patients 
with adult and sporadic onset cerebellar ataxia and were able to establish overall likely 
molecular diagnosis in 60% of the patients being studied. Interestingly, this study and 
the study by Fogel et al., 2014 shared only 3 known disease genes (SPG7, WFS1 and 
ZFYVE26) as a likely cause of the disease.  
This study, and the work by others mentioned above, contrasts with a targeted exome 
sequencing study in an ataxia cohort by Nemeth and colleagues (Nemeth et al., 2013), 
which had an overall detection rate of 18% in a similar heterogeneous ataxia cohort. 
The possible explanation is greater genomic coverage and unbiased approach of the 
whole exome sequencing. 
Importantly, this study is endorsed not only by exome sequencing studies in ataxia, but 
also by similar studies in other neurological disorders. Srivastava and co-workers 
assessed the diagnostic yield of whole exome sequencing in 78 patients with 
neurodevelopmental disorders and found an overall presumptive cause of the disease in 
41% of the patients (Srivastava et al., 2014). Similarly high diagnostic yield was 
documented in cohort studies with Charcot-Marie-Tooth disease (total yield = 53%) 
(Klein et al., 2014) and hereditary spastic paraplegia (diagnostic yield =75%) (Novarino 
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et al., 2014). Of note, the higher diagnostic rate in the latter study might be due to 
exome sequencing parent-child trios in some cases. These samples were not always 
available in this study. 
At the time this work commenced the Exome Aggregation Consortium (ExAC) data 
was not available and was not used. ExAC is a dataset which provides exome 
sequencing data for over 60,000 unrelated control individuals (available at 
http://exac.broadinstitute.org ) The current study subsequently reviewed ExAC data and 
the outcome is presented in Table 4.7. The population frequency data generated using 
ExAC database are in line with other databases (Table 3.7) for all variants found in 27 
patients in this study.  
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Table 4.7: Population frequency data generated from ExAC database for variants 
found in 27 patients with ataxia 
      Population Data 
P ID Gene Variant Allele count Allele frequency 
P1, 
SACS 
p.Thr692Thr fs*713  -   -  
P2 p.Gly1322Val fs*1343  -   -  
P3, P4 SACS p.Glu4350*  -   -  
P5, P6 SACS 
p.Ser527*  -   -  
p.Leu2261Ile 584/120970 0.004828 
P7, P8 KCNC3 p.Arg420His  -   -  
P9, P10 SPG7 
p.Ala510Val 306/121348  0.002522 
p.Ala572Val 1/121216  0.00000825 
P11, P12, 
P13 TUBB4A p.Met300Ile  -   -  
P14 TUBB4A p.Ala364Asp  -   -  
P15 
NPC1 
p.Met156Thr 10/121362 0.0000824 
P16 p.Pro237Sers 1262/120672 0.01046 
P17,P18 SLC1A3 p.Arg454Gln  -   -  
P19 ZFYVE26 
p.Leu817Cys fs*12  -   -  
p.Arg780*  -   -  
P20 WFS1 
p.Lys193Gln 487/120064 0.004056 
p.Arg456His 6908/121250  0.05697 
P21 FASTKD2 
c.-66A>G  -   -  
p.Lys50Arg 304/120810 0.002516 
P22, P23, 
P24 ZFYVE27 c.805-2A>G 3 / 121378 0.00002472 
P25 WNK1 
p.Thr665Ile 7755/121386  0.06389 
p.Thr1091Ile  -   -  
P26 KCNB2 
p.Ser530Phe 2/121214  0.0000165 
p.Leu784Pro  -   -  
P27 
ABCB7 p.Arg273Gln  -   -  
POLG 
p.Trp748Ser  -   -  
p.Glu1143Gly 3410/121226 0.02813 
WFS1 p.Leu432Val 439/121400  0.003616 
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4.4.2. Heterogeneity of inherited ataxia 
This study identifies 11 genes implicated in 14 families. No recurrent mutations in the 
same gene were observed (Pyle et al., 2014). This result reflects the high genetic 
heterogeneity of hereditary ataxia. 
4.4.3. Whole exome sequencing vs “ataxia multi-gene panel” 
This study and the work by other groups suggest that one of the disadvantages of the 
targeted exome sequencing is a lower diagnostic yield. Diagnostic yield in this study 
(64%) and similar studies (39-60%) contrasted with a recent targeted exome sequencing 
study (diagnostic yield =18%) (Nemeth et al., 2013). This could be due to a greater 
exome coverage, which allows identification of “new” ataxia genes, which were not 
previously considered as “known” ataxia genes and therefore were not included in the 
panel. Overlooking such genes is one of the disadvantages of targeted exome 
sequencing. An example of a gene, which was not included in the ataxia gene panel by 
Nemeth et al., 2013, but was found to be a definite cause of ataxia in one family in this 
study and in a similar work (Fogel et al., 2014b), is SPG7. Moreover, both findings of 
this study and the work by Fogel et al., 2014, prompted a study in a cohort of 70 
patients with adult onset unexplained ataxia (Pfeffer et al., 2015), which identified 
mutations in SPG7 as a cause of unexplained ataxia in 19% of the patients. This 
establishes SPG7 mutations as a common cause of unexplained ataxia. The latest 
published ataxia gene panel (Nemeth et al., 2013) included 118 known and speculative 
ataxia genes. In the current study an exome coverage analysis was performed for all 
these genes in all the patients and found that 89% of the coding regions of these genes 
were covered 20-fold (Chapter 3.3.2). This study, therefore, assumes that it would be 
able to detect the majority of the mutations identified by Nemeth et al., 2013. However, 
it is pointed out that only 29% of the disease genes identified in this study were 
included in the multi-gene panel of Nemeth et al., 2014 (Pyle et al., 2014).  
The other disadvantage of targeted exome sequencing over whole exome sequencing is 
that different diagnostic laboratories might provide different gene panels with limited 
overlap. This could be due to the variations in the local demographics, which would 
affect prevalence of different types of ataxia in different populations. Therefore, various 
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laboratories might prefer to include different genes in their panels, reflecting the need of 
the local population. Also, the list of genes included in the panel is based on the current 
knowledge of ataxia genes and therefore is far from being complete. Considering the 
whole exome may help to remove these biases.  
One of the advantages of whole exome sequencing is the identification of known 
disease genes in an unusual clinical setting, broadening the clinical phenotype of known 
disease genes. This study identified known pathogenic mutations in SPG7 in two 
siblings (patients P9 and P10) from a recessive family, presented with ataxia but no 
spasticity. SPG7 is a gene implicated in hereditary spastic paraplegia (Schule and 
Schols, 2011). Although SPG7 previously has been linked to ataxia, it has never been 
described in cases without spasticity. In another family, two siblings (patients P15 and 
P16) were found to have compound heterozygous mutations in NPC1. Mutations in this 
gene cause Niemann Pick type C, a neurological disorder with characteristic eye 
movement. Patients presented in this study did not exhibit this feature. However, exome 
sequencing result of this study was supported by the biochemical finding (Table 4.5), 
which helped to establish the diagnosis. (Carstea et al., 1997). In another patient (P19) 
this study identified compound heterozygous mutation in ZFYVE26 known to cause 
spastic paraplegia type 15 (SPG15). The current study prompted a review of the 
neuroimaging in this patient and confirmed thin corpus callosum, which is a 
characteristic of SPG15. 
Given that the cost of sequencing of a single candidate gene is comparable to whole 
exome sequencing (Pyle et al., 2014) and to a targeted capture of >50 genes (Nemeth et 
al., 2013), exome sequencing may be a faster and more cost effective method to 
discover disease causing gene mutations. Coupled with the continuing decrease in the 
cost of whole exome sequencing, this technique could be more advantageous in a 
clinical setting.  
4.4.4. Possible explanations why did we not solve all of cases 
This study was unable to identify the likely cause of ataxia in 36% of families. Given 
the relevant family history in most cases, this could be due to technical issues, for 
example, the capture probes being ineffective for GC-rich or repetitive regions, which 
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could result in incomplete coverage. Furthermore, large genomic rearrangements and 
trinucleotide repeat sequences are not reliably detected from exome-capture data. 
Finally, this study has not considered non-coding regions. It is likely that some causal 
variants will reside within non-coding regulatory regions. Some of these issues could be 
resolved by whole genome sequencing, albeit with additional cost. WGS produces over 
100 Gb of data. The main difficulty of WGS is interpretation of variations found in non-
coding regions due to lack of knowledge about the importance of such regions (Ward 
and Kellis, 2012). Therefore, the consequences of variations in non-coding regions of 
the genome are less well understood than variations in coding regions. 
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Chapter 5. Molecular genetic analysis and determining pathogenicity 
of a heterozygous splice site mutation in ZFYVE27 in an autosomal 
dominant pedigree 
5.1. Introduction 
Using whole exome sequencing we identified a predicted splice site mutation in 
ZFYVE27 (zinc finger, FYVE domain containing 27) gene (c.805-2A>G), which 
segregated with the disease in three members of an autosomal dominant pedigree 
(patient P22, P23 and P24). Mutations in ZFYVE27 have not been associated with ataxia 
before. Mannan and colleagues (Mannan et al., 2006) identified a p.Gly191Val 
mutation in ZFYVE27 (SPG33) and associated it with  the clinical phenotype in a 
German family with autosomal dominant hereditary spastic paraplegia (AD-HSP), a 
neurological disease characterised by selective degeneration of axons. The most 
common form of AD-HSP is due to heterozygous mutations in the spastin (SPG4) gene 
(Hazan et al., 1999). Mannan and co-workers reported ZFYVE27 as a specific spastin-
binding protein and suggested that ZFYVE27 binds spastin through its C-terminus via a 
short motif within the FYVE domain. Intriguingly, using a co-immunoprecipitation 
experiment, the authors showed reduced binding of the p.Gly191Val mutant ZFYVE27 
to spastin. The p.Gly191Val mutation was found to segregate with the disease in the 
family and was not present in 210 control chromosomes. The mutation falls within the 
third transmembrane domain of the protein. It was suggested that the mutation shifts the 
transmembrane domain motif forward and thus alters the conformation of ZFYVE27 in 
the region of the FYVE domain. They thus proposed that the failure of ZFYVE27 to 
interact with spastin was potentially a cause of the disease. However, it should be 
pointed out that the current study subsequently investigated the frequency of the 
p.Gly191Val mutation on ExAC database (available at http://exac.broadinstitute.org ) 
and found that the p.Gly191Val is a common variant (allele count 1329/121408; 
MAF=0.01095). No other ZFYVE27 pathogenic mutations were reported in other 
families so far. 
Shirane and Nakayama (Shirane and Nakayama, 2006) identified ZFYVE27 as a 
mammalian protein that promotes neurite formation through the interaction with a 
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guanosine diphosphate (GDP)-bound form of Rab11. Rab11 takes part in the regulation 
of membrane trafficking during neurite formation and has a specific role in membrane 
recycling. The authors showed that ZFYVE27 became phosphorylated by extracellular 
signal-regulated kinase (ERK) in response to nerve growth factor (NGF) and this leads 
to interaction between ZFYVE27 and Rab11. Down-regulation of ZFYVE27 inhibited 
neurite formation. 
Martignoni and colleagues (Martignoni et al., 2008) assessed the ability of wildtype and 
p.Gly191Val,mutant ZFYVE27 to extend neurites in immortalised murine motor 
neuronal cell lines and the ability to elongate HeLa cells, but found no difference 
between the wildtype and the mutant. The p.Gly191Val mutant of ZFYVE27 was also 
found to retain the ability to bind to Rab11-GDP and spastin indicating that the 
p.Gly191Val mutation does not result in the loss of function. These data question the 
contribution of the p.Gly191Val mutation to the disturbance of the interaction between 
ZFYVE27 and spastin, and therefore, the involvement of ZFYVE27 mutation in the 
disease phenotype, presented by Mannan et al., is still inconclusive (Mannan et al., 
2006). 
Saita and colleagues (Saita et al., 2009) found that ZFYVE27 associates and co-
localizes with a vesicle-associated membrane protein isoform A (VAP-A), which is 
expressed in the endoplasmic reticulum (ER). The VAP-A-binding domain of 
ZFYVE27 was found to be the prerequisite for the ZFYVE27-dependent formation of 
membrane protrusions in HeLa cells. Furthermore, depletion of VAP-A by RNA 
interference lead to the inhibition of nerve growth factor (NGF)-induced neurite 
outgrowth in the rat pheochromocytoma PC12 cells. Subsequent forced expression of 
human wildtype VAP-A, but not the VAP-A mutants that lost their ability to bind 
ZFYVE27, corrected the defect. Altogether, these results suggest that the interaction of 
ZFYVE27 with VAP-A is, firstly, an important regulator of subcellular localisation of 
ZFYVE27 and secondly, is essential for the ability of ZFYVE27 to stimulate neurite 
formation. 
A study by Zhang and co-workers (Zhang et al., 2012) supported the work by 
Martignoni and colleagues, in finding no difference in the ability of wildtype ZFYVE27 
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and the p.Gly191Val mutant to extend neurites in PC12 cells or to elongate the motor 
neuron axon of zebrafish embryos. They also showed that spastin promotes ZFYVE27-
dependent neurite outgrowth in PC12 cells and spinal cord motor neuron axon 
outgrowth in zebrafish and proposed that spastin and ZFYVE27 may work together in 
promoting motor axon outgrowth. They also suggested that the N-terminal region of 
ZFYVE27, and not the FYVE domain, mediated the interaction with spastin. Chang and 
co-workers proposed a membrane topology model for the ZFYVE27 protein, protrudin 
(Figure 5.1) (Chang et al., 2013).  
 
Figure 5.1: Membrane topology model for ZFYVE27. ZFYVE27 contains a Rab11-
binding domain (RBD). Three trans-membrane domains are followed by FFAT (two 
phenylalanines in an acidic tract) domain, an endoplasmic reticulum targeting signal. 
On its C-terminus protrudin contains a coiled coil (CC) domain followed by the FYVE 
(Fab1, YOTB, Vac1, and EEA1) domain (adapted from Chang et al., 2013). 
 
The RBD domain is necessary for interaction with RAB11A, which promotes neurite 
outgrowth (Shirane and Nakayama, 2006). The FFAT domain is necessary for 
interaction with VAP-A (vesicle-associated membrane protein-associated protein 
isoform A) (Saita et al., 2009). VAP-A is expressed in the ER and is responsible for 
subcellular localisation of ZFYVE27. The FFAT domain also mediates the interaction 
of protrudin with microtubule-associated molecular motor KIF5 (Matsuzaki et al., 
!! 123!
2011). Mutated KIF5A, a neuron-specific isoform of KIF5, was identified as a cause of 
autosomal dominant hereditary spastic paraplegia type 10 (SPG10) (Reid et al., 2002). 
Interaction of ZFYVE27 with KIF5A plays an important role in vesicular trafficking in 
neurons (Matsuzaki et al., 2011). The FYVE domain is suggested to be responsible for 
bringing proteins to the endosome (Stenmark et al., 2002).  
In a recent paper, investigating expression and function of ZFYVE27, the authors found 
that in mice the region corresponding to human exon 8 (21bp) is present only in a 
transcript expressed in neuronal tissue (cerebrum and spinal cord) (Ohnishi et al., 2014). 
The authors named the transcripts, including and lacking this 21 bp fragment, as 
Protrudin-L and Protrudin-S, respectively. Quantitative RT-PCR analysis of various 
mouse tissues revealed that Protrudin-L mRNA was expressed in the cerebrum and 
spinal cord but it was absent in the liver, heart, kidney, lung, thymus, spleen, stomach 
and the intestine. In brain the highest expression of Protrudin-L mRNA was in the 
cerebellum followed by the midbrain and the medulla. The authors concluded that 
Protrudin-L is a neuron-specific isoform. Importantly, this 21bp fragment encodes a 
VAP-A binding domain. VAP-A is expressed in ER and is responsible for subcellular 
localisation of ZFYVE27. Knock-in and knock-down experiments in PC12 cells 
highlighted the ability of VAP-A to stimulate neurite outgrowth (Saita et al., 2009). 
The mechanism by which ZFYVE27 regulates polarised endosome translocation and 
neurite outgrowths has recently been proposed (Raiborg et al., 2015).  
There are seven protein coding transcripts of the ZFYVE27 gene. (Table 5.1). As 
mentioned previously, the encoded protein is called protrudin. Protrudin belongs to the 
FYVE-finger family, with the majority of its members serving as regulators of the 
endocytic membrane trafficking (Stenmark et al., 2002).  
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Table 5.1: ZFYVE27 RNA transcripts and corresponding protein isoforms. The 
table depicts ZFYVE27 RNA transcript variants with corresponding NCBI reference 
sequences for mRNA and protein isoforms.  
 
Transcript 
variant 
NCBI Reference 
Sequence (mRNA) 
Length 
(bp) 
NCBI Reference 
Sequence (protein) 
Length 
(aa) 
1 NM_001002261 2858 NP_001002261  416 
2 NM_144588  3047 NP_653189  411 
3 NM_001002262  2997 NP_001002262 404 
4 NM_001174119  2927 NP_001167590  372 
5 NM_001174120  2765 NP_001167591  318 
6 NM_001174121  2769 NP_001167592  311 
7 NM_001174122 2669 NP_001167593  286 
 
This study aims to elucidate pathogenicity of the ZFYVE27 c.805-2A>G mutation and 
establish its causative role in a dominant family presenting with cerebellar ataxia. In 
order to do this, we will perform transcription and protein expression studies. 
5.2. Materials and Methods 
5.2.1. In silico splice-site prediction with Alamut software 
In silico prediction of pathogenicity of the putative causative variant was performed 
using Alamut software as described in Section 4.2.4. 
5.2.2. Sequencing of fibroblast cDNA (total PCR product) 
Reverse transcription PCR (RT-PCR) was performed as described in Section 2.9 using 
ZFYVE27 cDNA specific primers (Table 5.2). 
Table 5.2: Primers for RT-PCR 
Primer Sequence 
Forward 5´- TGTGGAGTTCTTCCGAGTTGTGT-3´ 
Reverse R1 5´- AGCCCGTGCAGTTCCCGAAG-3´ 
Reverse R2 5´- CAGCACCACCAAGTGGGTCTC-3´ 
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PCR conditions involved a hot start at 95oC for 4 minutes, followed by 40 cycles of 
denaturation at 95oC for 30 seconds, annealing at 53oC for 30 seconds, and extension at 
72oC for 1 minute. A final extension step was performed at 72oC for 10 minutes, 
followed by cooling and storage of the sample at 4oC. Sanger sequencing of total PCR 
product was performed using ZFYVE27 cDNA specific primers (Table 5.2), as 
described in Section 2.5.  
5.2.3. Emetine inhibition of nonsense-mediated decay in fibroblasts from controls and 
patient P23 
The ZFYVE27 c.805-2A>G mutation was predicted to affect mRNA splicing by causing 
downstream exon skipping. This, in turn, could introduce a frame shift and result in the 
introduction of a premature stop codon. Premature termination codons, which account 
for approximately one third of mutations causing human disorders, have been shown to 
trigger degradation of mutant transcripts by the nonsense-mediated decay pathway 
(Frischmeyer and Dietz, 1999). Treatment of a patient’s fibroblasts with 100 µg/ml 
emetine dihydrochloride hydrate has been shown to successfully inhibit the nonsense-
mediated decay pathway (Noensie and Dietz, 2001). Inhibition of the nonsense-
mediated decay pathway would allow read-through of premature stop codons and 
expression of the transcripts, that otherwise would be eliminated by the nonsense-
mediated decay pathway. In order to elucidate whether the c.805-2A>G mutation leads 
to nonsense-mediated decay, control and patient fibroblasts were treated with emetine 
dihydrochloride hydrate in order to inhibit nonsense-mediated decay. cDNA (total PCR 
product) was sequenced with the aim to study the effect of the candidate mutation on 
the possible exon skipping and activation of the nonsense mediated decay pathway. The 
outline of this experiment is presented in Figure 5.2. This study hypothesized that by 
inhibiting the nonsense mediated decay pathway and allowing read-through of a 
premature stop codon in the patient, it would be possible to amplify an additional 
ZFYVE27 RNA transcript by means of RT-PCR. Detecting an additional (aberrant) 
transcript in the patient’s sample would indicate that the ZFYVE27 c.805-2A>G 
mutation leads to nonsense-mediated decay 
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In order to elucidate whether the c.805-2A>G mutation leads to nonsense-mediated 
decay, this study aimed to inhibit nonsense-mediated decay in fibroblasts from controls 
and the patient by treating them with emetine. Untreated cells were cultured in parallel. 
The control and patient’s primary fibroblast cell lines were cultured as described in 
Section 2.8. Cells were grown in the standard fibroblast medium (Section 2.8) with 
exclusion of uridine, penicillin and streptomycin. After reaching 60-80% confluency, 
half of the cells were supplemented with 100 µg/mL emetine (Sigma-Aldrich, Dorset, 
UK) and the other half was left intact. After 10 hours incubation, all cell lines were 
harvested, total RNA extracted (Section 2.9.1), cDNA generated (Section 2.9.2) and 
amplified using primers specific for ZFYVE27 cDNA (Section 2.9.3 and Section 5.2.2). 
Sanger sequencing of the total PCR product was performed as described in Section 
5.2.2. The results for treated and untreated cells were compared.  
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5.2.4. Human tissue samples  
Control muscle tissue samples were obtained from the Mitochondrial Control Tissue 
Bank (Newcastle University) from anonymous healthy individuals. Informed consent 
was obtained from all individuals before skin biopsies were performed. Frozen muscle 
tissue sections were kindly provided by Dr Florence Burte (Newcastle University). 
Post-mortem brain tissue from patient P22 and three age-matched controls were 
obtained from the Newcastle Brain Tissue Resource (Newcastle University) in 
accordance with Newcastle University Ethics board. For each individual a sample was 
obtained from the frontal cortex and the cerebellum. The clinical and neuropathological 
data were obtained from the Newcastle Brain Tissue Resource. The quality of the post-
mortem tissue was assessed by means of pH readings of the starting material (Stan et 
al., 2006) (pH reading obtained from Newcastle Brain Tissue Resource). Frozen brain 
tissue sections for the protein expression study were obtained from the Newcastle Brain 
Tissue Resource. 
5.2.5. RNA extraction from human brain tissue 
A section of frozen brain tissue (not more than 0.5 cm in the smallest dimension) was 
placed into a sterile RNase-free 15ml tube (Corning) containing at least 10 volumes of 
ice cold RNAlater®-ICE Tissue Transition Solution (Life Technologies Ltd., Paisley, 
UK) and incubated at -20oC for at least 16 hours. RNAlater®-ICE Tissue Transition 
Solution is specifically designed for transition of tissue from frozen to pliable state at    
-20oC without compromising the RNA integrity. RNA was extracted using RiboPureTM 
Kit (Life Technologies Ltd., Paisley, UK) according to the manufacturer’s protocol. The 
extracted RNA samples were treated with DNase I in order to remove DNA 
contamination. This was performed using TURBO DNA-freeTM Kit (Life Technologies 
Ltd., Paisley, UK) as per the manufacturer’s manual. 
5.2.6. Sequencing of cDNA from the human brain tissue (total PCR product and 
plasmid DNA cloned from extracted PCR fragments) 
Reverse transcription PCR (RT-PCR) was performed as described in Section 2.9 using 
ZFYVE27 specific primers (Table 5.2) and PCR conditions outlined in Section 5.2.2. 
!! 129!
The efficiency of the cDNA amplification from each tissue specimen was assessed by a 
control RT-PCR using primers specific to a 133 bp fragment of the housekeeping gene         
GAPDH (forward: 5’-CTGACTTCAACAGCGACACC; reverse: 5’- 
ATGAGGTCCACCACCCTGT). RT-PCR was performed as described in Section 2.9.3. 
PCR conditions were as follows: a hot start at 95oC for 3 minutes followed by 30 cycles 
of denaturation at 95oC for 30 seconds, annealing at 55oC for 30 seconds and extension 
at 72oC for 45 seconds. The reaction was finished by a final extension step performed at 
72oC for 10 minutes, followed by cooling the sample to 4oC.  
Sanger sequencing of the total PCR product was performed as described in Section 
5.2.2. Sanger sequencing of plasmid DNA cloned from the extracted PCR fragments 
was performed as described in Section 2.6. 
5.2.7. Protein extraction from the human brain tissue 
Post-mortem human brain tissue samples were rapidly thawed and approximately 
500mg of tissue was homogenised on ice using a rotor stator homogenizer Polytron® 
(Thermo Fisher Scientific Inc., Leicestershire, UK) in 2 ml of lysis buffer containing 
0.2 M Triethylammonium bicarbonate buffer (TEAB) (Sigma-Aldrich, Dorset, UK) and 
cOmplete Protease Inhibitor Cocktail (Roche, Indianapolis, USA). Following this, 
Sodium Dodecyl Sulphate (SDS) (Sigma-Aldrich, Dorset, UK) was added to the 
homogenate to a final concentration of 0.2% and the sample was gently sonicated for 40 
minutes on ice in a sonicating bath. Finally, the homogenate was sonicated for 10 
seconds using ultrasonic processor Sonics® (Sonics & Materials, Newtown, USA). 
Protein concentration was determined using a Bradford assay (Bradford, 1976). 
5.2.8. Western blotting 
Homogenate samples (Section 5.2.7) containing 20 µg of protein and an equal volume 
of loading dye (250 mM Tris-HCl, pH 6.8; 20% glycerol; 4% SDS; 0.1% Bromophenol 
Blue, and 10mM Dithiothreitol (DTT), all Sigma-Aldrich, Dorset, UK) were heated at 
95oC for 5 minutes and separated on precast 4-15% Mini-PROTEAN®TGXTM sodium 
dodecyl sulphate-polyacrylamide gels (SDS-PAGE) (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK) with 1 x Tris-glycine running buffer (25mM Tris base; 190 mM 
glycine; 0.1% SDS, all Sigma-Aldrich, Dorset, UK). The protein gels were transferred 
to polyvinylidene fluoride (PVDF) membranes (iBlot®2 PVDF stacks; Life 
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Technologies Ltd., Paisley, UK) using the iBlot®2 Dry Blotting system (Life 
Technologies Ltd., Paisley, UK). The membranes were blocked in 5% milk in 1 x TBST 
(Tris buffered saline (Sigma-Aldrich, Dorset, UK), containing 0.2% Tween 20 (Sigma-
Aldrich, Dorset, UK)), for one hour at room temperature. Following the blocking step,  
membranes were incubated with primary antibody (Table 5.3) diluted in 5% milk in 1 x 
TBST overnight at 4oC. After three washes in 1 x TBST, membranes were incubated 
with secondary antibody (Table 5.3) diluted in 5% milk in 1 x TBST for one hour at 
room temperature. Finally, membranes were washed three times in 1 x TBST and 
developed using ECL blotting substrate (Bio-Rad Laboratories Ltd., Hemel Hempstead, 
UK) following the manufacturer’s protocol. The signal was detected using a 
BioSpectrum®500 Imaging System (UVP, LLC, Cambridge, UK). Protein molecular 
weight was determined by comparison with a SeeBlue® Plus2 Pre-Stained Standard 
(Life Technologies Ltd., Paisley, UK) and Biotinylated Protein Ladder (Cell Signaling 
Technology, Inc., Danvers, USA). 
Table 5.3: Antibodies used for the detection of GAPDH, ZFYVE27 and HSPA5 
(BiP/GRP78) proteins in human frontal cortex and cerebellum 
 
Antibody Source Catalogue 
number 
Dilution 
GAPDH (FL-335) rabbit polyclonal 
(primary) 
Santa 
Cruz 
sc-25788 HRP 1/500 
ZFYVE27 rabbit polyclonal (primary) Abnova PAB23125 1/250 
HSPA5 (BiP/GRP78) rabbit polyclonal 
(primary) 
Abnova PAB2462 1/1000 
Polyclonal Swine anti-rabbit Horseradish 
peroxidase (HRP)-conjugated (secondary) 
Dako p0399 1/2 000 
 
Statistical analysis 
Densitometric analysis was performed using ImageJ software (available at 
http://imagej.nih.gov/ij/ ). GAPDH was used to normalise the result. Ratios of the 
protein of interest/GAPDH, means and standard deviations were calculated for all 
samples. Data represent the mean of three independent replicates. Fold change (FC) was 
calculated as the ratio of average of ratios (protein of interest/GAPDH) for the patient / 
average of means of ratios (protein of interest/GAPDH) for the controls. 
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5.2.9. Immunohistochemistry (IHC) on frozen muscle and human brain tissue 
sections 
Frozen tissue sections were fixed in 4% paraformaldehyde (Sigma-Aldrich, Dorset, 
UK), permeabilised in 0.5% Triton-X100 (Sigma-Aldrich, Dorset, UK) in phosphate-
buffered saline (PBS) (Sigma-Aldrich, Dorset, UK), blocked in 10% goat normal serum 
(Sigma-Aldrich, Dorset, UK) in PBS (Sigma-Aldrich, Dorset, UK), for 30 minutes at 
room temperature and incubated with primary ZFYVE27 antibody diluted in 10% goat 
normal serum (Sigma-Aldrich, Dorset, UK) in PBS (Sigma-Aldrich, Dorset, UK) (Table 
5.4) overnight at 4oC.  
Table 5.4: Antibodies used for the detection of ZFYVE27 protein in human frontal 
cortex and cerebellum frozen sections 
 
Antibody Source Catalogue 
number 
Dilution 
ZFYVE27 rabbit polyclonal 
(primary) 
Sigma HPA037523 1/200 
Biotinylated goat anti-rabbit IgG 
(secondary) 
Vector 
Laboratories 
BA-1000 1/200 
 
After two washes in PBS (Sigma-Aldrich, Dorset, UK), the tissue sections were treated 
with 0.3% hydrogen peroxide (Sigma-Aldrich, Dorset, UK) in water for 5 minutes in 
order to quench endogenous peroxidase activity, blocked in 10% goat normal serum 
(Sigma-Aldrich, Dorset, UK) in PBS (Sigma-Aldrich, Dorset, UK) for 10 minutes and 
incubated with biotinylated goat anti-rabbit IgG secondary antibody (Vector 
Laboratories, Peterborough, UK). The target antigen signal was amplified with 
Vectastain® ABC detection kit (Vector Laboratories, Peterborough, UK). 
Immunoreactive product was visualised with diaminobenzidine (DAB) substrate for 
peroxidase (ImmPACTTM DAB Substrate Kit; Vector Laboratories, Peterborough, UK). 
The IHC protocol procedure was first tested on human control muscle tissue (positive 
control). Primary antibody was omitted from the procedure to act as a negative control, 
specifically testing for non-specific binding of the secondary antibody. Images were 
captured as described in Section 2.10.2. 
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5.3. Results 
5.3.1. In silico mutation pathogenicity study with Alamut software 
Splice predictions for ZFYVE27 c.805-2A>G show loss of acceptor site of exon 7 in 
five splice prediction programs (Alamut v2.4, Interactive Biosoftware, Rouen, France) 
(Figure 4.1). 
5.3.2. Functional studies of ZFYVE27 c.805-2A>G mutation in fibroblasts 
Transcriptional studies 
Sequencing of ZFYVE27 cDNA (total PCR product) 
The schematic representation of ZFYVE27 RNA transcripts is outlined in Figure 5.3. 
 
 
Figure 5.3: ZFYVE27 RNA transcripts. ZFYVE27 gene has seven protein coding 
RNA transcripts as a result of alternative splicing. Numbered boxes represent exons. 
The dotted line indicates the position of the c.805-2A>G mutation. Exons are aligned 
for convenience. The forward and reverse primer positions are represented by arrows. 
Primer R2 spans the entire exon 8 region. Primers F and R1 could potentially amplify 
PCR products of 425 bp, 410 bp, 404 bp and 389 bp; primers F and R2 could potentially 
amplify products of 265 bp and 250 bp. 
 
Patient and control cDNA, derived from RNA extracted from fibroblasts, was amplified 
using F and R1 primers which were specific for ZFYVE27 cDNA (figure 5.3). Agarose 
gel electrophoresis of the resulting PCR product revealed the amplification of two 
products (404 bp and 389 bp) (Figure 5.4). 
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Figure 5.4: Agarose gel (3.5%) electrophoresis of the PCR product amplified from 
ZFYVE27 cDNA using primers F and R1 (RNA was derived from fibroblasts of a 
healthy control and the patient P23)  
 
Sequencing of cDNA (total PCR product) revealed no differences between the control 
and patient. However, the sequence chromatograms did show overlayed peaks in the 5’ 
region of exon 7 and a homozygous deletion of the entire exon 8 (Figure 5.5). This 
study therefore concludes that both transcripts 1 and 2 (Figure 5.3) are absent in the 
fibroblasts of this particular control and patient. The sequencing results confirm that the 
band of 404 bp corresponds to transcript 6, whereas the band of 389 bp represents 
transcripts 3, 4, 5 and 7 (these could be present in any combination) (Figure 5.3). 
Research published after this study have been undertaken (Ohnishi et al., 2014) 
suggests that in mice the region corresponding to human exon 8 (21bp) is present only 
in transcripts expressed in neuronal tissue (cerebrum and spinal cord). The findings of 
this study are in line with these previous observations and provide evidence that human 
fibroblasts do not express the neuron-specific transcripts 1 and2 of ZFYVE27 (Figure 
5.3). 
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Figure 5.5: Sanger sequencing chromatograms for ZFYVE27 cDNA generated 
from the fibroblast RNA of a healthy control (A) and patient P23 (B) using 
primers F and R1. Red rectangles represent deleted sequences. 
 
 
Inhibition of nonsense-mediated decay in fibroblasts of controls and patient P23 with 
emetine compound (sequencing of total PCR product) 
Treated and untreated fibroblast cells from controls and patient P23 exhibited different 
morphology (Figure 5.6). Not treated fibroblasts from controls and the patient were 
characterised by normal morphology. Treated fibroblasts from controls and the patient 
exhibited accumulation of intracellular vesicles. This may represent the response to 
stress (Li et al., 2013) due to the emetine treatment. 
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Agarose gel electrophoresis of RT-PCR product generated using F and R1 primers 
which were specific for ZFYVE27 cDNA (RNA was derived from fibroblasts of healthy 
controls and the patient P23, which were treated with emetine) revealed amplification of 
two PCR products (404 bp and 389 bp) (Figure 5.7). The same result was observed for 
not treated cells. Notably, when compared with the treated control cells, the treated cells 
of the patient did not produce any additional band, which would be indicative of the 
effect of the mutation on RNA splicing. 
 
 
Figure 5.7: Agarose gel (3.5%) electrophoresis of the RT-PCR product generated 
using primers F and R1 which were specific for ZFYVE27 cDNA (RNA was 
derived from fibroblasts of healthy controls and the patient P23 without [not 
treated] and with [treated] inhibition of nonsense-mediated decay by emetine)  
Sequencing of ZFYVE27 cDNA (total PCR product) did not reveal any difference 
between treated and not treated fibroblast cells in controls and the patient. Sequence 
chromatograms showed mixed peaks in the 5’ region of exon 7 and the homozygous 
deletion of the entire exon 8 in all samples (Figure 5.8). Based on the sequencing result, 
this study concludes that the band of 404 bp corresponds to the transcript 6, whereas the 
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band at 389 bp represents transcripts 3, 4, 5 and 7, which could be present in any 
combination (Figure 5.3).  
 
Figure 5.8: Sanger sequencing chromatograms for ZFYVE27 cDNA obtained from 
the emetine treated fibroblasts of a healthy control (A) and patient P23 (B) using 
primers F and R1 which were specific for ZFYVE27 cDNA. Red rectangles represent 
deleted sequences. 
 
 
5.3.3. Functional studies of the ZFYVE27 candidate mutation in the human frontal 
cortex and cerebellum 
Transcriptional study 
Prior to the transcriptional study, the efficiency of the cDNA amplification was assessed 
by performing a control RT-PCR using primers specific to the housekeeping gene 
GAPDH, as described in Section 5.2.6. Agarose gel electrophoresis of RT-PCR product 
revealed amplification of GAPDH-specific product of 133 bp in all samples, confirming 
the satisfactory quality of the initial total RNA preparation (Figure 5.9). 
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Figure 5.9: Agarose gel electrophoresis of GAPDH RT-PCR product derived from 
the frontal cortex and cerebellum of controls and the patient 
 
 
Sequencing of ZFYVE27 cDNA (total PCR product and cloned cDNA fragments) 
This study used one forward (F) and two reverse (R1 and R2) primers to generate a 
range of amplicons (Figure 5.3). Primer R2 covers the entire neuron-specific exon 8, 
hence amplicons generated with primers F and R2 would represent only neuron-specific 
transcripts (transcript 1 and transcript 2). R1 spans across a boundary between exons 9 
and 10 and is pan-specific for all transcripts. Therefore, amplicons generated with 
primers F and R1 would represent all the variety of transcripts present in a sample. 
This study initially used three age-matched controls alongside the patient’s sample. 
Agarose gel electrophoresis of RT-PCR product for amplicon FR2 revealed expression 
of two bands of 265 bp and 250 bp (representing transcript 1 and transcript 2, 
respectively) in all samples but the patient’s cerebellum, which expressed only one band 
of 250 bp (Figure 5.10). In one control there was a striking difference in amounts of 
amplified PCR product (frontal cortex of control 3) when compared with the other 
samples. A subsequent enquiry into this control’s medical history revealed that the 
individual underwent a pituitary radiotherapy treatment, which could underlie the 
abnormal observations. This led to exclusion of this control from further investigations. 
Direct sequencing of RT-PCR reactions for amplicon FR2 revealed mixed peaks on the 
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electropherograms (which indicates the presence of both transcripts 1 and 2) for all 
samples but the patient’s cerebellum, where this study confirmed the presence of only 
transcript 2.  
 
 
Figure 5.10: 3.5% Agarose gel electrophoresis of ZFYVE27 RT-PCR product 
(amplicon FR2) derived from the frontal cortex and cerebellum of controls and the 
patient 
 
Agarose gel electrophoresis of RT-PCR product for amplicon FR1 showed 
amplification of multiple bands in all samples, with the patient’s cerebellum producing 
the least number of bands (Figure 5.11). Similar to the results for amplicon FR2 above, 
in the frontal cortex of control 3 there was a striking difference in quantities of 
amplified PCR product when compared with the other samples. As previously 
mentioned, this study excluded this control from further investigations. Direct 
sequencing of the total RT-PCR product for amplicon FR1 produced inconclusive 
results for all samples, which was manifested by mixed peaks on the sequencing traces 
in all samples.  
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Figure 5.11: 3.5% Agarose gel electrophoresis of ZFYVE27 RT-PCR product 
(amplicon FR1) derived from the frontal cortex and cerebellum of controls and the 
patient 
 
The current study concluded that the direct sequencing of total RT-PCR product was 
inconclusive and therefore the study moved on to cloning the cDNA fragments from 
each sample and subsequent sequencing of the clones. This investigation was performed 
only for amplicon FR1. 
Sequencing analysis of cDNA clones for amplicon FR1 revealed that whilst control 
frontal cortex and cerebellum express potentially all seven ZFYVE27 RNA transcripts, 
the patient’s frontal cortex does not express transcript 6. More strikingly, the patient’s 
cerebellum expressed only one transcript (the neuron-specific transcript 2). 
Protein expression study  
Western blot analysis of ZFYVE27 
Western blotting of ZFYVE27 was performed as described in Section 5.2.8. The 
commercial anti-ZFYVE27 antibody was generated against the C-terminus region of the 
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protein. The ZFYVE27 protein (protrudin) levels were increased approximately 2.5 fold 
in the cerebellum but not in the frontal cortex of the affected individual, when compared 
to controls (Figure 5.12).  
 
 
 
Figure 5.12: ZFYVE27 and GAPDH protein levels in the frontal cortex and the 
cerebellum in controls and the patient 
 
 
Western blot analysis of ER stress and UPR markers 
Western blotting of the master regulator of ER stress, BiP/GRP78, was performed as 
described in Section 5.2.8. The levels of BiP/GRP78 were significantly increased 
(approximately 2 fold) in the patient’s cerebellum but not in the frontal cortex, when 
compared to controls (Figure 5.13). The large standard deviation values for the controls’ 
frontal cortex may reflect the biological variation in the general population (Stan et al., 
2006). 
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Figure 5.13: BiP/GRP78 and GAPDH protein levels in the frontal cortex and the 
cerebellum in controls and the patient. The levels of BiP/GRP78 are significantly 
increased (approximately 2 fold) in the patient’s cerebellum but not in the frontal 
cortex, when compared to controls. The large standard deviation values for the controls’ 
frontal cortex may reflect the biological variation in the general population. 
 
 
IHC of ZFYVE27 
The commercially available ZFYVE27 antibody, which was used in this study, was 
generated against C-terminus region of the protein. 
 
• Optimization*of*the*protocol*using*human*control*muscle*
Human post-mortem brain is a precious sample and not always easily available. 
Therefore, prior to performing IHC for ZFYVE27 on the human brain tissue, the 
protocol was optimized on frozen human control muscle sections (Figure 5.14). This 
study observed some tissue preparation and handling artefacts (cell bubbles and 
separation of cells). Positive staining was observed in the cytoplasm of the muscle cells 
(Figure 5.14, B). No staining was observed in the negative control (Figure 5.14, A), 
however some background staining was observed. 
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Figure 5.14: IHC staining of frozen human control muscle tissue sections with anti-
ZFYVE27 antibody. Magnification x20. Negative control (no primary antibody) (A) 
and 1:100 dilution of anti-ZFYVE27 antibody (B). Sections are sequential. Numbers 
represent the same cell.  
 
• ZFYVE27*detection*in*human*frontal*cortex*and*cerebellum*
This study detected expression of ZFYVE27 in the frontal cortex and the cerebellum of 
controls and the patient, which supported the Western blot findings. The latter revealed 
that the ZFYVE27 protein (protrudin) levels were increased approximately 2.5 fold in 
the cerebellum but not in the frontal cortex of the affected individual, when compared to 
controls (Figure 5.12). In the frontal cortex ZFYVE27 staining was observed in neurons 
(Figure 5.15, arrows) and glial cells (Figure 5.15, arrow heads). No difference in 
staining intensity or localisation between controls and the patient was observed. In the 
cerebellum this study detected immunostaining of Purkinje cells in controls (Figure 5.16 
A, arrows). In the patient this study did not observe Purkinje cells immunostaining, 
probably due to their loss (Figure 5.16 E, arrows). This study observed some tissue 
damage in the patient’s cerebellum and some gaps in the Purkinje cell layer, which 
would indicate a loss of Purkinje cells. The current study observed occasional 
immunostaining in cells suggestive of astrocytes in the cerebellum of the controls 
(Figure 5.16 B, arrow heads). In the patient’s cerebellum this study detected pronounced 
immunostaining in cells resembling astrocytes in the molecular layer (Figure 5.16 F, G, 
H, arrow heads). The current study also noticed immunostaining in parallel fibres of the 
patient cerebellum (Figure 5.16 G, arrow heads). 
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Figure 5.15: IHC staining of frozen frontal cortex sections in controls and the 
patient with anti-ZFYVE27 antibody. Staining in patient (A) and control (B) frontal 
cortex with anti-ZFYVE27 antibody diluted 1:200. Negative control (C): patient frontal 
cortex with no primary antibody. Arrows represent neurons, arrow heads represent glial 
cells. Magnification x200. 
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Figure 5.16: IHC staining of frozen cerebellum sections in controls and the patient 
with anti-ZFYVE27 antibody. Staining in a control (A, B, C, D) and the patient (E, F, 
G, H). Negative control: no primary antibody in the patient’s cerebellum (I). 
Arrowheads represent cells resembling astrocytes. Magnification x200 and x400. 
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5.4. Discussion 
5.4.1. Transcriptional studies in fibroblasts 
Using an unbiased whole exome sequencing approach, in three members of an 
autosomal dominant pedigree (patient P22, P23 and P24), a predicted splice site 
mutation (c.805-2A>G) was detected in the ZFYVE27 gene, previously associated with 
spasticity, but not ataxia (Mannan et al., 2006). It is documented that approximately 
15% of mutations linked to human inheritable diseases cause splicing defects in mRNA 
(Blencowe, 2000). Mutations affecting splice sites are therefore of a particular interest. 
The routine method of studying the effect of a genomic DNA mutation on mRNA 
splicing involves sequencing of RNA from patients and controls. The total RT-PCR 
product is sequenced and the sequence chromatograms are compared between patients 
and controls. Any potential aberrant splicing event is detected when the sequence 
chromatogram of mutant and wildtype alleles show differences, which is manifested by 
mixed peaks on the chromatogram. In this study ZFYVE27 cDNA (total RT-PCR 
product) were initially sequenced in fibroblasts of the patient (P23) and two unrelated 
controls, however any abnormal splicing in the patient cells in comparison to the 
controls were not detected. Moreover, sequencing of cDNA from fibroblasts of the 
patient P23 and controls showed that exon 8 was absent in both the patient and controls. 
Therefore, it was concluded that fibroblasts do not express RNA transcripts 1 and 2, 
both of which contain exon 8. Furthermore, it was reasoned that fibroblasts are not the 
tissue of interest in a family with ataxia. The most relevant tissue for this study would 
be brain tissue, but it is precious and has not been available at that time. 
The mutation (c.805-2A>G) in ZFYVE27 was predicted to result in a loss of acceptor 
site of the coding exon 7 in five splice prediction programs [Alamut version 2.4 
(Interactive Biosoftware, Rouen, France)] (Figure 4.1). This could hypothetically lead 
to skipping of the downstream exon and result in a frameshift, which potentially could 
introduce a downstream premature stop codon. Literature suggests that premature stop 
codons, which account for approximately one third of mutations causing human 
disorders, could trigger degradation of mutant transcripts by nonsense mediated RNA 
decay pathway (Frischmeyer and Dietz, 1999). Nonsense-mediated decay is a quality 
control mechanism found in eukaryotic cells (Conti and Izaurralde, 2005). The primary 
role of nonsense-mediated decay is to degrade mRNA harbouring premature stop 
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codons, in order to prevent expression of truncated proteins with altered functions. If 
expressed, such proteins would be either partially functional, non-functional, or even 
deleterious to the cell (Wengrod et al., 2013). Elimination of the premature stop codon-
containing mRNA transcripts by nonsense-mediated decay creates a major problem in 
detecting the effect of mutations on mRNA splicing. Inhibition of the nonsense-
mediated decay pathway would allow read-through of premature stop codons and 
expression of the transcripts, that otherwise would be eliminated by the nonsense-
mediated decay pathway. Treatment of the patient’s fibroblasts with 100 µg/ml emetine 
dihydrochloride hydrate has been shown to successfully inhibit the nonsense mediated 
decay pathway (Noensie and Dietz, 2001). Based on the above observations, the 
identification of nonsense-mediated decay as a molecular mechanism of a disease could 
potentially lead to a therapy employing inhibition of this pathway. Recent clinical trials 
have indicated that treatment with gentamicin, an inhibitor of nonsense-mediated decay, 
could be effective in fibrosis and muscular dystrophy - diseases caused by nonsense-
mediated decay triggering mutations (Welch et al., 2007). This study was interested, 
therefore, to elucidate whether the c.805-2A>G mutation leads to nonsense-mediated 
decay. In this study control and patient fibroblasts were treated with emetine 
dihydrochloride hydrate in order to inhibit nonsense-mediated decay. cDNA (total PCR 
product) was sequenced with the aim to study the effect of the candidate mutation on 
the possible exon skipping and activation of the nonsense mediated decay pathway. The 
outline of this experiment is presented in Figure 5.2. This study hypothesized that by 
inhibiting the nonsense mediated decay pathway and allowing read-through of a 
premature stop codon in the patient, it would be possible to amplify an additional 
ZFYVE27 RNA transcript by means of RT-PCR. Detecting an additional (aberrant) 
transcript in the patient’s sample would indicate that the ZFYVE27 c.805-2A>G 
mutation leads to nonsense-mediated decay.  
Sequencing of cDNA (total RT-PCR product) from emetine treated and non-treated 
fibroblasts from both controls and the patient did not show any difference, however. 
The latter experiment showed also that exon 8 was absent in both the patient’s and 
controls’ fibroblasts. Since these experiments were carried out, new research has been 
published describing the first ZFYVE27 transcriptional study in mice (Ohnishi et al., 
2014). The authors found that in mice the region corresponding to human exon 8 (21bp) 
is present only in a transcript expressed in the neuronal tissue (cerebrum and spinal 
cord). This finding explained why this study was not able to detect exon 8 in control 
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and the patient’s fibroblasts. More importantly, this study showed that fibroblast cell 
lines are not ideal to study neurological diseases.  
5.4.2. Transcriptional study of ZFYVE 27 in the post-mortem frontal cortex and 
cerebellum 
Brain tissue is precious and has not been available at the beginning of this study. Later, 
regrettably a member of the family died and the brain tissue became available. Hence, a 
transcriptional study was carried out in the frontal cortex and cerebellum of post-
mortem brains from the affected individual (patient P22) and three age-matched 
controls. The yield and quality of RNA extracted from post-mortem brain tissue could 
be affected by many factors, which cannot be controlled. Therefore it is important to 
determine the quality of the starting material prior to research. It is established that pH 
is a good indicator of post-mortem brain tissue quality (Stan et al., 2006). Tissue 
samples used in this study were characterised by pH>6.4, which is considered good 
quality (Stan et al., 2006). The quality of the total RNA extracted from the post-mortem 
tissue was assessed by means of RT-PCR using primers specific to a housekeeping gene 
GAPDH. High expression levels of GAPDH were detected in all samples which is an 
indicator of good quality total RNA (Figure 5.9). Agarose gel electrophoresis of the RT-
PCR product for amplicon FR2 of ZFYVE27 revealed the amplification of two products, 
representing transcript 1 and transcript 2, in all samples apart from the patient’s 
cerebellum, which expressed only the lower band of 250 bp corresponding to RNA 
transcript 2 (Figure 5.10). This result may indicate that the patient’s cerebellum and 
Purkinje cells are more severely affected by the mutation than other neuronal 
populations. It has been previously documented that Purkinje cells, one of the largest 
neurons, are uniquely vulnerable and more susceptible to damage in response to genetic 
changes than other neuronal populations (Hekman and Gomez, 2015). Elsewhere, it has 
been documented that in mice ER stress leads to degeneration of Purkinje cells, which 
result in cerebellar degeneration and ataxia (Kyuhou et al., 2006). Also, it has been 
documented that defects in ER structure and function in dendrites and axons could 
result in neurological phenotypes (Ramirez and Couve, 2011). The aforementioned 
studies suggest that Purkinje cells might be more susceptible to damage due to ER 
stress, than other neuronal cell populations. Agarose gel electrophoresis of the RT-PCR 
product for amplicon FR1 showed amplification of multiple bands in all samples 
(Figure 5.11). Sequencing analysis of total RT-PCR products and cDNA clones 
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revealed that there is a difference in the expression of RNA transcripts in the brain of 
the patient, when compared to the controls. This study found that in control individuals 
frontal cortex and cerebellum potentially express all seven ZFYVE27 RNA transcripts 
(Figure 5.3). Interestingly, the current study did not detect expression of transcript 6 in 
the patient’s frontal cortex, however all other transcripts were evident. The patient’s 
cerebellum expressed only one transcript (neuron-specific transcript 2). The ZFYVE27 
gene has seven protein coding RNA transcripts as a result of alternative splicing (Figure 
5.3). Out of seven splice transcripts, only transcripts 1 and 2 contain exon 8. A recent 
study suggested that in mice, expression of ZFYVE27 transcripts, containing the 21bp 
region corresponding to human exon 8, is restricted to cerebrum and spinal cord 
(Ohnishi et al., 2014). The latter study also found that ZFYVE27 transcripts, which did 
not contain the 21bp region, were expressed in all tissues tested. The current study 
provides the evidence that human fibroblasts do not express the neuron-specific 
ZFYVE27 transcripts 1 and 2 (Section 5.4.1). The current study also suggests that the 
human brain potentially expresses all known ZFYVE27 transcripts. The results of this 
study showed a difference in the expression of ZFYVE27 RNA transcripts in the brain 
of the patient, when compared to the controls. For some genes, the ratio of alternatively 
spliced transcripts is strictly regulated. Splice site mutations might disrupt this ratio and 
result in a disease (Ward and Cooper, 2010). A recent study has shown that splice site 
mutations in the microtubule associated protein tau (MAPT) gene cause frontotemporal 
dementia and Parkinsonism linked to chromosome 17 (FDTP-17) (Liu and Gong, 
2008). Moreover, the latter study found that splice site mutations in MAPT disrupt 
alternative splicing of exon 10. This resulted in altering the ratio of alternatively spliced 
MAPT transcripts encoding isoforms containing either three (3R) or four (4R) 
microtubule-binding repeats. The authors suggested that deregulation of the 3R/4R ratio 
contributes to FDTP-17, however, the molecular mechanism of this deregulation is 
currently not understood. All the aforementioned studies suggest, that the splice site 
mutation in ZFYVE27 could result in deregulation of the ratio of splice variants in the 
brain of the patient. The deregulation of the ratio might change cellular conditions and 
lead to ER stress. The latter might lead to degeneration of Purkinje cells, which result in 
cerebellar degeneration and ataxia in the patient. It has to be highlighted that this study 
analysed only two regions of the brain (the frontal cortex and the cerebellum) for 
expression of ZFYVE27 gene transcripts in the subjects involved in the study. It would 
be beneficial to analyze other brain regions from the patient and control individuals in 
order to gain more insight into the expression profiles of ZFYVE27 under normal and 
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pathological conditions. 
The ZFYVE27 mutation (c.805-2A>G) is predicted to cause a loss of acceptor site of the 
coding exon 7. The putative role of the c.805-2A>G mutation in the hypothetical 
nonsense-mediated decay, which might have contributed to the patient’s clinical 
phenotype, has been explored in the patient’s fibroblasts. This study did not detect any 
alterations in expression of RNA transcripts in the patient cells compared to controls, as 
described in Section 5.4.1. Analysis of post-mortem brain tissue however is more 
relevant as ZFYVE27 RNA transcripts 1 and 2 are neuron specific and not expressed in 
fibroblasts (Figure 5.3) (Ohnishi et al., 2014). Nonsense-mediated decay has been 
established as a mechanism to eliminate altered mRNA species. Recently it has been 
shown however that nonsense-mediated decay also targets non-mutated transcripts, 
including transcripts which play an important part in cellular stress response, more 
specifically, ER stress response (Mendell et al., 2004). It is likely therefore that the 
c.805-2A>G mutation in ZFYVE27 leads to nonsense-mediated decay in the patient, 
which is supported by different expression of RNA transcripts in the patient as opposed 
to controls. This study speculates that nonsense-mediated decay, triggered by the 
mutation, could eliminate functional, not mutated ZFYVE27 transcripts and stabilize 
mutated transcripts (Gardner, 2010). Recently it has been documented that nonsense-
mediated decay efficiency varies between different tissues (Linde et al., 2007). This 
could explain the differences in transcript expression between the frontal cortex and the 
cerebellum observed in the patient. To support the hypothesis that the c.805-2A>G 
mutation could cause nonsense-mediated decay in the patient, and to clarify the 
molecular nature of the splicing, it would be useful to study the effect of the mutation in 
primary neuronal cell cultures. The experiment could involve transfection with 
constructs containing mutated or wildtype ZFYVE27 gene fragments. Subsequent 
treatment with emetine in order to inhibit nonsense-mediated decay, as described earlier 
in this Thesis, would help to elucidate the mechanisms of transcriptional regulation 
occurring in neuronal cells.  
5.4.3. Analysis of ZFYVE27 protein expression in the frontal cortex and cerebellum 
This study carried out a protein expression study using post-mortem frontal cortex and 
the cerebellum of patient P22 and age matched controls. Firstly, Western blot analysis 
was employed to study ZFYVE27 expression in the frontal cortex and the cerebellum. 
This study found that the ZFYVE27 levels are increased approximately 2.5 fold in the 
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cerebellum but not in the frontal cortex of the affected individual, when compared to 
controls. Many splice site mutations result in exon skipping, which could lead to the 
production of inactive or unstable protein. The latter is manifested in the decreased level 
of protein expression (Cooper et al., 2009). However, in some cases, a splice site 
mutation could result in the aggregation of protein (Liu and Gong, 2008). ZFYVE27 is 
expressed in the endoplasmic reticulum (ER) and is thought to be involved in shaping 
the ER network (Chang et al., 2013). ER is a key site for protein synthesis and quality 
control. Accumulation of unfolded proteins leads to ER stress and activation of 
unfolded protein response (UPR) (Wang et al., 2010). ZFYVE27 anomalies have 
previously been shown to cause ER stress (Hashimoto et al., 2014) and result in a 
neurological phenotype SPG33 (Mannan et al., 2006). This study therefore used 
Western blotting to determine levels of the master regulator of ER stress, BiP/GRP78 
(Wang et al., 2010). The results of this study show that levels of BiP/GRP78 were 
significantly increased in the patient’s cerebellum, which may indicate ER pathology. It 
would be interesting to use another ER stress marker (for example, 70-kDa heat shock 
proteins (HSP70)) to confirm the result with BiP/GRP78. It should be mentioned that in 
this family mitochondrial disease was not considered because standard mitochondrial 
tests were negative. Therefore, investigating mitochondrial parameters in the patient’s 
fibroblasts was not considered. It should also be highlighted that although 
overexpression of BiP/GRP78 suggests ER pathology on the one hand, and 
overexpression of ZFYVE27 is indicative of the consequence of the mutation on the 
other hand, this study only tested two regions of the brain (cerebellum and the frontal 
cortex) in the subjects involved in the study. Analysis of other brain regions from the 
patient and neurologically normal individuals would be beneficial in order to gain more 
insight into the expression profiles of ZFYVE27 under normal and pathological 
conditions. IHC with anti-ZFYVE27 antibody revealed staining in both frontal cortex 
(Figure 5.15) and the cerebellum (Figure 5.16) of controls and the patient, which 
supported this study’s Western blot findings. In the frontal cortex of controls and the 
patient ZFYVE27 staining was detected in neurons and glial cells. In the control 
cerebellum immunostaining was detected of Purkinje cells. In the patient 
immunostaining of Purkinje cells was not detected, probably due to their loss. This 
observation is supported by the pathological report of post-mortem tissue examination 
of the patient’s brain (provided by Newcastle Brain Tissue Resource, Newcastle 
University), which states depletion of the Purkinje cell population and cerebellar 
atrophy in the patient. There were detected gaps in the Purkinje cells’ layer of the 
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patient’s cerebellum. Based on the pathological report mentioned above, this finding 
suggests death of Purkinje cells, possibly due to apoptosis, in the patient (Dusart et al., 
2006). To elucidate the mechanism of Purkinje cells loss, screening of proapoptotic 
markers would be beneficial. Purkinje cells are the largest neurons in the brain, which 
together with other neurons and neuronal fibres form the cerebellar neuronal circuitry 
(Figure 5.17). A recent study in neurological disorders, featuring structural changes in 
the cerebellum, highlights the role of Purkinje cell degeneration in the development of 
the clinical phenotype. For example, post-mortem studies of essential tremor identified 
structural changes in the cerebellum, including Purkinje cell loss (Louis et al., 2013), 
which indicates that Purkinje cell degeneration may be central to the pathogenesis of 
essential tremor. In another study on essential tremor, authors found that abnormalities 
in climbing fibre - Purkinje cell connections could lead to dysfunctional motor control 
and possibly clinical tremor and/or ataxia (Lin et al., 2014). In mouse models of 
spinocerebellar ataxias, expression of mutant proteins in Purkinje cells causes Purkinje 
cell degeneration and abnormal climbing fibre-Purkinje cell connections (Furrer et al., 
2013). All the aforementioned studies suggest, that proper connections between 
Purkinje cells and other neuronal structures are of paramount importance for the normal 
function of the cerebellum. 
 
 
Figure 5.17: Schematic representation of a cerebellar cross-section. Figure depicts 
basic structure of the cerebellar cortex and shows Purkinje cells in relation to 
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cerebellum layers and other neurons and neuronal fibres including parallel, mossy and 
climber fibres (taken from De Schutter and Bower, 1994) 
Interestingly, current IHC studies detected immunostaining in cells suggestive of 
astrocytes in both – the control individual and the patient. These cells were not tested 
for expression of glial or astrocyte markers, therefore the term “astrocytes” is used to 
describe findings presented here. The control sample showed only an occasional 
staining of “astrocytes”, whereas the patient presented much more pronounced staining 
suggestive of proliferation of “astrocytes” and reactive astrogliosis. Astrocytes are the 
most abundant cells in the central nervous system (CNS), which traditionally were 
thought to play an important role in supporting neurons both structurally and 
metabolically (Hol and Pekny, 2015). Recent research has shown that astrocytes play a 
crucial role in synaptogenesis (Allen et al., 2012). Proliferation of astrocytes (reactive 
astrogliosis) is a response of the CNS to neuronal damage (Hol and Pekny, 2015). 
Astrogliosis plays an important role in health, stimulating recovery processes (Burda 
and Sofroniew, 2014) and disease progression (Barres, 2008). In this study the putative 
reactive astrogliosis in the patient is supported by the Western blot analysis, which 
showed almost a 2.5 fold increase in expression of ZFYVE27 in the patient’s 
cerebellum, when compared to controls. IHC analysis also revealed ZFYVE27 staining 
of parallel “fibres”, resembling astrocyte processes, in the patient cerebellum. As 
staining for astrocyte or glial markers was not performed, this study is not able to draw 
conclusions regarding the expression of ZFYVE27 in astrocytes in the cerebellum. 
Therefore, future work should focus on performing a colocalisation study which would 
involve immunofluorescent staining of ZFYVE27 along with a glia marker (for 
example, glial fibrillary acidic protein (GFAP)) (Hol and Pekny, 2015) and an astrocyte 
marker (for example, aldehyde dehydrogenase 1 family, member L1 (ALDH1L)) (Tong 
et al., 2014). More control subjects and more brain regions should also be analysed for 
expression of ZFYVE27. It would also be interesting to look into the expression of 
ZFYVE27 in other types of ataxia, to support current studies and confirm whether the 
identified genetic defect in ZFYVE 27 is a cause of disease in the case investigated in 
this Thesis.  
Recently ZFYVE27 has been found to serve as an adaptor molecule that connects the 
motor protein KIF5A and its’ cargoes in vesicular transport during process formation 
(Matsuzaki et al., 2011). KIF5A is a cause of human hereditary spastic paraplegia 
(SPG10) (Reid et al., 2002). The role of the interactions between ZFYVE27 and 
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KIF5A, which lead to connecting the ER with late endosomes and translocation of the 
latter during neurite outgrowths, has recently been elucidated (Raiborg et al., 2015). 
ZFYVE27 binds the C-terminus of the KIF5A protein and the binding site could 
potentially be disrupted by ZFYVE27 c.805-2A>G mutation. Given that both ZFYVE27 
and KIF5A are known disease genes in hereditary spastic paraplegia, it would be 
interesting to explore the effect of the ZFYVE27 mutation on the protein interactions by 
means of protein expression studies.  
5.4.4. Proposed model of functional consequences of the c.805-2A>G mutation  
Based on the findings presented here, this study proposes a model of functional 
consequences of the c.805-2A>G mutation in ZFYVE27 (Figure 5.18). Mutant protrudin 
may lead to ER stress, as evidenced in this study, however the mechanisms have not 
been identified as yet (Gardner, 2010). The effects of this mutation in ZFYVE27 may 
also disrupt the normal interaction of protrudin with KIF5A, which may further lead to 
the failure to recruit late endosomes and eventually result in failure of neurite 
outgrowths (Raiborg et al., 2015).  
 
Figure 5.18: Proposed model of functional consequences of the ZFYVE27 c.805-
2A>G mutation. 
1 2 9 3 4 5 6   7 8 10 11 12 
het c.805-2A>G 
Normal RNA splicing affected 
Exon skipping 
Stop codon 
Nonsense-mediated decay 
Functional RNA eliminated 
ER stress 
Perturbed recruiting of KIF5A 
fails to recruit late endosomes (LE) 
Neurite outgrowths failure  
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In summary, this study presents the evidence supporting a causative role of ZFYVE27 
gene mutation (c.805-2A>G) in a dominant family with cerebellar ataxia. The 
transcriptional studies, presented in this Thesis, show that the c.805-2A>G mutation 
could affect normal RNA splicing and cause nonsense-mediated decay of ZFYVE27 
transcripts. The protein expression studies show that the c.805-2A>G mutation could 
cause ER stress and lead to neuronal damage. This study has an important implication 
because it could potentially lead to therapy employing inhibition of nonsense-mediated 
decay with gentamicin (Welch et al., 2007). It should be highlighted that the current 
study subsequently investigated the frequency of the ZFYVE27 mutation c.805-2A>G 
on ExAC database (available at http://exac.broadinstitute.org ) and found that it is a rare 
mutation (allele count 3/121378; MAF=0.00002472). However, with no indisputable 
ZFYVE27 pathogenic mutations identified to date, it is difficult to draw conclusions as 
to the pathogenicity of the c.805-2A>G mutation. Therefore, at the time of writing this 
Thesis, these data could not be used in the clinical setting. It should be mentioned that 
although Patient 23’s muscle biopsy tests showed multiple mitochondrial DNA 
deletions and a small frequency of COX negative fibres, the appearances of the biopsy 
and the multiple mitochondrial DNA deletions were consistent with age-related 
changes, and thus not considered to be diagnostically relevant. However, it would be 
interesting to investigate mitochondrial dynamics in the patient’s fibroblasts. In order to 
elucidate the cause of disease in this family, it would be beneficial to perform whole 
genome sequencing with haplotype reconstruction. Haplotype reconstruction employs 
computational methods, which enables the identification of alleles that are located on 
the same chromosome. When performed on related affected individuals, haplotype 
reconstruction enables the identification of identical-by-decent haplotypes shared 
between those individuals. It is anticipated that haplotypes, being more specific markers 
than single nucleotide variants, will uncover novel haplotype-disease associations 
(Glusman et al., 2014). The latter will play an increasingly important role in 
personalised medicine.  
 
.   
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Chapter 6. Molecular genetic analysis and determining pathogenicity 
of TUBB4A gene mutations in an autosomal dominant pedigree and a 
sporadic case  
6.1. Introduction 
Tubulins are building blocks of microtubules, which are the major components of the 
cytoskeleton in eukaryotic cells (Oakley, 2000). Tubulins are organised into αβ-tubulin 
heterodimers which bind head to tail to form a protofilament (Figure 6.1). About 13 
protofilaments form a tubular structure (microtubule) with well-defined polarity 
(Akhmanova and Steinmetz, 2008). 
  
 
Figure 6.1: Tubulin heterodimer structure. αβ-Tubulin heterodimers  polymerize 
head-to-tail along their longitudinal direction to form protofilaments. Protofilaments 
interact with each other laterally in order to organize into a tubular structure 
(microtubule) (adapted from Miyatake et al., 2014). 
 
!! 158!
Microtubules are highly dynamic structures, which undergo assembly and disassembly 
(Kirschner and Mitchison, 1986). This process depends on guanine nucleotide binding 
and hydrolysis. Microtubules are involved in cell division including the formation of 
mitotic spindles, intracellular transport and cell motility. Intriguingly, β-tubulin contains 
a motif, which serves as a binding site for a pharmacological compound taxol (Turner 
and Margolis, 1984). Binding of taxol to β-tubulin leads to suppression of disassembly 
of microtubules and results in stabilization of the latter. This phenomenon made taxol 
and its derivatives as a drug of preference in cancer therapy because stabilized 
microtubules would supress cell division (Galassi, 1992). Strikingly, another group of 
drugs, which affect microtubule dynamics, was discovered recently. Compounds such 
as nocodazole and vinblastine were found to promote microtubule depolymerization 
(Jordan and Wilson, 2004). 
The role of microtubules in the formation and function of the nervous system was 
extensively studied in the past. It is well established that the neuronal microtubules are 
required for the division and migration of neurons, neuronal differentiation and circuit 
formation (Kuijpers and Hoogenraad, 2011). Depletion of microtubules in axons and 
dendrites is associated with neurodegenerative diseases (Sudo and Baas, 2011). 
Therefore, microtubule-stabilizing drugs are a promising target for therapy of injury and 
diseases of the nervous system, resulting in the prevention of microtubules from 
degrading (Baas and Ahmad, 2013).  
The pivotal role of microtubules in CNS development and maintenance was recently 
underscored by numerous reports implicating tubulins in a spectrum of neurological 
disorders. More recently several genes encoding α- and β-tubulin isotypes, crucial for 
microtubule assembly in neurons, have been linked to neurological phenotypes 
characterised by impaired neuronal migration, differentiation, axon guidance and 
maintenance. Missense mutations in TUBA1A (Tischfield et al., 2011), TUBB2B (Jaglin 
et al., 2009), TUBB3 (Tischfield et al., 2010) (Poirier et al., 2010), TUBB5 (Breuss et 
al., 2012), TUBA8 (Abdollahi et al., 2009) and TUBG1 (Poirier et al., 2013) were all 
implicated.  
More recently, TUBB4A was linked to several neurological phenotypes. TUBB4A is 
located on the chromosome 19 and encodes a member of β-tubulin family comprising 
444 amino acids. TUBB4A is a major isotype in brain representing 46% of all beta 
tubulins. The highest expression in the brain is in the cerebellum, followed by putamen 
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and white matter (Leandro-Garcia et al., 2010; Lohmann et al., 2012).  
In 2012 two groups independently studied an extended Australian family with dystonia 
type 4 (DYT4) (Hersheson et al., 2012; Lohmann et al., 2012). Both groups performed 
genetic linkage and subsequent exome sequencing and identified a missense TUBB4A 
p.Arg2Gly mutation as a cause of the disease in the family. Lohmann and colleagues 
studied TUBB4A mRNA expression level in different tissues in one affected person. 
Compared with controls, TUBB4 RNA levels were decreased in all tissues of the 
affected person. The authors concluded that the disease mechanism is through reduced 
levels of TUBB4 RNA rather than affecting its functionality. This group also screened 
394 unrelated individuals with dystonia and identified one individual with a causative 
TUBB4A p.Ala271Thr mutation. Interestingly, shortly after these two studies were 
published, another neurological phenotype was linked to TUBB4A. Simons and 
colleagues employed whole exome sequencing in five family trios, two family quartets 
and three single probands who presented with hypomyelination with atrophy of the 
basal ganglia and cerebellum (H-ABC syndrome). They subsequently identified a de 
novo p.Asp249Asn mutation in TUBB4A as a cause of disease in all 11 affected 
individuals (Simons et al., 2013). H-ABC is a rare neurological disease diagnosed on 
the basis of MRI findings such as hypomyelination and cerebellar atrophy. The 
mutation was predicted to affect longitudinal interaction between tubulin subunits. 
Strikingly, in one family, with unaffected parents and two affected siblings, detailed 
investigations revealed maternal mosaicism for the mutation. The authors reasoned that 
the phenotypically neutral de novo mosaic mutation in the mother caused the disease in 
the subsequent generation. Numerous reports on a causative role of TUBB4A in H-ABC 
soon followed the findings by Simons and colleagues. Presently, 19 additional TUBB4A 
mutations have been reported in H-ABC (Ferreira et al., 2014; Hamilton et al., 2014; 
Miyatake et al., 2014; Purnell et al., 2014)(Blumkin et al., 2014)(Carvalho et al., 2015; 
Erro et al., 2015). Mutations in TUBB4A were recently reported in other neuroimaging 
phenotypes. Pizzino and colleagues performed whole exome sequencing on 5 patients 
from 4 families with hypomyelinating leukodystrophy with or without cerebellar 
atrophy but lacking other characteristic features of H-ABC such as basal ganglia 
abnormalities (Pizzino et al., 2014). Four novel de novo mutations in TUBB4A were 
identified in all 5 affected individuals (p.Val255Ile, p.Arg282Pro, p.Gln292Lys, 
p.Arg391His). All these mutations were predicted to affect longitudinal interactions 
between tubulin subunits, similar to the p.Asp249Asn mutation published by Simons 
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and colleagues. In a more recent publication, Kancheva and colleagues applied whole 
exome sequencing to a highly consanguineous family with five children who presented 
with complicated hereditary spastic paraplegia (HSP), exhibiting regional 
hypomyelination, mild cerebellar atrophy, and no dystonia, basal ganglia atrophy, or 
cognitive dysfunction (Kancheva et al., 2015). The authors identified a p.His190Tyr 
mutation in TUBB4A in all affected children. Noticeably, the mutation was also present 
in the asymptomatic mother suggesting mosaicism. Quantitative PCR in the mother’s 
blood showed that the mutant allele was present at 10%, therefore supporting mosaicism 
The precise molecular mechanism underlying TUBB4A-associated phenotypes remains 
to be elucidated.  
This study aims to evaluate pathogenicity of two TUBB4A mutations, c.900G>T and 
c.1091C>A, and establish their causative role in two families who presented with ataxia 
and hypomyelinating leukodystrophy. 
6.2. Materials and Methods 
6.2.1. Patients 
This study involved two families. Family 1 included three affected individuals (the 
mother P13 and daughters P11 and P12), who were subjected to whole exome 
sequencing. Both siblings presented during infancy with a severe disease phenotype. 
The mother presented in her late 30s with milder disease features (Appendices 1 and 2). 
Family 2 was represented by a female patient P14 with no family history (Appendices 1 
and 2).  
 6.2.2. MRI scan 
Magnetic resonance imaging (MRI) was performed at the Royal Victoria Infirmary 
(Newcastle upon Tyne Foundation Hospitals NHS Trust, UK) following the routine 
referrals of the patients to the regional neurogenetic service at Newcastle upon Tyne, 
UK.  
6.2.3. Exome read depth at the position of the TUBB4A mutation c.900G>T 
Bioinformatic analysis was performed as described in Section 2.4.2. Coverage analysis 
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of CCDS bases and known ataxia genes was performed as described in Sections 3.2.6 
and 3.2.7, respectively. Analysis of the variant file in the variant caller Varscan, the raw 
Varscan output file, variant frequency and exome read depth at the position of the 
TUBB4A mutation were performed by Dr Helen Griffin (Newcastle University). The 
readings for the reference and variant alleles were obtained from Dr Helen Griffin 
(Newcastle University) and the ratios of reference to variant reads were calculated for 
patients P11, P12 and P13.  
6.2.4. Conservation study 
Multiple sequence alignment of TUBB4A, in human and animal orthologs, was 
performed using Clustal Omega software (available on 
http://www.ebi.ac.uk/Tools/msa/clustalo/). 
6.2.5. Pyrosequencing 
Pyrosequencing is a DNA sequencing technology, which is based on the sequencing-by-
synthesis principle. The technique employs four enzymes, which work in a cascade 
reaction. Each event of incorporation of a nucleotide results in a release of 
pyrophosphate (PPi) in an equimolar quantity to the amount of nucleotide incorporated. 
PPi is then quantitatively converted to adenosine triphosphate (ATP). The end of the 
reaction is manifested by emission of light in an amount that is proportional to the 
amount of ATP. The light is detected as a peak on the pyrogram. The proportion of 
mutated alleles is calculated by the software by comparing wildtype and mutant peak 
heights.  
The proportion of mutated alleles in various tissues was determined using a quantitative 
pyrosequencing assay according to the manufacturer’s protocol. Pyromark Assay 
Design software v.2.0 (QIAGEN, Manchester, UK) was used to design gene-specific 
PCR and pyrosequencing primers (Table 6.1). Pyrosequencing was performed on the 
Pyromark Q24 platform (QIAGEN, Manchester, UK). 
The assay was validated with a series of controls using a reference DNA sample. The 
controls were as follows: 
1) PCR without template DNA. This control is used to check unspecific 
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amplification during PCR.  
2) PCR with template DNA but with no sequencing primer. This control will 
ensure that the template is not forming a loop, which could result in a 
background signal in pyrosequencing reactions.  
3) Sequencing primer without any PCR product. This control will check whether 
the sequencing primer forms duplexes or hairpins, which could result in 
unspecific DNA amplification during PCR.  
4) Biotinylated primer without any PCR product. This control will check whether 
biotinylated primer forms duplexes or hairpins, which could result in a 
background signal in pyrosequencing reactions. 
5) Sequencing primer and biotinylated primer together without PCR product. This 
control will ensure that the sequencing primer and the biotinylated primer don’t 
form duplexes, which could result in a background signal in pyrosequencing 
reactions.  
In order to pass the quality control, pyrograms from all the above controls should not 
show any significant peak after any nucleotide addition. 
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6.2.6. 3D structure modelling 
Refined structure of bovine αβ-tubulin heterodimer, published by Lowe and colleagues 
(Lowe et al., 2001), was obtained from Protein Database (PDB number 1JFF) and the 
stereo plot was obtained using the online program Cn3D (available at 
http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml). The mutated amino acids 
were mapped to the 3D structure of αβ-tubulin heterodimer. The assessment of the 
possible effect of the mutations was based on a linear structure of β-tubulin published 
by Wade and colleagues (Wade et al., 2009). 
6.3. Results 
6.3.1. MRI scan 
The images were kindly provided by Newcastle upon Tyne Foundation Hospitals NHS 
Trust, UK. In family 1, MRI for the mother (patient P13, Figure 6.2 A and B) and 
daughter (patient P12, Figure 6.2 C and D) revealed leukodystrophy and cerebellar 
atrophy in both patients (Figure 6.2). T2 and T1 images (Figure 6.2 A and B) revealed 
generalized atrophy and periventricular high signal, indicative of an abnormality within 
the white matter. T2 images (Figure 6.2 C and D) showed marked cerebellar atrophy 
and diffuse hypomyelination. MRI for patient P13 revealed similar findings to patient 
P12 (image is not provided). In family 2 (patient P14) MRI revealed diffuse 
hypomyelination including brainstem and diffuse white matter changes (image is not 
provided). 
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Figure 6.2: MRI from the mother P13 and daughter P12. Brain MRI for patient P13, 
the mother (A and B) and patient P12, the daughter (C and D) revealed leukodystrophy 
and cerebellar atrophy in both patients. T2 and T1 images (A and B) revealed 
generalized atrophy and periventricular high signal, indicative of an abnormality within 
the white matter. T2 images (C and D) showed marked cerebellar atrophy and diffuse 
hypomyelination. Adapted from Pyle et al., 2014 
 
6.3.2. Analysis of the exome read depth at the position of the p.Met300Ile mutation in 
family 1 
Exome read depth at the position of the TUBB4A mutation revealed that both offspring 
had a normal ratio of reference to variant reads (approximately 1:1) reflecting 
heterozygosity. The mother had an abnormal ratio (13:1) suggesting mosaicism (Table 
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6.2). With no history of the disorder in previous generations of this family, it was 
suspected that the mother had a de novo mutation. 
 
Table 6.2: Exome read depth at the position of the p.Met300Ile mutation in 
patients P11, P12 and P13. 
Patient Target Chr Variant Position Coverage 
Ref-
base 
Var-
base 
Ref-
reads 
Var-
reads 
% 
Var-
freq 
Ratio 
Ref:Var 
P11 
Chr19:6494330-
6495958:TUBB4A 19 6495610 
400 
C A 
162 146 47.4 1.1:1 
P12 477 145 148 50.51 0.98:1 
P13 422 359 27 6.99 13.3:1 
 
6.3.3. Conservation of residues p.Met300Ile and p.Ala364Asp 
Both the p.Met300Ile and p.Ala364Asp mutations were found to be evolutionary 
conserved (Figures 6.3 and 6.4, respectively). 
 
 
Figure 6.3: Multiple sequence alignment of a section of human TUBB4A and 
animal orthologs. Residue Met300 is boxed in red. 
 
 
H.sapiens))))))))))) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLSVQSKNSSYFVEWIPNNVKTAVC5 354)
P.troglodytes)))) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLSVQSKNSSYFVEWIPNNVKTAVC5 354)
C.lupus) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLSVQSKNSSYFVEWIPNNVKTAVC5 354)
B.taurus) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLSVQSKNSSYFVEWIPNNVKTAVC5 354)
M.musculus) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLSVQSKNSSYFVEWIPNNVKTAVC5 354)
R.norvegicus) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLSVQSKNSSYFVEWIPNNVKTAVC5 354)
D.rerio) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLNVQNKNSSYFVEWIPNNVKTAVC5 354)
D.melanogaster) DAKNMMAACDPRRHGRYLTVAAVFRGRMSMKEVDEQMLAVQNKNSSYFVEWIPNNVKTAVC5 360)
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Figure 6.4: Multiple sequence alignment of a section of human TUBB4A and 
animal orthologs. Residue Ala364 is boxed in red. 
 
6.3.4. Quantification of the mutated allele p.Met300Ile with pyrosequencing 
(family 1)  
Validation of the assay revealed that pyrograms from all the validation controls didn’t 
show any significant peaks after any nucleotide addition (Figure 6.5). 
H.sapiens))))))))))) DIPPRGLKMAATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESN3 414)
P.troglodytes)))) DIPPRGLKMAATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESN3 414)
C.lupus) DIPPRGLKMAATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESN3 414)
B.taurus) DIPPRGLKMAATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESN3 414)
M.musculus) DIPPRGLKMAATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESN3 414)
R.norvegicus) DIPPRGLKMAATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESN3 414)
D.rerio) DIPPRGLKMAATFIGNSTAIQELFKRISEQFTAMFRRKAFLHWYTGEGMDEMEFTEAESN3 414)
D.melanogaster) DIPPRGLKMASTFIGNTTAIQELFKRISEQFSAMFRRKAFLHWYTGEGMDEMEFTEAESN3 420)
! !168!
 
Fi
gu
re
 6
.5
: P
yr
os
eq
ue
nc
in
g 
as
sa
y 
va
lid
at
io
n.
 T
hi
s 
fig
ur
e 
de
pi
ct
s 
py
ro
gr
am
s 
fo
r c
on
tro
l p
yr
os
eq
ue
nc
in
g 
ru
ns
: P
C
R
 w
ith
ou
t t
em
pl
at
e 
D
N
A
 (A
); 
PC
R
 w
ith
 te
m
pl
at
e 
D
N
A
 b
ut
 w
ith
 n
o 
se
qu
en
ci
ng
 p
rim
er
 (B
); 
Se
qu
en
ci
ng
 p
rim
er
 w
ith
ou
t a
ny
 P
C
R
 p
ro
du
ct
 (C
); 
B
io
tin
yl
at
ed
 p
rim
er
 w
ith
ou
t a
ny
 
PC
R
 p
ro
du
ct
 (D
); 
Se
qu
en
ci
ng
 p
rim
er
 a
nd
 b
io
tin
yl
at
ed
 p
rim
er
 to
ge
th
er
 w
ith
ou
t P
C
R
 p
ro
du
ct
 E
). 
 
!! 169!
 
Proportion of the mutated allele was determined by pyrosequencing. This study tested 
blood, hair root cells, buccal epithelial cells and fibroblasts in the mother and blood 
cells in both offspring. The result supported mosaicism in the mother (Figure 6.6, 
Figure 6.7, Table 6.3). 
 
 
Figure 6.6: Confirmatory Sanger sequencing and pyrosequencing in blood DNA 
samples from the mother (P13) and her daughters P11 and P12.  
!! 170!
 
 
Figure 6.7: Confirmatory Sanger sequencing (left) and pyrosequencing (right) in 
hair root cells (A, B), buccal epithelial cells (C, D), and fibroblasts in the mother 
(P13). 
 
 
Table 6.3: Pyrosequencing result for allele quantification of the p.Met300Ile 
mutation in different tissue in the mother (P13) and her daughters (P11 and P12). 
This table was used in Pyle et al., 2014 
Patient Tissue Pyrosequencing % variant % reference 
P13 
Blood 8 92 
Hair root cells 59 41 
Buccal epithelial cells 31 69 
Fibroblasts 35 65 
P11 Blood 56 44 
P12 Blood 54 46 
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6.3.5. Investigation of putative pathogenicity of TUBB4A mutations p.Met300Ile and 
p.Ala364Asp via 3D modelling 
3D structure of αβ-tubulin heterodimer (Lowe et al., 2001), with mapped mutated 
residues, is presented in Figure 6.8. The assessment of the possible effect of the 
mutations was based on a linear structure of β-tubulin published by Wade and 
colleagues (Wade et al., 2009). In family 1 (patients P11, P12 and P13) the mutation 
p.Met300Ile might affect longitudinal interactions between tubulin monomers, possibly 
affecting polymerizations of αβ-tubulin heterodimers 
In family 2 (patient P14) the p.Ala364Asp mutation affects a residue which is directly 
involved in the taxol binding. Therefore, the mutation might affect taxol binding and 
therefore prevent stabilizing of microtubules.  
 
 
Figure 6.8: 3D structure of αβ-tubulin heterodimer (Lowe et al., 2001). α-tubulin 
subunit is represented in magenta and β-tubulin in blue. Helices, β-sheets and loops are 
represented by crayons, flat arrows and threads, respectively. Taxol binding motif is 
shown in orange. The green and yellow tubes represent Met300Ile and Ala364Asp 
mutated residues, respectively 
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6.4. Discussion 
Using whole exome sequencing, likely de novo dominant TUBB4A mutations were 
found in two families who presented with cerebellar ataxia. In family 1 (patients P11, 
P12 and P13) MRI additionally revealed leukodystrophy in the affected individuals. 
This studye found that the TUBB4A p.Met300Ile mutation segregated with the disease 
in this family. In family 2 the affected individual (patient P14) exhibited diffuse 
hypomyelination including brainstem (revealed by MRI). The TUBB4A p.Ala364Asp 
mutation segregated with the disease in the latter family. Both these mutations are 
evolutionary conserved (Figure 6.3 and Figure 6.4).  
TUBB4A seemed to fit the phenotype in the both families (Simons et al., 2013). 
However, in family 1 exome sequencing revealed that the variant p.Met300Ile was in 
the heterozygous state in both offspring, but wildtype in the mother. The mother 
presented with a similar, but much milder phenotype and later onset, which led this 
study to suspect mosaicism. Sanger sequencing of blood DNA samples from all three 
patients confirmed the mutation in the both offspring, but, strikingly, revealed 
heterozygozity in the mother as well. This finding pointed towards mosaicism and 
prompted revisiting the exome sequencing output data. The current study first analyzed 
the variant file in the variant caller Varscan and found that the mother (P13) didn’t carry 
the variant allele for the p.Met300Ile mutation. This finding prompted a detailed 
investigation of the raw Varscan output file. This study found that the mother had a 
predicted variant frequency of 6.99% (Varscan detected 359 reference allele readings 
and 27 variant allele readings at the chromosome position Chr19:6495610). It was 
reasoned that these readings allowed the variant to pass the Varscan base quality filter. 
However, the variant didn’t get reported in the 'on-target' variant file because this file is 
filtered for variants with frequencies greater than 25%. The ratios of reference to variant 
reads were calculated and found that both offspring had a normal ratio of reference to 
variant reads (approximately 1:1) reflecting heterozygosity, the mother had an 
unexpected ratio (13:1), suggesting mosaicism. Exome sequence read depth also 
revealed an even coverage of the mutated base at approximately 400-fold in all three 
patients. Similar findings were recently reported in the literature (Simons et al., 2013). 
In order to establish a molecular cause of the disease, Simons and co-workers (2013) 
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performed exome sequencing in five family trios, two family quartets, and three single 
probands with a total of 11 individuals, who presented with hypomyelination with 
atrophy of the basal ganglia and cerebellum (H-ABC). The authors found that all 11 
individuals carried the same de novo p.Asp249Asn mutation in TUBB4A. One quartet 
with two affected children and seemingly unaffected parents was investigated further. 
Exome sequencing showed that the siblings and the mother were heterozygous for the 
mutation, while the father was wildtype. More detailed investigation of the exome 
readings revealed that in the heterozygous mother the ratio of wildtype to alternative 
reads is much higher than in all other heterozygous patients from the study. Taking into 
account that the mutation was covered at least 50-fold in all samples, the authors 
concluded that the mother is mosaic for that variant. Deep sequencing (MiSEQ 
platform, Illumina) of DNA samples from blood, saliva and buccal cells, from all 
individuals of the quartet, revealed that in the asymptomatic mother the alternative 
allele was present in 25% of reads from blood, 29% of reads from buccal cells and 26% 
of reads from saliva. The result confirmed mosaicism in the mother and showed that a 
rare de novo mutation, which is phenotypically neutral in a mosaic individual, could be 
transmitted in a dominant manner and result in a disease phenotype in the subsequent 
generation.  
In the family 1, in order to determine the proportion of alternative alleles in different 
tissues in the mother (P13), this study performed quantitative pyrosequencing in blood, 
hair root cells, buccal epithelial cells and fibroblasts. To allow comparison, this study 
also performed quantitative pyrosequencing in blood cells in both offspring. 
Confirmatory Sanger sequencing was also performed in all these tissues. The 
p.Met300Ile mutation showed varying degrees of tissue mosaicism in the mildly 
affected mother and heterozygosity in the two severely affected offspring (Figures 6.6 
and 6.7 and Table 6.3). Exome reads support this finding (Table 6.2).  
The current study also investigated how the two TUBB4A mutations, mentioned above, 
might affect the microtubule structure. The mutations were mapped to the refined 
structure of bovine αβ-tubulin heterodimer (Lowe et al., 2001) and the data was 
visualised by Cn3D software (Figure 6.8). Based on the TUBB4A structure, it was 
predicted that the p.Ala364Asp mutation could disrupt the taxol binding domain (Wade 
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et al., 2009), possibly affecting stabilization of microtubules. The p.Met300Ile mutation 
could affect longitudinal interactions between tubulin monomers (Wade et al., 2009), 
possibly disrupting polymerizations of αβ-tubulin heterodimers 
The precise molecular mechanism of TUBB4A mutations, discovered to this day, is not 
known. However, the proposed working hypothesis is alteration of microtubule 
dynamic and stability (Hamilton et al., 2014). It is also proposed that the defective 
microtubule system would impair axonal transport, which would lead to axonal loss and 
subsequently to hampering of the myelination process. Disrupted axonal transport could 
also account for the loss of neurons in basal nuclei and cerebellum. Indeed, impaired 
microtubule dynamic and stability was recently found to be a common functional 
consequence of TUBB4A mutations (Table 6.4). 
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Kancheva and co-workers mapped known TUBB4A mutations to a 3D model in order to 
establish genotype-phenotype correlation (Figure 6.9). The most common mutation 
causing H-ABC (p.Asp249Asn) was found to cause the most benign H-ABC, in 
comparison with other TUBB4A mutations causing H-ABC. Interestingly, there are 
several mutations of Arg2. A heterozygous change of Arg2 to glycine caused a milder 
phenotype (dystonia, DYT4), whereas an Arg2 to tryptophan or glutamine causes a 
more severe phenotype H-ABC (Table 6.4). The possible explanation for this could be 
that a change to the chemically inert glycine would have a very mild effect on the 
function of the resulting TUBB4A. On the other hand, an Arg2 change to the polar 
glutamine or hydrophobic tryptophan would probably lead to a drastic change of 
TUBB4A function (Hamilton et al., 2014).  
 
 
Figure 6.9: Published TUBB4A mutations mapped to a 3D structural model of 
TUBB4A. This picture depicts the 3D structure of TUBB4A with the β tubulin subunit 
represented in light blue and the α subunit in grey. Alpha helixes are depicted as ribbons 
and beta strands are shown as arrows. Loops are presented as threads. The m-loop is 
shown as a green thread. The GDP and GTP molecules are depicted in light green. The 
mutated residues are presented as yellow spheres. Adapted from Kancheva et al., 2015. 
 
To elucidate the precise molecular mechanism of the TUBB4A mutations and to 
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understand how these mutations result in a clinical phenotype and imaging 
abnormalities, functional studies are warranted. For the c.900G>T mutation, which 
occurred in the family with three affected individuals, it would be worthy to undertake a 
transcriptional study. Different tissues of the mother could be employed in order to 
determine the expression levels of TUBB4A mRNA when compared to controls. In 
order to investigate the effect of both mutations (c.900G>T and c.1091C>A) on 
microtubule dynamics in vitro, it would be interesting to transfect wildtype and mutant 
FLAG-tagged human TUBB4A expression constructs into commercial cells (for 
example HEK293). To observe incorporation of wildtype and mutant constructs into the 
microtubule polymer, co-localisation for transgenic and endogenous tubulins should be 
performed. For this the cells are stained sequentially with anti-FLAG (to detect 
transgenic TUBB4A) and anti- α-tubulin (to detect endogenous tubulin) and the result is 
visualised by means of confocal microscopy. 
It is of particular interest that mutations in TUBB4A were recently associated with 
several neuroimaging phenotypes, namely dystonia type 4 (DYT4) (Hersheson et al., 
2012; Lohmann et al., 2012), hypomyelination with atrophy of the basal ganglia and 
cerebellum (H-ABC) (Simons et al., 2013), isolated hypomyelination (Pizzino et al., 
2014) and hereditary spastic paraplegia (HSP) with no basal ganglia involvement or 
cognitive impairment (Kancheva et al., 2015). This makes TUBB4A a primary candidate 
for genetic screening, following MRI, meaning that the overall cost of a diagnosis could 
be greatly reduced. It is clear, that to this day the full spectrum of neurological 
phenotypes associated with TUBB4A mutations is not exhausted. Therefore, it is 
anticipated that whole exome sequencing will be instrumental in discovering new 
TUBB4A mutations.  
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Chapter 7. Molecular genetic analysis and determining pathogenicity 
of mutations in ZFYVE26, FASTKD2 and KCNB2 
7.1. Introduction 
Delineating the molecular cause of clinically and genetically heterogeneous ataxias is 
important because treatment is available for some ataxias (Jayadev and Bird, 2013). 
Whole exome sequencing is rapidly becoming instrumental in establishing a genetic 
diagnosis in ataxia. New disease genes are being discovered, new mutations in 
previously implicated genes are being identified and the phenotypic spectrum of ataxia 
is being broadened. However, the interpretation of exome sequencing data is not always 
straightforward. Identification of a new disease gene or an unexpected gene would need 
further confirmation by functional studies and sometimes re-assessment of previous 
clinical tests such as neuroimaging.  
In this chapter investigation of the potential pathogenicity of the variants in the 
following three genes is described: ZFYVE26, FASTKD2 and KCNB2. These genes 
were identified following exome sequencing approach in 35 affected individuals with 
suspected inherited ataxia. 
ZFYVE26 
Zinc Finger, FYVE Domain Containing 26 (ZFYVE26) gene encodes a protein of 2539 
amino acids, which is localized to the cytoskeleton and the lysosome. The ortholog of 
spastizin in zebrafish is required for spinal motor neuron axon outgrowth (Martin et al., 
2012). Recently spastizin was shown to mediate the formation of new lysosomes and 
therefore, to be a key player in lysosomal biogenesis (Chang et al., 2014). Mutations in 
ZFYVE26 were identified as the cause of hereditary spastic paraplegia type 15 (SPG15) 
(Hanein et al., 2008). Subsequently, thin corpus callosum was identified as an MRI 
hallmark of SPG15 (Goizet et al., 2009). Interestingly, mutations in ZFYVE26 were 
recently identified in a patient with cerebellar ataxia (Fogel et al., 2014).  
 
FASTKD2 
A fas activated serine-threonine domain 2 (FASTKD2) gene encodes a protein, which is 
localized in the mitochondrial inner compartment. FASTKD2 was predicted to be 
involved in regulating apoptosis in breast cancer (Yeung et al., 2011). A nonsense 
mutation in this gene was found in two siblings with infantile mitochondrial 
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encephalopathy associated with a deficiency of cytochrome c oxidative activity, 
however the molecular mechanism of the disease was not elucidated (Ghezzi et al., 
2008). Recently, decreased expression of FASTKD2 in astrocytes was associated with 
Alzheimer’s disease, which suggested that FASTKD2 might be involved in apoptosis 
regulation in astrocytes (Sekar et al., 2015).  
 
KCNB2 
A potassium channel, voltage gated subfamily B, member 2 (KCNB2) gene encodes a 
member of a diverse voltage-gated potassium (Kv) channel family. Kv channels are 
pivotal mediators of neuronal excitability and key participants in the signalling pathway 
that regulates neuronal apoptosis (Guan et al., 2007). Voltage-gated potassium channels 
form protein pores, which open and close in response to the voltage difference across 
the membrane, allowing potassium ion transport in excitable membranes (Jensen et al., 
2012). The precise function of KCNB2 is not known. However, in a recent study Guan 
and co-workers showed that KCNB2 mRNA and protein are expressed in the dendrites 
of pyramidal neurons in rat cortex (Guan et al., 2007). The authors therefore speculated 
that KCNB2 might play a role in regulating distal dendritic excitability. Ion channels 
are of a particular interest due to the recent link between mutations in these genes and 
several neurological phenotypes, including ataxia (Kullmann and Waxman, 2010). 
Intriguingly, voltage-gated potassium channels are predicted to become the latest 
therapeutic targets in the treatment of a wide range of neurological disorders (Shah and 
Aizenman, 2014).  
The aim of this study is to elucidate pathogenicity of mutations in ZFYVE26 
(c.2450delT:p.Leu817Cysfs*12 and c.2338C>T:p.Arg780*; patient P19), FASTKD2 
(c.-66A>G and c.149A>G:p.Lys50Arg; patient P21) and KCNB2 (p.Ser530Phe and 
p.Leu784Pro; patient P26) by means of functional studies. For this, transcription 
(FASTKD2) and segregation studies (ZFYVE26 and KCNB2) will be performed.  
7.2. Materials and Methods 
7.2.1. In silico mutation analysis (splice-site prediction with Alamut software) 
In silico prediction of pathogenicity of the putative causative variants was assessed with 
Alamut software, as described in Section 4.2.4. 
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7.2.2. Allelic cis-trans study via cloning of genomic DNA (sequencing of cloned 
alleles) 
PCR amplicons were generated as described in Section 2.5.2 using gene-specific 
primers (Table 7.1) and electrophoretically separated on a 1.5% agarose gel as 
described in Section 2.5.3. Following separation, the bands were excised from the gel, 
DNA was extracted, cloned and sequenced, as described in Section 2.6. 
Table 7.1: Primers used for generating PCR amplicons for KCNB2 and ZFYVE26 
Gene Forward primer 
sequence 5’-3’ 
Reverse primer 
sequence 5’-3’ 
Anneal 
temp. 
(˚C) 
PCR 
product size 
(bp) 
KCNB2 GAAACAAGCTCCA
ACAAGTC 
CCTGGGAGCTCTA
AGAAGTCT 
58 959 
ZFYVE26 TGCTCCCAGGTGG
CTCTGGT 
AGCCCACCCTTTG
CCTTTGGT 
58 904 
 
7.2.3. Sequencing of fibroblast cDNA (total PCR product and cDNA cloned from 
extracted PCR fragments) 
Reverse transcription PCR (RT-PCR) was performed as described in Section 2.9 using 
FASTKD2 specific primers (Table 7.2). 
 
Table 7.2: FASTKD2 primers used for RT-PCR 
FASTKD2 primer Sequence 
Forward 5´- GAAGCGCAGCTTCTCGGGGA -3´ 
Reverse  5´- CATTGATACGTTCCTGGGTCAC -3´ 
 
PCR conditions included a hot start at 95oC for 3 minutes, followed by 35 cycles of 
denaturation at 95oC for 1 minute, annealing at 53oC for 1 minute, and extension at 
72oC for 2 minutes. The final extension step was performed at 72oC for 10 minutes, 
followed by cooling the sample to 4oC. Sanger sequencing of total PCR product was 
performed using FASTKD2 specific primers (Table 7.2), as described in Section 2.5.  
The efficiency of the cDNA amplification from fibroblasts of controls and the patient 
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was assessed by conducting a control RT-PCR test using primers specific for a 353 bp 
fragment of the housekeeping gene beta-actin (Table 7.3) 
 
Table 7.3: Beta-actin primers for mRNA quality control RT-PCR 
Beta actin primer Sequence 
Forward 5´- GCTCGTCGTCGACAACGGCTC -3´ 
Reverse  5´- CAAACATGATCTGGGTCATCTTCTC -3´ 
 
The quality control RT-PCR was performed as described in Section 2.9.3. PCR 
conditions were as follows: a hot start at 95oC for 2 minutes followed by 30 cycles of 
denaturation at 95oC for 15 seconds, annealing at 58oC for 30 seconds and extension at 
72oC for 1 minute. The reaction was finished by a final extension step performed at 
72oC for 10 minutes, followed by cooling the sample to 4oC.  
Sanger sequencing of plasmid DNA cloned from the extracted PCR fragments was 
performed as described in Section 2.6. 
7.3. Results 
7.3.1. ZFYVE26 (patient 19) 
This male patient presented at age 32 with cerebellar ataxia. There was no family 
history. Whole exome sequencing identified one frameshift mutation 
(c.2450delT:p.Leu817Cysfs*12) and one stop gain mutation at a highly conserved 
residue (c.2338C>T:p.Arg780*) in ZFYVE26 in patient P19. The p.Arg780* is 
predicted to be disease causing or damaging by three prediction programmes (Table 
3.4). Detailed clinical investigations are presented in Table 4.5. Additional clinical data 
are presented in Appendix 1.  
Allelic cis-trans study via cloning of genomic DNA  
The parental samples were unavailable for analysis. Segregation of alleles was 
confirmed with sequencing of the cloned alleles. 
PCR amplicon was generated from the patient’s genomic DNA using ZFYVE26 specific 
primers spanning both mutations. Agarose gel electrophoresis of the PCR amplicon 
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revealed amplification of a 904 bp PCR product in patient P19 (not shown). The band 
was excised from the gel and the DNA fragment was ligated into pGEM®-T easy 
vector. Competent cells JM109 were then transformed with the ligation reaction, and 
the cells were plated out on agar plates supplemented with ampicillin, IPTG and X-Gal 
to allow blue/white colonies selection. Plasmid DNA was extracted from the single 
white colonies and Sanger sequenced.  
31 clones were sequenced. Sanger sequencing of the cloned alleles revealed that the 
mutations occur in trans (Figure 7.1). There were two types of alleles each containing 
only one homozygous mutation. Allele A contained a homozygous mutation 
c.2338C>T:p.Arg780* and a wildtype c.2450T (Figure 7.1, A). Allele B contained a 
homozygous mutation c.2450_2450delT:Leu817Cysfs*12 and wildtype c.2338C 
(Figure 7.1, B). Out of 31 clones, 17 were type A and 14 represented type B allele.  
 
Figure 7.1: Sanger sequencing chromatograms for cloned alleles types A and B. 
This figure depicts two types of alleles that were cloned. Allele A containes a 
homozygous mutation c.2338C>T:p.Arg780* and a wildtype c.2450T (A). Allele B 
contained a homozygous mutation c.2450_2450delT:Leu817Cysfs*12 and wildtype 
c.2338C (B). The mutations are inherited in trans. 
7.3.2. FASTKD2 (patient P21) 
This female patient presented in infancy with a walking delay at 23 months, wobbly 
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walking and frequent falls. There was no evidence of family history. Whole exome 
sequencing identified putative pathogenic compound heterozygous FASTKD2 mutations 
(c.-66A>G and c.149A>G:p.Lys50Arg) in this patient with ataxia (Table 4.5). Sanger 
sequencing confirmed segregation of these variants with disease in the family 
(Appendix 1). The p.Lys50Arg mutation is rare in the population and conserved among 
species (Table 3.4).  
In silico mutation pathogenicity study (splice-site prediction with Alamut software) 
Splice predictions for FASTKD2 (NM_001136194.1) c.-66A>G show a gain of acceptor 
site at c.-65 by one program and loss of acceptor site at –c.64 by another program 
(Alamut v2.4, Interactive Biosoftware, Rouen, France) (Figure 4.1).  
 
Sequencing of FASTKD2 fibroblast cDNA (total PCR product and plasmid DNA 
cloned from extracted PCR fragments) 
Prior to the transcription study, the efficiency of the cDNA amplification was assessed 
by means of RT-PCR using primers specific for the housekeeping gene beta-actin. 
Agarose gel electrophoresis of the RT-PCR product revealed amplification of a beta-
actin-specific product of 353 bp in all samples, confirming the satisfactory quality of the 
initial total RNA preparation (Figure 7.2). 
 
Figure 7.2: Agarose gel electrophoresis of beta-actin RT-PCR product generated 
from controls’ and patient’s fibroblasts 
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Agarose gel electrophoresis of the FASTKD2 RT-PCR product, generated from RNA 
derived from fibroblasts of healthy controls and patient P21 using primers specific to 
FASTKD2 cDNA, revealed amplification of a strong band of 907 bp and a weak band of 
approximately 1000 bp in controls. The patient sample produced two strong bands of 
1000 bp and 907 bp (Figure 7.3) 
 
Figure 7.3: Agarose gel (1.5%) electrophoresis of FASTKD2 PCR product, 
amplified from cDNA (RNA was derived from fibroblasts of healthy controls and 
the patient P21) 
Sequencing of FASTKD2 RT-PCR product generated from fibroblasts (total PCR 
product) was inconclusive in the patient. Sequence chromatograms obtained from the 
patient showed mixed peaks indicating the presence of several alleles. This study 
concluded that direct sequencing of total RT-PCR product was inconclusive in patient 
P21 and therefore the study moved on to cloning the cDNA fragments in the patient and 
subsequently sequencing the cloned DNA. For controls, sequence chromatograms 
showed a deletion of 108 bp from the 5’ untranslated region (UTR) of exon 1 on both 
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alleles. It was therefore concluded that the normal splicing event involves a deletion of 
108 bp. Interestingly, the c.-66A mutation falls within the 108 bp deletion. Based on the 
clear Sanger sequencing result, cDNA cloning for controls was not performed. Also, the 
clear Sanger sequencing result for controls, which reveals the presence of only one 
allele, suggests that the weak band at approximately 1000 bp in both controls represents 
a non-specific PCR product (Figure 7.3). 
In order to extract the patient’s DNA from the gel for subsequent cloning, both bands 
were excised in a single preparation. This fragment was cloned into pGEM®-T Easy 
vector, 22 white colonies were selected and sequenced. Sequencing in 4 clones failed, 
possibly due to the primers’ failure to anneal. From the remaining clones, 3 represented 
the aberrant allele and 15 represented the normal allele (Figure 7.4). 
A normal allele (Figure 7.4, A and B) has a deletion of 108 bp on the 5’UTR of exon 1, 
including the c.-66A mutation; the second c.149A>G:p.Lys50Arg mutation is present 
on this allele confirming occurrence of the mutations in trans. An aberrant allele (Figure 
7.4, C and D) has a deletion of 15 bp from the 5’UTR of exon 1, including the c.-66A 
mutation; the second c.149A>G:p.Lys50Arg mutation is shown to be present on the 
opposite allele confirming occurrence of the mutations in trans. 
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7.3.3. KCNB2 (patient P26) 
Allelic cis-trans study via cloning of genomic DNA  
Patient P26 (female) presented with cerebellar ataxia in her teens. There was no family 
history. Whole exome sequencing identified putative pathogenic compound 
heterozygous KCNB2 mutations in this patient (p.Ser530Phe and p.Leu784Pro). Both 
mutations were not found in the public databases, such as NHLBI Exome Sequencing 
Project, 1000 genomes and dbSNP137, or the in-house control panel of 286 unrelated 
exomes (Table 3.4). Mutation p.Ser530Phe is conserved across species and 
p.Leu784Pro is conserved across the primates (Table 3.4). Detailed clinical 
investigations are presented in Table 4.5. Segregation study employing Sanger 
sequencing confirmed both mutations in the patient, but revealed that the mother was 
wildtype for both variants. This suggested that the patient inherited the variants in cis. 
However, with no father’s DNA available, it was not possible to affirm this with 
confidence due to a chance, albeit very little, for these mutations being de novo 
compound heterozygous. Therefore the KCNB2 amplicon, which was amplified from 
the patient’s genomic DNA, was cloned and sequenced. PCR amplicon was generated 
from the patient’s genomic DNA using KCNB2 specific primers spanning both 
mutations. Agarose gel electrophoresis of the PCR amplicon revealed amplification of a 
959 bp PCR product in patient P26 (Figure 7.5). This band was excised from the gel and 
cloned. 
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Figure 7.5: Agarose gel (1.5%) electrophoresis of a PCR amplicon generated from 
the patient’s genomic DNA using KCNB2 specific primers spanning both KCNB2 
mutations c.1589C>T:p.Ser530Phe and c.2351T>C:p.Leu784Pro 
 
24 clones were sequenced. Sanger sequencing of the cloned alleles revealed that there 
were two type of alleles present (Figure 7.6). Allele A represented a wildtype allele and 
had both bases c.1589C and c.2351T present in a homozygous wildtype state (Figure 
7.6, A). Allele B had both KCNB2 mutations c.1589C>T:p.Ser530Phe and 
c.2351T>C:p.Leu784Pro present in a homozygous state. Out of 24 clones, there were 9 
clones representing the wildtype allele A and 15 clones representing allele B containing 
both mutations.  
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Figure 7.6: Sanger sequencing chromatograms for cloned KCNB2 alleles type A 
and B. This figure depicts two types of alleles that were cloned. Type A represents a 
wild type allele, type B contains both KCNB2 mutations c.1589C>T:p.Ser530Phe and 
c.2351T>C:p.Leu784Pro. The mutations are inherited in cis.  
 
Segregation study 
Sanger sequencing of blood DNA of an unaffected brother confirmed that the variants 
are inherited in cis (Figure 7.7)  
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Figure 7.7: Segregation analysis of KCNB2 mutations in the family of patient P26. 
This figure shows that the patient P26 and her unaffected brother inherit the KCNB2 
heterozygous mutations in cis, probably from the father. 
7.4. Discussion 
7.4.1. ZFYVE26 (patient 19) 
Whole exome sequencing identified ZFYE26 (SPG15) compound heterozygous 
mutations (p.Leu817Cysfs*12 and p.Arg780*) in patient P19. Detailed clinical 
investigations are presented in Table 4.5. Additional clinical data are presented in 
Appendix 1. The p.Arg780* was predicted to be disease causing or damaging by three 
pathogenicity prediction programs (Table 3.4). The parental samples were unavailable 
for analysis. However, this study shows, via sequencing of cloned alleles from the 
patient, that the variants were inherited in trans, supporting a recessive inheritance 
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model. This led the clinicians to re-assess the neuroimaging and confirm the thin corpus 
callosum, which is a characteristic of SPG15 (Figure 7.8).  
 
Figure 7.8:  T1 Axial (A) and T2 sagittal (B) MRI in P19. The MRI shows global 
cerebral atrophy with marked atrophy of the corpus callosum (arrows) (adapted from 
Pyle et al., 2014). 
SPG15 is a neurological disorder with a recessive mode of inheritance, which is 
characterised by slowly progressive spastic paraparesis, cognitive impairment, 
ophthalmologic abnormalities and often ataxia. The main MRI characteristic of SPG15 
is thin corpus callosum (Goizet et al., 2009). SPG15 is caused by mutations in 
ZFYVE26, which encodes spastizin (Hanein et al., 2008). 
This study underscores the advantages of whole exome sequencing in a clinical setting. 
The finding of compound heterozygous mutations in ZFYVE26 prompted re-assessing 
the neuroimaging of the patient’s brain and subsequently establishing the diagnosis in a 
patient with previously undiagnosed ataxia. 
7.4.2. FASTKD2 (patient P21) 
Using unbiased whole exome sequencing this study identified putative pathogenic 
compound heterozygous FASTKD2 mutations (c.-66A>G and c.149A>G:p.Lys50Arg) 
in one patient (P21) with ataxia (Table 4.5). Sanger sequencing confirmed segregation 
of these variants with disease in the family (Appendix 1). The p.Lys50Arg mutation is 
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rare in the population and conserved among species (Table 3.4). The c.-66A>G 
mutation, which is situated in the untranslated exon 1 (5’UTR) was predicted to affect 
normal splicing of exon 1 (Figure 4.1).  
Genomic variations causing splicing abnormalities account for approximately 15% of 
mutations linked to human inheritable diseases (Blencowe, 2000). 5’- and 3’ UTRs of 
the mRNA contain regulatory elements, which mediate protein synthesis (Chatterjee 
and Pal, 2009). Recently it has been shown that mutations in the 5’- and 3’ UTRs are 
causing human diseases (Scheper et al., 2007). In particular, mutations in 5’UTR were 
shown to cause such neurological phenotypes as Alzheimer’s disease (Mihailovich et 
al., 2007) and Charcot-Marie-Tooth disease (Hudder and Werner, 2000). This study 
shows, via sequencing analysis of cDNA clones, that the c.-66A>G mutation, which 
was predicted to affect splicing, is indeed causing an aberrant splicing event in the 
patient. This study therefore hypothesises that the aberrant splicing could cause a 
neurological phenotype in the patient presented here. Previously, a nonsense FASTKD2 
mutation was found in two siblings with infantile mitochondrial encephalopathy 
(Ghezzi et al., 2008). FASTKD2 is located to the mitochondria and was shown to be 
involved in regulating apoptosis in breast cancer (Yeung et al., 2011). Recently it was 
shown that in the astrocytes of patients with Alzheimer’s disease FASTKD2 expression 
level is decreased. This suggested that FASTKD2 might be involved in the regulation of 
apoptosis in astrocytes (Sekar et al., 2015). The latter finding is of a particular interest 
because recently astrocytes emerged as the cells playing a crucial role in synaptogenesis 
(Allen et al., 2012). This study therefore hypothesises that the FASTKD2 mutation c-
66A>G, which resides in the 5’UTR, could, together with the second mutation 
p.Lys50Arg, cause dis-regulation of apoptosis in the astrocytes and therefore affect 
synaptogenesis in the patient. The functional studies of these and other FASTKD2 
mutations are warranted in order to dissect the molecular mechanism of the associated 
phenotypes. This could potentially lead to therapy and counselling of families with 
similar disorders. 
7.4.3. KCNB2 (patient P26) 
Using whole exome sequencing this study identified putative pathogenic compound 
heterozygous KCNB2 mutations in patient P26 (p.Ser530Phe and p.Leu784Pro) 
(Appenxix 1). Both mutations were not found in the public databases, such as NHLBI 
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Exome Sequencing Project, 1000 genomes and dbSNP137, or the in-house control 
panel of 286 unrelated exomes (Table 3.4). Mutation p.Ser530Phe is conserved across  
species and p.Leu784Pro is conserved across the primates. Segregation study employing 
Sanger sequencing confirmed both mutations in the patient, but revealed that the mother 
was wildtype for both variants. This suggested that the patient inherited the variants in 
cis. However, with no father’s DNA available, this study was unable to affirm this with 
confidence due to a chance, albeit very little, for these mutations being de novo 
compound heterozygous. Therefore the KCNB2 amplicon, which was amplified from 
the patient’s genomic DNA, was cloned and sequenced. The latter confirmed 
inheritance of the variants in cis. Sanger sequencing of the blood genomic DNA of an 
unaffected brother revealed the presence of both variants. This finally confirmed the 
inheritance of the both variants in cis by the patient P26 and her unaffected brother. 
This study therefore excluded KCNB2. The current study was unable to solve this case 
possibly due to the technical issues such as ineffectiveness of the exome sequencing 
probes for GC-reach or repetitive issues, which could result in incomplete coverage. 
The causative variants could also reside within non-coding regulatory regions, large 
genomic rearrangements and trinucleotide repeat sequences, which are not reliably 
detected from exome-sequencing data. Therefore, in order to solve this case the 
patient’s DNA should be subjected to whole genome sequencing. 
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Chapter 8 
Concluding Discussion  
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8. Concluding Discussion 
8.1. Overview 
Neurological disorders are complex traits, manifesting as a range of diverse phenotypes. 
Most neurological disorders are highly heterogeneous and individually very rare. This 
clinical spectrum, coupled with vast genetic heterogeneity, makes genetic diagnosis 
particularly difficult. Moreover, many neurological diseases exhibit phenotypic overlap, 
which further complicates establishing the diagnosis. Accurate and timely diagnosis is 
crucial because for some neurological diseases treatment could be available (Jayadev 
and Bird, 2013; Toscano and Schoser, 2013). Precise molecular diagnosis could also 
assist patient management (Dixon-Salazar et al., 2012). Application of next generation 
sequencing tools promises to speed up the discovery of causative variants and 
subsequently aid in elucidating the molecular mechanisms of different neurological 
diseases.  
The most comprehensive type of NGS is whole genome sequencing, which was shown 
to be effective in identifying mutations causing neurological phenotypes (Lupski et al., 
2010). However, the drawbacks include the large data output, difficulties in interpreting 
non-coding variations and ultimately a higher cost (Warman Chardon et al., 2015). The 
solution could be targeted next generation sequencing, which involves panels of known 
disease genes. Targeted next generation sequencing is considerably less expensive and 
more rapid than whole genome sequencing. This approach has proved to be successful 
in establishing a diagnosis for neurological patients (Calvo and Mootha, 2010; Nemeth 
et al., 2013; Rehm et al., 2013; Shanks et al., 2013). Although effective, this approach 
remains a biased technique, which requires a subjective decision as to which exact 
genes to include in the panel. This could lead to a limited portfolio of genes in the panel. 
Also, as new disease genes are being discovered and unusual clinical presentations are 
being described, such panels may quickly become outdated and the correct diagnosis 
could be overlooked. Unlike the targeted sequencing panels, whole exome sequencing 
allows discovery of rare mutations in novel disease genes, which were not linked to a 
disease before. After the proof of principle for using whole exome sequencing for 
dissecting rare Mendelian disorders (Ng et al., 2009; Ng et al., 2010b), numerous 
exome sequencing studies have followed. In the early exome sequencing studies, 
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several groups simultaneously reported an unexpected excess of rare variations, many 
of which are deleterious, in populations of various ancestry (Nelson et al., 2012; 
Tennessen et al., 2012; Fu et al., 2013). The authors hypothesised that the excess of rare 
deleterious variants is due to the recent explosion of the population growth and weak 
purifying selection. This new paradigm highlighted potential difficulties researchers 
could confront when interpreting exome sequencing data. An additional obstacle is 
phenotypic overlap, which is not uncommon among neurological disorders. As outlined 
above, defining the genetic cause of rare neurological disorders is crucial because it 
would ultimately define the pathways involved in the disease. This would potentially 
result in identifying new therapeutic targets. Exome sequencing is gradually 
establishing itself as an excellent tool to elucidate causative variants in various 
neurological diseases. 
In order to prioritize candidate genes and to reduce their number, step-wise filtering is 
applied (Ng et al., 2010a). The filtered variants are subjected to verifications by means 
of Sanger sequencing. The confirmed mutations are additionally verified in multiple 
affected and unaffected family members via Sanger sequencing (segregation study). If 
the variant is found to segregate with the disease, then this would point towards 
pathogenicity of the variant and support candidate gene status. Also, if the variant 
segregates with the disease in other unrelated cases or pedigrees, then this would 
strengthen the causality of the gene. De novo mutations in genes, previously reported to 
be involved with a similar phenotype, are regarded as being highly informative about 
their functionality. De novo mutations in previously unreported genes require further 
investigation (Sunyaev, 2012). Case-control studies should also be performed. It has 
been documented that many rare variants will be restricted to particular geographical 
regions (Nelson et al., 2012). Therefore it is particularly important to carefully match 
case and control samples. In a case-control study, allele frequencies of genetic variants 
in patients are compared with a group of controls from the same population.  
The fundamental question of every exome sequencing study is how do we prove that the 
particular mutation is a cause of the disease? Literature suggests that evidence of 
causality of a particular mutation could be finding different mutations in the same gene 
in other unrelated individuals with a similar phenotype (Ng et al., 2010a; Ng et al., 
2010b). For rare phenotypes, which segregate in a family, the accepted proof of 
pathogenicity of a mutation in a given gene is establishing involvement of this gene 
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with the same phenotype in three unrelated families (Brunham and Hayden, 2013). 
Mutations in the another gene from the same biological pathway, found in unrelated 
individuals with the same phenotype, would also suggest involvement of that gene in 
this biological event (McClellan and King, 2010). The ultimate goal of a genetic study 
is to understand the mechanisms behind the disease onset and progression. That is why 
it is important to know the functional significance of identified novel rare variants. 
Functional studies depend on the type of the putative causative variant and could 
include, but will not be exhausted by, transcriptional and translational studies, as well as 
studies in live cells and animal models (MacArthur et al., 2014). 
After the first exome sequencing studies were carried out, researchers began to verify 
this technique for a clinical setting. Yang and colleagues sequenced exomes of 250 
unselected patients with suspected Mendelian disorders, 80% of which were children 
with neurodevelopmental disorders (Yang et al., 2013). The authors reported the overall 
diagnostic yield of 25%. Whole exome sequencing of parent-child trios was shown to 
be very useful in dissecting neurological disorders, such as intellectual disability and 
developmental disorders. For example, de Ligt and co-workers performed whole exome 
sequencing on 100 patients with unexplained severe intellectual disability and their 
unaffected parents (de Ligt et al., 2012). Having evaluated de novo, autosomal recessive 
and X-linked mutations, the authors established the molecular cause in 16% of the 
patients tested. Interestingly, the majority of identified putative causative mutations 
were de novo. In another study, exomes of 51 patients with severe sporadic intellectual 
disability and their unaffected parents were sequenced (Rauch et al., 2012). The authors 
found that de novo variants (both point mutations and small indels) were present in 50% 
of patients in the cohort.  
The research presented in this study aimed to evaluate the use of whole exome 
sequencing for diagnostic purposes in neurological disorders. Whole exome sequencing 
was performed in a heterogeneous cohort of patients with suspected inherited ataxia as 
an example of a neurological disorder, with the aim to identify candidate gene 
mutations. 35 affected individuals from 22 randomly selected families of white 
European descent with no known consanguinity were studied. Prior to inclusion in this 
study, all participating individuals had undertaken routine clinical investigations in 
order to exclude common sporadic, inherited and metabolic causes of ataxia. 30 affected 
individuals were subjected to whole exome sequencing. The interpretation of the raw 
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whole exome sequencing data utilised an in-house bioinformatic pipeline. A subsequent 
variant filtering algorithm excluded synonymous variants and focused on protein 
altering variants, nonsense mutations, exonic insertions/deletions and splice site 
variants. All variants with a minor allele frequency (MAF) greater than 1%, in the 
public databases (dbSNP137, 1000 genomes (April 2012 data release) and NHLBI-
ESP6500 databases) and in 286 unrelated in-house controls, were excluded. The 
remaining variants were selected based on mode of inheritance. Priority was given to 
variants in genes that were expressed in brain or nerve cells, and variants in genes 
previously linked to ataxia or related neurological disorders. Subsequently, an extensive 
literature search was performed in order to identify current genes associated with ataxia 
and related neurological disorders. The published variants were cross-referenced with 
the filtered variants. All variants were defined using carefully selected criteria. Further 
molecular genetic techniques (Sanger sequencing, reverse transcription PCR, 
quantitative pyrosequencing, cloning for allelic cis-trans study) and proteomics 
(Western blotting, immunohistochemistry) were employed in order to support the 
exome sequencing finding. 
8.2. Main findings 
In this study, whole exome sequencing was performed on 35 individuals with suspected 
inherited ataxia, which were selected randomly from 22 families with no known 
consanguinity. This work made a new and certain molecular diagnosis in several 
families. Confirmed pathogenic variants were found in 9/22 probands (41%) 
implicating 6 genes. Three families, each presenting with a pair of affected siblings, had 
novel compound SACS mutations (Pyle et al., 2012; Pyle et al., 2013). Interestingly, 
one of these families exhibited an adult onset disorder considered to present in 
childhood. A known dominant KCNC3 mutation was found to segregate with ataxia in 
four members of a three-generation autosomal dominant pedigree (Waters et al., 2006). 
Previously reported compound heterozygous SPG7 mutations were found in two 
affected siblings from a family with no spasticity (Casari et al., 1998). SPG7 is a gene 
implicated in hereditary spastic paraplegia. Although SPG7 has previously been linked 
to ataxia, it has yet to be described in cases without spasticity. Therefore this study 
allowed to broaden the phenotype implicated with SPG7 mutations. Likely de novo 
dominant TUBB4A mutations were found in two families (Simons et al., 2013). Both 
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mutations are evolutionary conserved. In one family, quantitative pyrosequencing 
showed varying degrees of mosaicism in the mildly affected mother and heterozygosity 
in the severely affected offspring. In silico analysis further supported pathogenicity of 
the mutation and revealed that it could potentially disrupt polymerizations of αβ-tubulin 
heterodimers. Two siblings who presented with adult onset ataxia had compound 
heterozygous mutations in NPC1, confirmed by subsequent oxysterol analysis (Carstea 
et al., 1997). These two patients were lacking the characteristic clinical features linked 
to Niemann Pick type C, which is diagnosed in childhood. This finding allowed us to 
consider a known disease gene in an unusual clinical presentation, hence broadening the 
phenotype. A novel dominant mutation in a known ataxia gene SLC1A3 segregated with 
ataxia in three members of one family (de Vries et al., 2009).  
Possible pathogenic variants were identified in 5/22 probands (23%) implicating 5 
genes. This study provides information on inheritance patterns and potential prognosis. 
Likely de novo compound heterozygous mutations in ZFYVE26 (SPG15) in one family 
was validated with sequencing of cloned alleles and the result confirmed the occurrence 
of the mutations in trans, therefore supporting their autosomal recessive inheritance 
(Hanein et al., 2008). This finding led the clinicians to re-assess the neuroimaging and 
confirmed thinning of the corpus callosum, which is a characteristic of SPG15. 
Previously described compound heterozygous WFS1 mutations were identified in one 
family (Cryns et al., 2002; Cryns et al., 2003). In one family with possible pathogenic 
compound heterozygous FASTKD2 mutations, the in silico splice-site prediction was 
validated by sequencing analysis of cDNA clones. A predicted splice site mutation was 
detected in three members of an autosomal dominant pedigree in the previously 
described spastic paraplegia gene ZFYVE27 (SPG33) (Mannan et al., 2006). This study 
showed that the ZFYVE27 protein (protrudin) levels were increased approximately 2.5 
fold in the cerebellum but not in the frontal cortex of the affected individual. Protrudin 
is an endoplasmic reticulum (ER) protein and its anomalies have previously been shown 
to cause ER stress. In this study levels of the master regulator of ER stress, BiP/GRP78, 
were significantly increased in the patient’s cerebellum, which may indicate the ER 
pathology. The preliminary data presented in this study also suggested that protrudin 
levels were increased in the astrocytes in the cerebellum but not in the frontal cortex of 
the affected individual. Finally, novel compound heterozygous mutations, which 
segregated in the family, were found in WNK1 in one patient (Lafreniere et al., 2004). 
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WNK1 is a known disease gene, which was previously described in families with 
hereditary sensory and autonomic neuropathy type II (HSAN2), but has yet to be 
associated specifically with ataxia.  
Taken together, this study defined the likely molecular diagnosis in 14 of 22 families 
(64%) with 11 genes implicated. With no recurrent mutation in the same gene observed, 
this study reiterates the known genetic heterogeneity of inherited ataxias. Importantly, 
the diagnostic yield in this study is similar to studies in other neurological disorders 
(Klein et al., 2014; Novarino et al., 2014; Gonzaga-Jauregui et al., 2015) and ataxia 
(Fogel et al., 2014; Sawyer et al., 2014). Together, these studies highlight the potential 
clinical significance of whole exome sequencing. 
The diagnostic yield in this study contrasted with a targeted next generation sequencing 
approach of a similar sized UK cohort of inherited ataxia patients (18% of patients) 
(Nemeth et al., 2013). This could be due to greater exome coverage in this study. The 
unbiased approach of the current study also means that genes, which are linked to 
ataxia, but are not considered as “ataxia genes”, were not excluded from this study. In 
fact, this study identified confirmed pathogenic mutations in SPG7, which is known to 
cause spastic paraplegia type 7 (SPG7), in one family with ataxia but no spasticity. This 
surprising finding prompted the prospective exome sequencing study of 70 patients with 
unexplained ataxia by Pfeffer and the colleagues (Pfeffer et al., 2015). The latter study 
identified mutations in SPG7 as a likely cause of disease in 19% of patients with 
unexplained ataxia. This suggested that the occurrence of SPG7-related diseases could 
be comparable with that of dominant spinocerebellar ataxia (SCA) and Friedrich ataxia. 
The implication of this finding is significant, because it could lead to a change in a 
diagnostic workflow making SPG7 a top candidate for initial genetic tests. This could 
eventually decrease the cost of a diagnostic test. 
The current study reveals the importance of whole exome sequencing in identifying 
pathogenic variants in known disease genes when the clinical presentation is less 
specific, broadening the phenotype. This study identified compound heterozygous 
WFS1 mutations in one family (patient P20). The patient didn’t present with early 
diabetes mellitus, which is a characteristic of classic Wolfram syndrome or other WFS1-
related disorders (Fogel et al., 2014). Based on the phenotype, WSF1 would not have 
been considered for routine clinical investigations in this patient. Similarly, this study 
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identified confirmed pathogenic mutations in SPG7, which is known to cause spastic 
paraplegia type 7 (SPG7), in one family with ataxia but no spasticity (patients P9 and 
P10). The absence of spasticity is uncharacteristic of SPG7, therefore SPG7 would not 
have been prioritised for routine gene test.  
The current study identified likely de novo dominant TUBB4A mutations in two families 
presented with cerebellar ataxia and leukodystrophy. In one family quantitative 
pyrosequencing revealed varying degrees of mosaicism in the mildly affected mother 
and heterozygosity in the severely affected offspring. In silico analysis further 
supported pathogenicity of the mutation and revealed that it could potentially disrupt 
polymerizations of αβ-tubulin heterodimers. Mutations in TUBB4A were recently 
associated with several neuroimaging phenotypes, namely dystonia type 4 (DYT4) 
(Hersheson et al., 2012; Lohmann et al., 2012), hypomyelination with atrophy of the 
basal ganglia and cerebellum (H-ABC) (Simons et al., 2013), isolated hypomyelination 
(Pizzino et al., 2014) and hereditary spastic paraplegia (HSP) with no basal ganglia 
involvement or cognitive impairment (Kancheva et al., 2015). This makes TUBB4A a 
primary candidate for genetic screening, following MRI, meaning that the overall cost 
of a diagnosis could be greatly reduced. 
This study has demonstrated the impact of exome sequencing in a group of patients 
difficult to diagnose genetically. This study indicates that exome sequencing is an 
efficient tool, which can help with rapid, cost effective identification of genetic 
mutations causing neurological diseases. The approach presented in this study could be 
applied to other neurological disorders, which are also challenging to solve.  
8.3. Study limitations and future directions 
As demonstrated by recent studies, exome sequencing is an excellent tool for 
discovering rare variants as a cause of classical rare Mendelian (Ng et al., 2010a) and 
more common sporadic (O'Roak et al., 2011) neurological disorders. In addition to 
studying individual pedigrees, exome sequencing, when applied to large cohorts of 
cases and controls, could reveal if any single gene is responsible for the phenotype 
(Bras and Singleton, 2011). 
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However, despite the clear potential of whole exome sequencing in solving rare 
inherited neurological disorders, there are several drawbacks. Firstly, an exome 
sequencing study could uncover unexpected findings, such as rare mutations 
predisposing to some types of cancer or mutations causing familial neurodegenerative 
disorders. This ethical issue should be considered when obtaining informed consent for 
an exome sequencing study (Bamshad et al., 2011). Secondly, exome sequencing 
studies of different populations may elucidate different causative alleles and disease 
genes. This is because different populations might exhibit local genetic variations, 
which could be due, for example, to a founder effect. Also, different populations are 
pre-disposed to different types of neurological disorders (including ataxia), which 
would affect the outcome of the exome sequencing study. The cohort presented in this 
study consisted of individuals from an outbred population of white European ancestry. 
It is anticipated, that similar exome sequencing studies of cohorts from other geographic 
regions may result in an outcome, which may differ from the one described here. 
Thirdly, an exome sequencing study potentially faces some technical issues, for 
example, incomplete coverage of exons. Typical coverage of exons in exome 
sequencing is about 90-95% (Bamshad et al., 2011). Poor coverage could be due to the 
capture probes being ineffective for GC-rich or repetitive regions (Sulonen et al., 2011). 
Also, because the probes for exome capture are designed based on known sequences 
found in the public databases, all yet-to-be-found exons cannot be captured. That is why 
exome sequencing cannot be considered exhaustive (Ku et al., 2011). Another technical 
issue for an exome sequencing study is detecting copy number variants (CNVs), which 
were recently associated with common and rare diseases (Weischenfeldt et al., 2013). 
Owing to the fact that exome sequencing employs PCR-based sample preparation 
techniques, it will be difficult to detect copy number variation in a sample where all 
templates are amplified to a similar concentration. The exome sequencing study 
described here did not consider non-coding regions or synonymous variants. It is still 
not clear to what extent these types of variants can be classed as disease causing 
(Cooper et al., 2010). It could be, however, foreseen that some of the causal variants 
may reside within these regions. It is anticipated that the technical issues outlined above 
prevented this study from confidently identifying likely causative variants in 8/22 
probands (36%). It is assumed that some of these technical issues could be addressed by 
whole genome sequencing, albeit with additional cost. In fact, 8/22 probands where 
diagnosis has not been established, have been sent for whole genome sequencing. 
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Another limitation of this research needs to be acknowledged. One of the aims of the 
current study was to elucidate pathogenicity of the rare ZFYVE27 c.805-2A>G mutation 
(allele count 3/121378; MAF=0.00002472 in ExAC database) and establish its 
causative role in a dominant family presenting with cerebellar ataxia. This study 
resulted in several interesting findings. The ZFYVE27 protein (protrudin) levels were 
increased in the cerebellum but not in the frontal cortex of the affected individual, when 
compared with controls. This study also founds that levels of the master regulator of ER 
stress, BiP/GRP78, were significantly increased in the patient’s cerebellum, which may 
indicate the ER pathology. It would be beneficial to use another ER stress marker to 
confirm the result with BiP/GRP78. It has to be highlighted that this study analysed 
only two regions of the brain (the frontal cortex and the cerebellum). It would be 
valuable to analyze other brain regions from the patient and control individuals in order 
to gain more insight into the expression profiles of ZFYVE27 under normal and 
pathological conditions. Despite the interesting findings mentioned above, with no other 
indisputable ZFYVE27 pathogenic mutations identified to this date, it is difficult to draw 
conclusions as to the pathogenicity of the c.805-2A>G mutation. Therefore, at the time 
of writing this Thesis, these data could not be used in the clinical setting. In order to 
elucidate the cause of disease in this family, it would be beneficial to perform whole 
genome sequencing with haplotype reconstruction. 
It is predicted that the cost of NGS will continue to fall (Boycott et al., 2013), which 
will increase the speed of the discovery of rare variations. Many of the mutations will 
be extremely rare, if not private, therefore ascribing the pathogenicity might become 
problematic for simplex cases. Studies like this not only verify whole exome 
sequencing as an excellent tool in delineating the cause of rare neurological disorders. 
This study, together with similar work by other groups, which report unusual clinical 
presentations and rare variations with uncertain significance, will aid in creating public 
databases. The latter will reinforce collaboration and data sharing, which in turn will aid 
in defining pathways implicated in neurological disorders. Therefore, there is no doubt 
that whole exome sequencing will aid in establishing a clear diagnosis and finding new 
therapies in a complex field of neurological disorders. 
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Appendix 1. Clinical data and segregation analysis  
The data presented here are included in Pyle et al. 2014. 
Confirmed pathogenic mutations 
Patient 1 and 2: (SACS, c.2076delG:p.Thr692Thr fs*713 and c.3965_3966delAC:p. 
Gly1322Valfs*1343). Patient 1 (male) presented with learning difficulties and 
pyramidal signs in his teens. He now has a gait disturbance and is wheelchair bound. 
MRI revealed cerebellar atrophy. Peripheral electrophysiology showed a large-fibre 
sensorimotor axonal-demyelinating neuropathy. Muscle biopsy showed normal 
mitochondrial histochemistry and respiratory complex activity with no evidence of 
mitochondrial DNA deletions. His affected sister (P2) presented at age 26 with poor 
coordination and urinary urgency. She also developed a gait disturbance and is 
wheelchair bound. The patient developed a jerky ocular pursuit, and had reduced visual 
acuity secondary to bilateral epiretinal membrane formation within the macula. She 
progressed to develop dysarthria and difficulty swallowing. MRI revealed generalised 
atrophy, and marked cerebellar atrophy. Peripheral electrophysiology showed mixed 
demyelinating axonal neuropathy. Type I fibre clustering was found in her muscle 
biopsy, however respiratory complex activity was normal and there was no evidence of 
mitochondrial DNA deletions. Exome sequencing was performed on both these patients. 
DNA was available from the mother and Sanger sequencing confirmed that the 
mutations segregated with the disease phenotype in the family.  
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Patient 3 and 4: (SACS, hemizygous c.13048G>T: p.Glu4350*; 0.7Mb deletion on 
Chr13q12.12). Patient 3 (male) presented with clumsiness and poor sporting 
performance in his teens. He went on to develop a spastic ataxic gait, bilateral optic 
atrophy, jerky ocular pursuits, hypometric saccades and gaze-evoked nystagmus. His 
speech became slurred with a brisk jaw jerk. His affected brother walked late at 18 
months and was diagnosed with a mild cerebral palsy. He progressed with a spastic 
ataxic gait, bilateral optic atrophy, jerky ocular pursuits and gaze evoked nystagmus in 
all directions. Patient 4 also developed cerebellar dysarthria and brisk jaw jerk. MRI 
revealed marked cerebellar vermian atrophy, moderate diffuse cortical atrophy and 
reduced spinal cord volume. Neurogenic features were present on muscle biopsy 
examination including angulated fibres, small group atrophy, type II fibre predominance 
and fibre type grouping. Exome sequencing was performed on patient P3.  
Sanger sequencing of the mutation in all family members confirmed segregation with 
the disease phenotype. 
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Patient 5 and 6: (SACS, c.1580C>G:p.Ser527* c.6781C>A:p.Leu2261Ile). Patient 5 
(male) presented with difficulty walking and increasing leg stiffness at age 40. He went 
on to develop spastic paraplegia and is now wheelchair bound. MRI revealed 
generalised atrophy with foci of subcortical periventricular white matter signal change, 
consistent with early small cerebrovascular disease. Electrophysiology tests highlighted 
demyelinating sensory-motor neuropathy. His affected sister (Patient 6) presented 
during her 40s with difficulty walking and balance problems. She went on to develop an 
ataxic gait with a positive Romberg test. Her speech developed a subtle slurring and eye 
examination revealed jerky ocular pursuits with a restricted upward gaze (20 degrees). 
Mixed sensory-motor neuropathy was identified on peripheral electrophysiology 
testing. This patient died at age 62. Exome sequencing was performed on patient P5. 
Segregation analysis in the daughter of patient 5 confirmed that the SACS mutations 
were on complementary chromosomes.  
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Patient 7 and 8: (KCNC3, het. c.1259G>A:p.Arg420His). Patient 7 presented at age 23 
with speech and balance problems. She went on to develop an appendicular and ataxic 
gait with a positive Romberg test. Eye examination revealed bilateral disc pallor, an 
afferent pupillary defect, square wave jerks with a jerky pursuit. Additional symptoms 
included dysarthria and hearing impairment. MRI results showed cerebellar atrophy 
most marked in vermis and superior folia. Myopathic changes and a single cytochrome 
c oxidase (COX) negative fibre were found on muscle biopsy examination. Her affected 
sister (Patient 8) presented at age 57 with upper limb clumsiness followed by gait 
ataxia, jerky ocular pursuits, optic atrophy and dysarthria. MRI examination showed 
cerebellar atrophy and incidental degenerative disc disease in cervical spine. Exome 
sequencing was performed on patient P7.  
The mutation segregated with the phenotype in the next generation. 
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Patient 9 and 10: (SPG7, c.1529C>T:p.Ala510Val; c.1715C>T:p.Ala572Val). Patient 9 
(male) presented at age 30 with clumsiness. He went on to develop an ataxic gait, 
dystarthria, a convergent squint, bilateral optic atrophy, jerky ocular pursuit movements 
which were brisk but with sustained horizontal nystagmus. MRI revealed cerebral 
atrophy and his muscle biopsy showed a single COX deficient fibre. Routine 
haematological and biochemical blood tests were normal apart from a mild elevation of 
aminotransferase (ALT) 50 IU/L. Patient 10 is his affected sister who presented at age 
29 with clumsiness and a tendency to fall. She has a short stature. She subsequently 
developed gait and appendicular ataxia, nystagmus, night blindness, slurred speech, 
wasting and fasciculations of the right side of tongue. MRI revealed cerebellar atrophy 
affecting vermis and hemispheres. Muscle biopsy results showed mild or moderate fibre 
size variation with 1% COX negative fibres. Routine haematological and biochemical 
blood tests were normal apart from a mild elevation of the ALT 44 and alkaline 
phosphatase (ALP) 124 IU/L. Exome sequencing was performed on both these patients. 
Both siblings had the same genotype on Sanger sequencing. The mother was 
hemizygous, confirming that Patient 9 and 10 were compound heterozygotes. 
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Patient 11 and 12: (TUBB4A, het c.900C>A:p.Met300Ile). Patient 13: (TUBB4A, 
mosaic c.900C>A:p.Met300Ile). Patient 11 (female) presented in infancy with delayed 
motor and speech developments. She developed dysarthria, slow speech, titubation and 
is now wheelchair bound. Eye examination revealed nystagmus on lateral gaze, slow 
saccades in the horizontal plane and bilateral optic disc pallor. MRI results showed 
hypomyelination, leukodystrophy and cerebellar atrophy. Her affected sister (Patient 
12) also presented in infancy with delayed motor and speech developments. She went 
on to develop, dysarthria, truncal ataxia and is wheelchair bound. Slow saccades were 
found on eye examination. MRI revealed hypomyelination, leukodystrophy and 
cerebellar atrophy. The mother of these affected sibs (Patient 13) presented at age 30 
with balance problems and slurred speech. She went on to develop dystonic posturing, 
bilateral optic atrophy, dysarthria, echolalia and some swallowing difficulty. MRI 
revealed hypomyelination, leukodystrophy and cerebellar atrophy (Figure 6.2). Muscle 
biopsy results showed an age-related multiple mitochondrial DNA deletions. Exome 
sequencing was performed on all three patients. Sanger sequencing of the candidate 
variant confirmed segregation with the disease phenotype in the family, and the 
proportion of the mutated allele was determined by pyrosequencing (Table 6.3). 
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Patient 14: (TUBB4A, het c.1091C>A:p.Ala364Asp). This female patient present at age 
5 with learning difficulties, ataxia and falls. There was no relevant family history. 
Developing symptoms included spastic, scissoring gait with wheelchair dependence and 
use of a walking frame. Eye examination revealed horizontal ocular dyspraxia which 
was poor in vertical directions, with blinking to relocate saccades. Additional symptoms 
were a quiet, spastic dysarthria, slow tongue movements, dribbling tendency, brisk jaw 
jerks and positive glabellar tap. MRI revealed diffuse hypomyelination including 
brainstem and diffuse white matter changes with T2 hyperintensity. This patient was 
subjected to exome sequencing.  
DNA was only available from the patient and mother, who was consequently wildtype 
for the variant. 
 
  
c.1091&wildtype&
P14&
het&c.1091C>A:p.Ala364Asp&
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Patient 15 and 16: (NPC1, c.467T>C: p.Met156Thr c.709C>T:p.Pro237Ser). These 
two affected sisters presented at age 21. Patient 15 presented with unsteady walking 
which resulted in frequent falls. She went on to develop a spastic gait, hypermetric 
saccades and subtle cerebellar dysarthria. MRI revealed bilateral symmetrical abnormal 
high T2 signal involving corticospinal tracts. Patient 16 presented with clumsy hands, 
pins and needles and slurred speech. She went on to develop ataxia, a high steppage 
gait, and was Romberg test positive. Additional symptoms included jerky ocular 
pursuits, slow saccades, myoclonic jerks and cerebellar dysarthria. Dysphasia and 
hearing impairment developed late in the progression of the disease. Exome sequencing 
was performed on both these patients. Sanger sequencing of the variant confirmed 
segregation of the mutation with the disease phenotype in the family. Biochemical 
analysis of plasma oxysterols confirmed the functional consequences of the NPC1 
mutation (Table 4.5). 
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Patient 17 and 18: (SLC1A3, het c.1361G>A:p.Arg454Gln). Patient 17 (male) 
presented at age 30 with a speech disturbance, dexterity problems and a deteriorating 
gait. He went on to develop ataxia, jerky ocular pursuits and hypometric saccades. 
Additional symptoms included cerebellar dysarthria, dysphagia and slow repeating 
tongue movements. His mother is also affected. Patient 18 is a female cousin who 
presented at age 39 with a speech disturbance. She went on to develop cerebellar ataxia, 
jerky ocular pursuits, dysarthria, urinary urgency and frequency. Exome sequencing was 
performed on patient P17 and his unaffected brother. 
Sanger sequencing of the mutation confirmed segregation with the disease in the family.  
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Possibly pathogenic mutations 
Patient 19: (ZFYVE26, c.2338C>T:p.Arg780*; c.2450delT:p.Leu817Cysfs*12). This 
male patient developed muscle weakness and frequent falls aged 32. He was wheelchair 
bound. There was no family history. The patient developed bilateral facial weakness 
with dystonia of the facial muscles. MRI investigations revealed generalised atrophy of 
both the white and grey matter with hazy diffuse gliotic white matter change in both 
corona radiata. The corpus callosum was severely atrophic (Figure 7.8) showing the 
characteristic thin corpus callosum frequently associated with mutations in 
ZFYVE26/SPG15 (Goizet et al., 2009). There was also some secondary midbrain 
involution. Electrophysiology showed large fibre axonal sensory motor neuropathy. 
This patient was subjected to exome sequencing.  
This patient has one frameshift mutation (c.2450delT:p.Leu817Cysfs*12) and one stop 
gain mutation at a highly conserved residue (c.2338C>T:p.Arg780*)  in ZFYVE26. The 
p.Arg780* is predicted to be disease causing or damaging by three prediction 
programmes. The majority of reported ZFYVE26 mutations are a loss of function type 
(33 of 38 mutations described are nonsense and frameshifts). ZFYVE26 encodes the 
protein spastizin, in zebrafish this protein is essential for the establishment of motor 
neuron axonal development (Martin et al., 2012). Spastizin is known to interact with 
Beclin 1 which is a key regulator of autophagy (Sagona et al., 2011). A recent study by 
Vantaggiato and co-workers investigated four patient cell lines, two with truncating 
mutations and two with missense mutations in ZFYVE26. The truncating mutations led 
to a loss of spastizin protein. They also observed a lack of spastizin interaction with 
Beclin 1 and therefore an impairment of autophagosome maturation. This led to an 
accumulation of immature autophagosomes. The authors hypothesised that this is likely 
to occur in neuronal cells linking defective autophagy in the neurodegenerative process 
underlying the SPG15, although they did not directly test this (Vantaggiato et al., 2013). 
In addition ZFYVE26 knockout mice develop late-onset spastic paraplegia with 
cerebellar ataxia giving further confirmation that SPG15 is caused by spastizin 
deficiency (Khundadze et al., 2013).  
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Patient 20: (WFS1, c.577A>C:p.Lys193Gln; c.1367G>A:p.Arg456His). This female 
presented aged 40 with ataxia, dysarthria and vertigo. She went on to develop a 
worsening visual acuity, optic atrophy, dysarthria and dysphasia. Initial hearing 
problems improved with surgery. Facial weakness was apparent during stroke-like 
episodes. Muscle biopsy showed 5% COX negative ragged-red fibres and multiple 
mitochondrial DNA deletions in muscle DNA. Detailed neuroendocrine testing was not 
possible because the patient died before the molecular diagnosis was reached. This 
patient was subjected to exome sequencing. Sanger sequencing showed that only one of 
the WFS1 variants was present in her unaffected sibling, confirming that the mutations 
were compound heterozygous.  
Mutations in WFS1 cause a severe early onset neurodegenerative disorder, which 
includes diabetes and optic atrophy, of which ataxia is also one symptom. Dominant 
milder combinations of optic atrophy and deafness (but not ataxia) have also been 
described with WFS1 missense mutations (Hogewind et al., 2010). The mutations 
p.Lys193Gln and p.Arg456His have been previously described in patients with 
Wolfram syndrome (Cryns et al., 2003). Both mutations occur at conserved residues 
with two and three prediction tools supporting a pathogenic role. 
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Patient 21: (FASTKD2, c.-66A>G; c.149A>G:p.Lys50Arg). This female patient 
presented in infancy with a walking delay at 23 months, wobbly walking and frequent 
falls. There was no evidence of family history. She went on to develop moderate 
learning difficulties, dysarthria, gait or truncal ataxia and was wheelchair bound with 
spastic quadraparesis. Eye examination revealed poor bilateral visual acuity, spectacle 
corrected hypermetropia, pendular nystagmus, ocular motor apraxia and bilateral optic 
atrophy. Electrophysiology revealed electroencephalography and non-specific mild 
cortical disturbance. Muscle biopsy results showed low coenzyme Q10 in muscle. 
Exome sequencing was performed on this patient. 
Sanger sequencing of these variants showed the segregation within the family. 
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The c.-66A>G FASTKD2mutation is predicted to affected the splicing of exon 1 in 
FASTKD2 (Figure 4.1, A). The p.Lys50Arg mutation is rare in the population. A 
missense mutation in FASTKD2 was reported in a patient with infantile mitochondrial 
encephalopathy. The patient also had developmental delay, asymmetrical brain atrophy 
and low cytochrome c oxidase activity in skeletal muscle (Ghezzi et al., 2008). 
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Patient 22, 23 and 24: (ZFYVE27, c.805-2A>G). Patient 22, the affected father of 
Patient 23, presented at age 37 with clumsiness. He went on to develop ataxia with 
decreased mobility, dysarthria, bilateral horizontal nystagmus on lateral gaze, left 
cataract and dysarthria. MRI revealed cerebellar and pontine atrophy. His affected son 
(Patient 23) presented at age 35 with clumsiness. He went on to develop ataxia, 
dysarthria, diplopia and dysphagia. MRI revealed cerebellar atrophy. Muscle biopsy 
tests showed multiple mitochondrial DNA deletions and a small frequency of COX 
negative fibres. Patient 24 (affected half-brother of P22 and son of P23) presented at age 
25 with clumsiness. He went on to develop ataxia, dysarthria, jerky ocular pursuits, 
gaze-evoked nystagmus and hypometric saccades. MRI revealed cerebellar ataxia. 
Exome sequencing was performed on these three patients. 
Sanger sequencing of this variant showed the segregation of the mutations with the 
disease phenotype in the family. 
 
 
ZFYVE27, c.805-2A>G is very rare in the population and predicted to cause the loss of 
acceptor site of exon 7 (Figure 4.1, B). Sanger sequencing of this variant showed the 
segregation of the mutations with the disease phenotype in the family. ZFYVE27 
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encodes Protrudin, a novel member of the FYVE family, which play a role in the 
formation of neurite extensions by promoting directional membrane trafficking in 
neurons. Protrudin is a specific spastin-binding protein (Stenmark et al., 2002). In 
autosomal dominant hereditary spastic paraplegia, spastin is the most commonly 
mutated protein. Although mutations in ZFYVE27 have not previously been associated 
with ataxia, p.G191V in ZFYVE27 has been reported in one family with hereditary 
spastic paraplegia (SPG33) (Mannan et al., 2006). Although the functional 
consequences of p.G191V have been disputed (Martignoni et al., 2008). subsequent 
studies showed that the interaction with spastin is mediated by the N-terminal domain of 
protruding, and that p.G191V altered the subcellular distribution of protrudin and 
impaired the yolk sac extension in zebrafish (Zhang et al., 2012).  
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Patient 25: (WNK1, c.1994C>T:p.Thr665Ile; c.3272C>T:p.Thr1091Ile). This female 
patient presented at age 11 with unsteadiness and was unable to tie her shoe laces. Her 
symptoms progressed with ataxia, dysarthria, gaze-evoked nystagmus. MRI revealed 
cavum velum interpositum variant. This patient was subjected to exome sequencing. 
Sanger sequencing of these variants showed the segregation of the mutations with the 
disease phenotype in the family. 
 
WNK1 p.Thr665Ile occurs at a highly conserved residue and is predicted to be 
pathogenic by four different prediction tools. WNK1 is a known disease gene but has 
not been previously associated specifically with ataxia. Mutations in WNK1 (HSN2) 
have previously been reported in families with hereditary sensory and autonomic 
neuropathy type II (HSAN2) (Lafreniere et al., 2004; Shekarabi et al., 2008).  
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Appendix 2. List of variants in patients where we were unable to 
confidently identify likely candidates 
Key:  AFP – alpha-fetoprotein  
This table is included in Pyle et al., 2014. 
 
Patient 
Gene Mutation Reason for exclusion    Sanger sequenced !
ID 
P28 
CYP27A1 het c.1183C>T:p.Arg395Cys 
Cholestanol results for 
P28 were normal no 
KCNA1 het c.912G>C:p.Lys304Asn Variant was wildtype on Sanger sequencing yes 
AKAP1 het  c.98T>G:p.Val33Gly !! no 
ASPM het  c.8558G>A:p.Arg2853Gln !! no 
NAB2 het  c.689C>G:p.Thr230Ser !! no 
SLC35C1 het  c.1055C>A:p.Pro352His !! no 
GARS het c.112G>A:p.Ala38Thr !! no 
NDE1 het c.921C>A:p.Ser307Arg !! no 
GSC het c.488A>G:p.His163Arg !! no 
CELSR2 
c.2008G>C:p.Ala670Pro; 
c.5099A>C:p.His1700Pro; 
c.6044G>A:p.Arg2015Lys; 
c.7649G>A:p.Arg2550Gln 
!! no 
AHNAK het c.12113A>G:p.Lys4038Arg !! no 
PDE1B het c.307T>C:p.Ser103Pro !! no 
LRP1 het c.10295G>A:p.Arg3432His !! no 
PKD1 
c.11815T>G:p.Trp3939Gly
; 
c.7913A>G:p.His2638Arg; 
c.7065+2T>G; 
c.4195T>C:p.Trp1399Arg 
!! no 
SNTG2 c.149A>C:p.Glu50Ala; c.1018G>C:p.Asp340His !! no 
PKDREJ het c.4498C>T:p.Pro1500Ser !! no 
CHL1 het c.671T>C:p.Val224Ala !! no 
BSN 
c.10318A>G:p.Ser3440Gly
; 
c.10331G>A:p.Arg3444Gln 
!! no 
!!
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HTT 
c.107A>C:p.Gln36Pro; 
c.110A>C:p.Gln37Pro; 
c.113A>C:p.Gln38Pro 
!! no 
REST c.2013G>T:p.Glu671Asp; c.2206C>T:p.Pro736Ser !! no 
UTRN 
c.404_405insG: 
p.Val136Glyfs*18; 
c.7984C>T:p.Arg2662Cys 
!! no 
PLXNA4 c.5608C>T:p.His1870Tyr; c.1249G>A:p.Asp417Asn !! no 
SFTPD het c.883G>A:p.Ala295Thr !! no 
APPL2 c.209A>G:p.Lys70Arg !! no 
APOBR c.1083G>C:p.Glu361Asp; c.1090G>T:p.Gly364Trp !! no 
DOK2 het c.821C>T:p.Pro274Leu !! no 
RASGRP
2 
c.1528G>A:p.Val510Ile; 
c.1466C>G:p.Ser489Cys !! no 
P29  
 
 
 
 
and 
TTBK2 c.3691A>C:p.Thr1231Pro 
Variant was wildtype in 
both patients on Sanger 
sequencing 
yes 
!! ATXN2 het c.454T>C:p.Cys152Arg 
 Genetic test for  ATXN2 
trinucleotide repeat 
expansions was negative 
no 
P30 ATP6V1B1 
het 
c.1493A>G:p.Tyr498Cys !! no 
!! ASPM het c.8128A>G:p.Thr2710Ala !! no 
!! TYRO3 het c.1246C>T:p.Arg416Cys !! no 
!! SLC18A2 het c.607+2T>G !! no 
!! SRRM4 het c.1091C>T:p.Pro364Leu !! no 
!! CSPG4 het c.4397T>C:p.Val1466Ala !! no 
!! ABCC1 het c.3725A>G:p.Asn1242Ser !! no 
!! CDH13 het c.2069T>G:p.Leu690Arg !! no 
!! FEZ2 het c.1025C>G:p.Pro342Arg !! no 
!! GLI1 het c.651C>G:p. Ser217Arg !! no 
!! PLEKHA6 
het 
c.3082A>C:p.Met1028Leu !! no 
!!
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!! EXOC8 het c.485T>C:p.Leu162Pro !! no 
!! DDHD1 het c.455C>T:p.Ala152Val !! no 
!! SREBF1 het c.422C>T:p.Pro141Leu !! no 
P31 
MT-ATP6 m. 9006_A>G Not pathogenic no 
MT-ND5 m.14002_A>G Not pathogenic no 
MT-ND6 m.14040_G>A Not pathogenic no 
IKBKAP c.934G>A:p.Glu312Lys; c.751A>G:p.Ser251Gly !! no 
HSPG2 c.9422G>A:p.Arg3141His; c.G1238A:p.Arg413Gln !! no 
NOTCH1 het c.4111A>C:p.Thr1371Pro !! no 
CELSR2 
c.2008G>C:p.Ala670Pro; 
c.3602C>T:p.Pro1201Leu; 
c.5099A>C:p.His1700Pro;  
c.5699A>G:p.Asn1900Ser 
!! no 
MEF2D het c.1330T>C:p.Ser444Pro !! no 
NCSTN het c.1229C>T:p.Ala410Val !! no 
CACNA1
S 
het 
c.2099C>T:p.Thr700Met !! no 
ITGA8 het c.851T>C:p.Leu284Ser !! no 
NELL1 het c.578G>A:p.Arg193His !! no 
MLST8 het c.175G>C:p.Ala59Pro !! no 
TSHZ3 het c.3082A>G:p.Met1028Val !! no 
SNTG2 het c.149A>C:p.Glu50Ala !! no 
JAG1 het c.800C>G:p.Pro267Arg !! no 
PLCG1 het c.1073G>A:p.Arg358Gln !! no 
PIGT het c.109A>C:p.Thr37Pro !! no 
EOMES het c.200A>G:p.Glu67Gly !! no 
SRRT het c.1520A>G:p.Asn507Ser !! no 
ACHE het c.1673A>C:p.Gln558Pro !! no 
LAMB1 het c.1046C>G:p.Ala349Gly !! no 
CSGALN
ACT1 het c.16C>T:p.Arg6Trp !! no 
EXOC8 het c.395A>C:p.His132Pro !! no 
ARHGAP
21 
het 
c.1718G>A:p.Ser573Asn !! no 
ABCA7 het c.717C>A:p.Asn239Lys !! no 
AP3D1 het c.3418C>T:p.Arg1140Trp !! no 
!!
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UGT1A4 het c.310_310delG: p.Glu104Asnfs*4 !! no 
NCOA3 het c.3374G>A:p.Gly1125Asp !! no 
SLCO2A1 het c.166C>T:p.Leu56Phe !! no 
CLVS2 het c.922G>T:p.Val308Leu !! no 
NEU1 het c.428T>A:p.Val143Glu !! no 
CADPS2 c.1151G>A:p.Arg384Gln !! no 
PCLO het c.2290A>G:p.Thr764Ala !! no 
PREX2 het c.2971A>G:p.Thr991Ala !! no 
MELK 
c.77A>G:p.Lys26Arg; 
c.1481_1484delTGTT: 
p.Phe495Glyfs*30 
!! no 
UROS het c.689G>C:p.Arg230Pro !! no 
OGDHL het c.2869C>T:p.Pro957Ser !! no 
APEX1 c.416_419delCACT: p.Leu140Lysfs*6 !! no 
TBC1D21 het c.902A>G:p.Asn301Ser !! no 
TSHZ3 het c.3082A>G:p.Met1028Val !! no 
TMEM14
7 het c.488C>T:p.Thr163Ile !! no 
PTPRH het c.2425G>A:p.Val809Ile !! no 
CYP2D6 het c.360_361insGTT: p.Phe120delinsLeuPhe !! no 
LRRN1 c.460C>A:p.Gln154Lys; c.1676C>A:p.Ala559Asp !! no 
SCAF8 het c.80A>G:p.Glu27Gly !! no 
VARS2 c.423G>A:p.Met141Ile; c.1735+1G>T variants inherited in cis yes 
GNMT het c.113C>G:p.Thr38Ser !! no 
ATM het c.146C>G:p.Ser49Cys only one variant (ATM is recessive); AFP test neg no 
P32 
PPP2R2B 
(SCA12) het c.752A>G:p.Tyr251Cys 
SCA12 trinucleotide 
repeat expansion test neg no 
MFN2 het c.1988G>T:p.Arg663Leu 
MFN2 sanger sequencing 
neg no 
TPP1 het c.101G>A:p.Gly34Asp TPP1 biochemical assay normal  yes 
POLG c.2492A>G:p.Tyr831Cys; c.1550G>T:p.Gly517Val Not pathogenic no 
!!
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MYH14 het c.5504G>A:p.Arg1835His 
Variant does not 
segregate with disease 
phenotype in the family 
yes 
KIAA019
6 (SPG8) het c.925G>A:p.Ala309Thr 
Variant does not 
segregate with disease 
phenotype in the family 
yes 
CEP152 het c.1507A>G:p.Ile503Val !! no 
PNKP het c.1360C>A:p.Leu454Met !! no 
INPPL1 het c.1706C>T:p.Thr569Met !! no 
BRCA1 het c.1487G>A:p.Arg496His !! no 
BARHL2 het c.371C>A:p.Pro124His !! no 
AGRN het c.3353C>A:p.Thr1118Lys !! no 
P2RY2 het c.515T>C:p.Val172Ala !! no 
GAS6 het c.1690C>A:p.Leu564Ile !! no 
SYNM het c.1050G>T:p.Arg350Ser !! no 
IRX3 het c.1016C>T:p.Ala339Val !! no 
PRKCD het c.1213G>A:p.Ala405Thr !! no 
PCDHA1
1 
het 
c.1930C>G:p.His644Asp !! no 
PRKAR1
B het c.695G>A:p.Arg232Gln !! no 
PRKACG het c.558C>G:p.Phe186Leu !! no 
ACAP3 het c.2336C>G:p.Ala779G ly !! no 
ATP8B2 het c.2321A>G:p.Lys774Arg !! no 
FERMT3 het c.119C>T:p.Ser40Leu !! no 
PLCB3 het c.1492T>C:p.Ser498Pro !! no 
CDC42B
PG het c.4272-2A>G !! no 
APOBR c.1083G>C:p.Glu361Asp; c.1090G>T:p.Gly364Trp !! no 
ATP8B3 c.2950G>A:p.Val984Met; c.637G>A:p.Ala213Thr !! no 
LIPE 
het 
c.2827_2828insC:p.Glu943
fs 
!! no 
ROCK2 het c.1802A>T:p.Asp601V al !! no 
!!
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LSS het c.1564G>A:p.Gly522Arg !! no 
P33 
and 
P34 
IGDCC3 c.1984G>A:p.Gly662Ser; c.1207G>A:p.Glu403Lys 
Variant does not 
segregate with disease 
phenotype in the family 
yes 
HIF1a c.217C>A:p.Leu73Met; c.517G>T:p.Asp173Tyr 
Variant does not 
segregate with disease 
phenotype in the family 
yes 
MT-CO1 m.6869_C>T polymorphism no 
ZEB2 c.34T>G:p.Cys12Gly; c.49C>A:p.Gln17Lys !! no 
IRS1 c.2482A>C:p.Ser828arg; c.1159A>C:p.Thr387Pro !! no 
CHRND c.158A>C:p.His53Pro; c.280C>G:p.Gln94Glu !! no 
PCDHB1
5 
c.1490A>C:p.His497Pro; 
c.1717A>C:p.Thr573Pro !! no 
TNC 
c.5731C>T:p.Arg1911Trp; 
c.5341G>A:p.Ala1781Thr; 
c.2374G>T:p.Gly792Cys 
!! no 
PLXNA2 c.4606G>A:p.Val1536Met; c.2161A>C:p.Thr721Pro !! no 
ACAD8 c.118A>C:p.Thr40Pro; c.124A>C:p.Thr42Pro !! no 
SYT7 c.950T>G:p.Val317Gly; c.607A>C:p.Thr203Pro !! no 
P35 
TIMMDC
1 
c.176G>A:p.Arg59Gln; 
c.285G>T:p.Arg95Ser 
inconclusive (mother is 
heterozygous for one 
variant; father’s DNA 
sample unavailable) 
yes 
SACS Het c.11032C>G:p.P3678A only one variant found yes 
MTATP6 m.9052 A>G Not pathogenic yes 
ASCL1 
c.150_152delGCA:p.50_51
del; 
c.152_153insGCA:p.Q51de
linsQQ 
!! no 
ABCB6 c.1028G>A:p.Arg343Gln; c.490G>A:p.Ala164Thr !! no 
HTT 
c.107A>C:p.Gln36Pro; 
c.110A>C:p.Gln37Pro; 
c.113A>C:p.Gln38Pro 
!! no 
BHLHE2
2 
c.673G>A:p.Gly225Ser; 
c.676A>G:p.Ser226Gly !! no 
!!
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UGT1A4 
c.119C>A:p.Pro40His; 
c.310_310delG:p.Glu104As
nfs*4 
!! no 
TNXB 
c.12520G>A:p.Asp4174As
n; 
c.10673G>A:p.Arg3558His
; 
c.9631C>G:p.Arg3211Gly; 
c.7235C>T:p.Pro2412Leu 
!! no 
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